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LEONARD, SUSAN RUTH, Ph.D. The Treatment Validity of 
Identifying and Treating Depression and Behavior Change 
Symptom Clusters in Women Complaining of the Premenstrual 
Syndrome. (1985) Directed by Dr. Rosemery 0. Nelson. 256 pp. 
The main goal of the present study was to test a 
treatment validity hypothesis in relation to premenstrual 
syndrome (PMS): that selection of specific target 
behaviors and matching treatments to them would enhance 
treatment outcome. Thus, this study assessed the treatment 
validity of identifying depression and behavior change 
symptoms within the general classification of PMS. This 
study also addressed the question of whether, on a general 
measure of PMS, in comparison to a no-treatment control 
group, it is more effective to use an interventio~ designed 
to treat depression or behavior change symptoms of PMS. 
Thirty-six women reporting premenstrual symptoms of 
depression and behavior change were randomly assigned to one 
of three treatment groups: cognitive therapy for 
depression, operant intervention for behavior change, and 
no-treatment control. Treatment occurred between the first 
and second menses. Control subjects engaged in record 
keeping only. All subjects completed ratings of depression 
and behavior change daily, and recorded crying frequency and 
time resting daily throughout three menstrual cycles. 
Within one week of each menses onset, subjects also 
retrospectively completed the Menstrual Symptom 
Questionnaire (MSQ}, 
Menstrual Distress 
an overall measure of PMS, 
Quesionnaire (MDQ) which 
and the 
included 
negative affect and behavioral change symptom clusters. 
It was predicted that the MDQ negative affect cluster, 
daily depression rating, and crying frequency would 
differentially improve in the depression treatment group; 
the MDQ behavioral change cluster, daily behavior change 
rating, and time resting would differentially improve in the 
behavior change treatment group; and the MSQ would 
differentially improve for one of the treatment groups. 
Multivariate and univariate analyses of variance did not 
support these predictions. 
Four of the seven dependent measures showed 
the MSQ, both MDQ clusters, significant changes over time: 
and the daily behavior change 
significant differences between 
control group. 
rating. 
groups, 
There were 
including 
no 
the 
Lack of support 
discussed 
ineffective 
identifying 
in light 
treatments 
for the experimental hypotheses is 
of the confound of potentially 
with the treatment validity of 
symptom clusters. The change over time 
regardless of intervention is discussed as consistent with 
placebo or common factor effects within 
for future treatment validity and 
suggested. 
PMS 
PMS. Directions 
research are 
ACKNOWLEDGEMENTS 
It is customary to thank the doctoral dissertation 
committee: Rosemery Nelson (Chair), Bob Eason, Steve Hayes, 
Carol Tittle, and Jackie White. I would like to acknowledge 
their contributions to the two year duration of this 
project. 
I am grateful for the support of the Wake Forest 
University Psychology Department during the data analysis 
and preparation of the final manuscript. Specifically, I 
would like to thank two graduate students in the Wake Forest 
University Psychology Department: Deborah Parker, who 
s~~7ed as a b~e~apist for tr~s study; and Michael Walker, 
who served as a statistical and computer consultant. 
I would like to express my sincere gratitude to the 
Wake Forest University Counseling Center for their 
support, and cooperation throughout the execution 
trial) of this study. 
iii 
help, 
(and 
TABLE OF CONTENTS 
Page 
APPROVAL PAGE . • . ii 
ACKNOWLEDG~~NTS iii 
LIST OF TABLES vii 
LIST OF FIGURES . ix 
CHAPTER 
r. 
II. 
INTRODUCTION 1 
Behavioral Medicine 2 
Mind/body Issue . 5 
Premenstrual Syndrome 9 
Importance of PMS . . . . . . 15 
Nature of Premenstrual Symptoms . . 16 
Identification o: Clusters 
(Pilot Study) . . . . 26 
Etiology and Treatment 33 
Proposed Management . . 44 
Evaluation of Behavioral Assessment 48 
Treatment Validity . . . . . 49 
Treatment Validity Literature Review 58 
Statement of Purpose . . 
METHOD 
Treatment Validity of Targeting 
Specific PMS Symptoms . 
Subjects . 
Screening Assessment . 
Design . . . . . . . 
Dependent Measures . 
iv 
66 
67 
71 
71 
71 
75 
77 
CHAPTER 
III. 
IV. 
Page 
Treatment . • . • . . • . . . . • . . 79 
Therapist Training and Monitoring . . • . 82 
Procedure . . . • . . . . . . . • • 83 
RESULTS . . . . 85 
Experimental Design . . . . . . . . . 85 
Did Treatments Differentially Affect 
Types of Symptoms? . . . . . . . . . 86 
Did the Treatments Differentially 
Affect the Depression Measures? 87 
Did the Treatments Differentially 
Affect the Behavior Change 
Measures? . . . . . . • . . . . . . . 89 
Did the Treatments Differentially 
Affect Overall PMS Complaints? . 
Correlation Among Dependent Measures . 
Correlation Among Depression 
91 
92 
Measures . . . . . . 93 
Correlation Among Behavior Change 
Measures . . . . . . . . . . . 93 
Correlation Between Depression 
and Behavior Change Measures . . . . 94 
Correlation Between the Overall 
Measure of PMS and the Symptom 
Cluster Measures . . . . 95 
Individual Subject Data and 
Nonparametric Sign Tests . . 95 
Change over Time Sign Tests . 95 
Individual Treatment Group 
Sign Tests 97 
DISCUSSION 
Treatment Validity Hypothesis 
Outcome . . . . 
v 
99 
101 
101 
CHAPTER 
BIBLIOGRAPHY 
APPENDIX A. 
APPENDIX B. 
APPENDIX c. 
APPENDIX D. 
APPE~'"DIX E. 
APPENDIX F. 
APPENDIX G. 
APPENDIX H. 
APPENDIX I. 
APPENDIX J. 
APPENDIX K. 
Choice of Treatment . 
Choice of Cluster •. 
Overall Treatment Effects on PMS • 
Significant Main Effects fer Ti~e . 
Change over Time . • . • • . • 
Lack of Differential Treatment 
Effects • . • • . • . • 
Differential Responsiveness of 
Measures . . . • 
Limitations of the Present Study . 
Directions for Future Research . 
Conclusions . . . . . . . . . 
PILOT STUDY ~~TERIALS 
Page 
104 
112 
116 
i.17 
l j/ -. 
122 
124 
137 
145 
150 
154 
169 
SCREENING ASSESSMENT . 179 
MENSTRUAL DISTRESS QUESTIONNAIRE (MDQ) 181 
TABLES . . . . . 183 
CONSENT FORMS 
DAILY SELF ASSESSMENT FORM . 
214 
219 
MENSTRUAL SYMPTOM QUESTIONNAIRE (MSQ) 220 
DEPRESSION TREATMENT MATERIALS . . . . 223 
BEHAVIOR CHANGE TREATMENT MATERIALS 229 
DEBRIEFING 234 
FIGURES 236 
vi 
LIST OF TABLES 
Table 
1. Subject Data Screening Assessment Scores 
2. Individual Subject Data 
3. Mutivariate Analysis of Variance for 
Depression Symptom Measures 
4. Analysis of Variance for MDQ Negative 
Affect Symptom Cluster . . . . . . . 
5. Newman-Keuls Post Hoc Tests: Means of MDQ 
Negative Affect Symptom Cluster 
Scores for Time . . . . 
6. Analysis of Variance for Daily Depression 
Ratings . . . . . . . . . . 
7. Analysis of Variance for Crying Frequency 
Measure . . . . . . . . . . . . 
8. Multivariate Analvsis of Variance for 
Behavior Change~Symptom Measures .. 
9. Analysis of Variance for MDQ Behavioral 
Change Symptom Cluster 
. 
10. New.man-Keuls Post Hoc Tests: Means of MDQ 
Behavioral Symptom Cluster 
Scores for Time 
11. Analysis of Variance for Daily Behavior 
Change Ratings . . . . . . . 
. 
. 
. 
. 
12. Newman-Keuls Post Hoc Tests: Means of Daily 
Behavior Change Ratings for Time . . 
13. Analysis of Variance for Time Resting 
Measure . . . . . • . . . . 
14. Analysis of Variance for MSQ Overall 
Measure of PMS Complaints . . . . 
Page 
184 
186 
195 
. . . 196 
. . . 197 
. . . 198 
. . . 199 
200 
201 
202 
203 
204 
205 
206 
.· 
Table Page 
15. New.man-Keuls Post Hoc Tests: Means for MSQ 
O~eral: Meas~re of PMS Complaints 
for '!'ime . • . . 
16. Correlation ~atrix . 
17. Individual Subjects Change from Baseline 
and Sign Tests . . . . . . . . . . . . . . . . 
18. Percentage of Total Possible on Targeted Symptom 
Clusters Based on Screening Assessment 
Scores . . . . . . . . . . . . . . . . . . . . 
viii 
207 
208 
. 209 
. 213 
LIST OF FIGURES 
Figure Page 
1. MDQ Negative Affect Symptom Cluster Scores . 237 
2. Daily Depression Ratings • 238 
3. Reported Crying Frequency 239 
4. MDQ Behavioral Change Symptom Cluster Scores . 240 
5. Daily Behavior Change Ratings 241 
6. Reported Time Resting in Minutes 
7. MSQ Congestive Scores 
8. Depression Treatment Group, Individual Subject 
242 
243 
MSQ Scores . . . . • . . • . . . . . . 244 
9. Behavior Change Treatment Group, Individual 
Subject MSQ Scores . . . . . . . . . . . . . 245 
10. Control Group, Individual Subject MSQ Scores . 246 
11. Depression Treatment Group, Individual Subject 
¥illQ Negative Affect Scores . . . • . • . • . 247 
12. Behavior Change Treatment Group, Individual 
Subject MDQ Negative Affect Scores . . . . 248 
13. Control Group, Individual Subject 
MDQ Negative Affect Scores . • . 
14. Depression Treatment Group, Individual Subject 
249 
MDQ Behavioral Change Scores • . . . 250 
15. Behavior Change Treatment Group, Individual 
Subject MDQ Behavioral Change Scores 251 
16. Control Group, Individual Subject 
MDQ Behavioral Change Scores . . 
ix 
252 
Figure 
17. Depression Treatment Group, Individual Subject 
Daily Behavior Change Ratings • . • . • • 
18. Behavior Change Treatment Group, Individual 
Subject Daily Behavior Change Ratings 
19. Control Group, Individual Subject Daily 
Behavior Change Ratings 
20. Premenstrual and Postmenstrual Group Means 
of Daily Depression and Behavior Change 
Ratings for Baseline and 
Post-Treatment Menses . • • . . . . . . 
X 
Page 
253 
254 
255 
256 
CHAPTER I 
INTRODUCTION 
1 
Three relatively recent developments contributed to the 
formulation of this experiment. First, fairly recently, 
behavioral psychology has entered the domain of medicine 
with growi~g respect and mutual benefit. Their integration 
has resulted in the development of a field called behavioral 
medicine. Second, women have gained prominence within the 
professions of both psychology and medicine. They have 
redirected research on women's problems. Female scientist-
practitioners in behavioral medicine approach common 
gynecological complaints from a behavioral perspective, 
eschewing "anatomy is destiny" and pursuing relief of 
discomfort (Calhoun & Sturgis, 1984). One such complaint is 
premenstrual syndrome (PMS). Third, and finally, the 
application of behavioral approaches to traditionally 
medical problems brings with it issues inherent in 
behavioral research. One such issue presently of concern is 
the utility of behavioral assessment. 
The central concern of this dissertation is the utility 
of behavioral assessment. This concern is more precisely 
characterized as the value of matching treatment procedures 
to target behaviors as evaluated specifically through the 
use of treatment validity methodology. To date, treatment 
2 
validity has been examined primarily using the disorder of 
depression. This dissertation is an attempt to apply the 
methodology of treatment validity to a different disorder, 
PMS. 
The present chapter reviews and elaborates upon the 
factors leading to the choice of this disorder. First, 
the philosophical underpinnings of the field of behavioral 
medicine are addressed. Second, the specific disorder of 
premenstrual syndrome (PMS) is reviewed. Previous research 
pertaining to the nature of PMS preludes the identification 
of the specific symptoms of PMS addressed in the present 
study (depression and behavior change). A review of the 
etiological considerations in PMS and various treatment 
procedures precedes the proposed management procedures 
in the present study (cognitive therapy of depression 
operant intervention for behavior control). Third, 
used 
and 
and 
central to this dissertation, issues in the evaluation of 
behavioral assessment are addressed and the particular topic 
of interest here, treatment validity, is reviewed. Finally, 
these topics (PMS' and treatment validity) are integrated in 
the statement of purpose. 
Behavioral Medicine 
Behavioral medicine has been conceptualized as a 
clearly interdisciplinary field which emphasizes the 
integration of behavioral and biomedical knowledge (Schwartz 
3 
& Weiss, 1978). Behavioral psychology has been credited 
with providing the means to change behavior that affects 
health ~nd diseas~ {Agras, 1975}. Ir. behavioral medicine, 
psychological intervention is applied to physiological 
processes. 
It has been demonstrated that psychological processes 
can exacerbate physical disorders (Blanchard & Ahles, 1979; 
Melamed & Siegel, 1980). The Diagnostic and Statistical 
Manual of Mental Disorders of the American Psychiatric 
Association (DSM III) delineates specific conditions under 
which psychological fa~ors are judged as affecting physical 
conditions. The diagnostic criteri~ for the c~tegory a~e 
the following: 
This 
A. Psychologically meaningful environmental 
stimuli are temporarily related to the 
initiation or exacerbation of a physical 
condition. 
B. The physical condition has either 
demonstrable organic pathology (e.g., 
rheumatoid arthritis) or a known 
pathophysiological process (e.g., 
migraine headache, vomiting). 
c. The condition is not due to a Somatoform 
disorder (no organic pathology or 
process). (DSM I!I, pp. 303-304). 
focus on an interaction between behavioral and 
biomedical events suggests that psychological interventions 
may be applied to normal physiological processes, as well as 
to pathophysiological processes. The psychological 
interventions may not directly affect the cause or physical 
basis of the process. Nonetheless, behavioral interventions 
4 
have been effective with a variety of physical disorders; 
for example, vascular (Kallman & Gilmore, 1981), muscular 
(Bird, Cataldo, & Parker, 1981), and central nervous system 
(Mostofsky, 1981). This success suggests that there are 
psychological effects on physical systems, for probably both 
diseased and nondiseased processes. 
psychological ap9roaches were used 
In the present study, 
with components of 
premenstrual syndrome, which may be considered a nondiseased 
physiological process. 
The DSM III criteria suggest an interaction 
psychological and physical conditions rather 
between 
than the 
dichotomous view promoted by defining a specific set of 
disorders as psychogenic. Psychosomatic medicine is 
differentiated from behavioral medicine as it classically 
has been separate from the rest of medicine. Psychosomatic 
medicine is presumed to deal exclusively with disorders of 
psychological origin (psychogenic disorders), clearly 
differentiated from disorders of organic origin. Schwartz 
and Weiss (1978) suggest that the integrative focus of 
behavioral medicine transcends the " ... mind/body dualism 
that plagued the early development of psychosomatic 
medicine" (p. 250). The focus of psychological 
interventions on physical systems, the basis of behavioral 
medicine, clearly has bearing on the mind/body issue. 
5 
Mind/body Issue 
The integration of the behavioral and biomedical fields 
relates to the philosophical stances on the mind/body issue. 
These stances may be classified as monistic or dualistic 
(Bunge, 1980). The mind/body issue concerns the nature of 
the psychological (mind) and its relationship to the 
physical (body). Dualistic positions maintain that both 
aspects of the mind/body distinction are necessary to 
provide an adequate explanation of experience. Dualistic 
positions include psychophysical parallelism, 
interactionism, and emergentism or epiphenomenalism. 
Monistic positions maintain that one aspect of the mind/body 
dyad is sufficient to explain experience. Monistic 
positions include mental monism and physical reductionism. 
The dualistic approaches differ in terms of their 
interpretation of the relationship between mind and body. 
Psychophysical parallelism acknowledges the existence of 
both the psychological and the physical, contending they are 
separate and synchronous processes which do not interact. 
Psychophysical parallelism requires the acceptance of the 
mind separate from the physical world. The unobservable and 
unmeasurable aspects of this separatist view and its denial 
of the impact of the physical on the psychological and the 
psychological on the physical are difficult to incorporate 
in an empirically based scientific position (Bunge, 1980). 
6 
The philosophical position of interactionism attempts 
to resolve the mind/body issue by contending that mind and 
body are separate, but interacting. Behavioral medicine 
demonstrations of psychological interventions effective with 
physical functioning appear to suggest such a relationship 
between mind and body. This position, however, seems more 
closely related to the field of psychosomatic medicine which 
epitomizes the separation of organic and psychological 
origins (Schwartz & Weiss, 1978). Interactionism accepts a 
distinction between the psychological and physical, but 
suggests an impact of one upon the other. Whether the 
impact is psychological to physical or physical to 
psychologica~ or reciprocal, the argument suffers mostly 
from separatism (Pomerleau, 1979). From a scientific 
approach, the interaction seems reasonable, because 
available data are interpretable as suggesting psychological 
impact on physical processes. The separation of the two, 
however, seems arbitrary. What is physical versus 
psychological may be indistinguishable. 
An alternate attempt to allow the psychological to be 
separate, but related to the physical is the position 
contending that mind is an emergent of the brain, 
epiphenomenalism. This position suggests that the . 
psychological are emergent brain processes, that is, the 
psychological are based on physical processes, but are 
7 
different from and more than the physical events from which 
they emerge. According to this view, psychological 
processes are emergent from physical brain processes in the 
same sense that water (a liquid) is an emergent of the gases 
hydrogen and oxygen; the parts are known, but the outcome is 
not predictable from the parts. Epiphenomenalism is 
presumed to maintain a scientific approach even as chemistry 
must deal with emergents (Sperry, 1969). This suggests the 
whole is greater than the sum of the parts, a stance 
consistent with current thinking in some disciplines 
(Bindra, 1970; Sperry, 1970). It seems incompatible with 
behavioral medicine, however, as it maintains a separatist 
stance and tends to remove the psychological portion of 
behavioral medicine from the realms of science. In general, 
Bunge (1980) suggests the dualistic positions are 
antithetical to a scientific approach. 
The monistic positions seem to overcome the dualism 
criticism that separation of psychological and physical 
processes is arbitrary; the two processes may be 
indistinguishable. Essentially, the monistic positions 
differ in terms of the process which is necessary to account 
for experience. Mental monism assumes all that exists is 
the mind which creates only ~e impression of the physical 
world. This is a difficult position to uphold if one 
desires to maintain a scientific approach; science depends 
8 
on sensory data. This stance has been offhandedly 
discounted as unscientific (Bunge, 1980). This position is, 
thus, ~~tenable from the perspective of behavioral medici~e. 
An alternate monistic position is physical 
reductionism. This position suggests that ultimately all 
that is called psychological will be reduced to and 
explained by physical processes. From this perspective, 
psychological processes are considered a product of physical 
function, to be explained by biological/physiological 
processes. This is considered a popular stance among the 
sciences (Sperry, 1970). 
Physical monism is the commonly accep~ed philosophical 
stance in behavioral medicine. It is a monistic position 
which views the mental and physical as indistinguishable 
and, thus, is consistent w~th the use of psychological 
interventions with physical and health-related disorders. 
While explanations may ultimately be derived from biomedical 
research, the presence of organic etiology does not 
establish the ineffectiveness of psychologically based 
interventions. Since we know that psychological 
interventions can be effective with physical processes 
(Blanchard & Ahles, 1979), it seems reasonable to pursue the 
demonstration and explanation of these effects within 
behavioral medicine. 
9 
This study addressed the specific health-related 
problem of premenstrual syndrome (PMS). Psychologically 
based interventions were used with PMS symptoms. This 
approach is consistent with the preferred philosophical 
stance within behavioral medicine, physical monism. 
Prem~~trual Syndrome 
Dysmenorrhea is a noun of Greek origin defined simply 
as "painful menstruation." A number of authors have found 
this simplistic view to be insufficient to encompass the 
full range of menstrually related distress reported by 
women. This study is primarily concerned with one subset of 
menstrually related distress: premenstrual syndrome (PMS). 
PMS is a topic which has received much attention in the 
popular press recently (Paige, 1973). There is a dearth, 
however, of controlled empirical work on the topic. Most of 
the work that has been done is presented in relation to 
other subsets of dysmenorrhea. 
Premenstrual syndrome is ill-defined, and its existence 
as a distinct disorder is questioned. There are three 
issues central to making a distinction between menstrual and 
premenstrual problems: (a) the basis upon which the 
distinction is made, (b) the exclusiveness of the respective 
syndromes in different women, and (c) whether there is a 
functional distinction between syndromes. There are 
basically three criteria upon which the distinction has been 
10 
made: the cause of the symptoms, the 
temporal occurrence of 
nature of the 
symptoms, and the the symptoms. 
Various researchers contend that women can have only one or 
both of the syndromes. The functional nature of the 
distinction between the syndromes in prescribing treatment 
has also been disputed. The definitions and distinguishing 
issues related to perimenstrual symptoms are discussed. 
Behrman and Gosling (1966) delineated four categories 
of dysmenorrhea: primary, secondary, membranous, and 
premenstrual tension syndrome. Primary and secondary 
dysmenorrhea are distinguished essentially by their 
relationship to identifiable pelvic disease; no organic 
pathology is associated with primary dysmenorrhea, and 
secondary dysmenorrhe~ is caused by another disease state. 
Membranous dysmenorrhea is rare and gains its name from the 
appearance of the material passed from the uterus during the 
painful menses. Their premenstrual tension syndrome is 
viewed as a complex of cyclic and recurrent physical and 
psychological symptoms. 
More recently, Chesney and Taste (1975a) also 
distinguished between secondary and primary dysmenorrhea. 
Additionally, they upheld Dalton~s (1969) distinction of 
spasmodic 
Spasmodic 
beginning 
and congestive forms of primary dysmenorrhea. 
dysmenorrhea refers to abdominal cramping pains 
on the first day of menstruation. Congestive 
11 
dysmenorrhea is considered to be a variation of the 
premenstrual syndrome and refers to dull, 
affective changes beginning prior to 
aching pains and 
the onset of 
menstruation. 
Dalton (1977) proposed a faulty progesterone feedback 
pathway as the physiological process underlying "congestive" 
dysmenorrhea. Thus, she contended that insufficient 
progesterone is the cause of premenstrual (congestive) 
problems and that excess progesterone is the cause of 
spasmodic dysmenorrhea. Chesney and Taste (1975a) upheld 
the congestive-spasmodic distinction through the development 
of a questionnaire (the Menstrual Symptom Questionnaire or 
MSQ) which clearly distinguished among 48 women whose 
menstrual complaints parallel Dalton's dichotomous 
descriptions. The MSQ consists of 24 statements which 
describe symptoms associated with the menstrual period. 
Twelve of the items are associated with congestive 
dysmenorrhea, and 12 with spasmodic dysmenorrhea. Each item 
is rated regarding the subject's typical menstrual period on 
a 5-point scale ranging from never to always. In addition, 
the 25th item offers the subject a choice between two 
descriptions of menstrual discomfort: one is characteristic 
of congestive and the other of spasmodic complaints. The 
subject chooses the description which most closely matches 
her experience. Chesney and Tasto (1975a) found no subjects 
12 
with both kinds of symptoms. They also found a differential 
effect of treatment on the two groups (Chesney & Taste, 
1975b). 
The distinction between congestive and spasmodic 
dysmenorrhea has been questioned, however. Cox (1977) used 
Chesney and Taste's (1975a) MSQ with 14 women and did not 
find dichotomous groups. He found a fairly even 
distribution of respondents throughout the range of scores 
on the MSQ. He identified scores of 48-68 as congestive, 
scores of 69-80 as mixed, and scores of 81 and above as 
spasmodic. Chesney and Taste 
subjects in the middle range, 
(1975a & b) reported no 
and Dalton's (1977) theory 
does not account for mixed symptomatology. 
Webster, Martin, Uchalik, and Gannon (1979) also 
disputed Dalton's theory of hormonal imbalance. They factor 
analyzed MSQ's from 275 women and found seven (not two) 
factors which accounted for 62% of the variance: 
premenstrual negative affect, menstrual pain (cramping), 
premenstrual pain, menstrual back pain, water retention, and 
two factors without clear labels. This breakdown does not 
support the congestive-spasmodic distinction proposed by 
Dalton. Stephenson, Denney, and Aberger (1983) also factor 
analyzed the MSQ using the responses of 423 women and cross-
validated the analysis on the responses of 294 other women. 
They used a severity scale rather than the frequency scale 
13 
used with the MSQ. Their analyses also revealed seven 
factors which accounted for 64% of the variance. These 
factors did not parallel the congestive-spasmodic 
distinction considered inherent in the MSQ. Their clearly 
labelled factors were essentially the same as those of 
Webster and colleagues (1979). Their factors included 
menstrual pain, premenstrual negative affect, water 
retention, premenstrual pain, and menstrual back pain. The 
congestive-spasmodic dichotomy appears to have little 
support. 
Instead of distinguishing between premenstrual and 
menstrual disorders on the basis of symptoms, an alternative 
way is temporally. Moos (1969) in developing the Menstrual 
Distress Questionnaire (MDQ), used a time of menstrual flow-
premenstrual week distinction. Each of the 839 women in 
Moos (1969) study rated their experience of 47 symptoms for 
the menstrual, premenstrual, and intermenstrual time 
periods, and for their worst period. Their responses were 
factor analyzed separately for each time period, and the 
same eight clusters emerged for all the analyses (Moos, 
1969). The clusters were pain, concentration, behavioral 
change, autonomic reactions, 
affect, arousal, and control. 
water retention, negative 
The control cluster is made 
up of symptoms derived 
menstrual complaints. 
from menopausal complaints, not 
These clusters are quite similar to 
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those derived from the MSQ by factor analyses (Stephenson 
et al., 1983; Webster et al., 1979). This temporally,based 
distinction, menstrual versus premenstrual, also seems to be 
related to symptoms. Women complain of discomfort 
accompanying their menstrual flow and of discomfort 
preceding their menstrual flow; they tend to characterize 
the nature of this discomfort differently (Dalton, 1969; 
Moos, 1969). Moos (1969) suggests his pain scale reflects 
symptoms usually associated with dysmenorrhea (menstrual 
complaints) and the negative affect scale reflects symptoms 
"almost definitional" of premenstrual complaints (p. 392). 
There appears to be an inconsistency in Moos' (1969) report 
of similar clusters in menstrual and premenstrual phases and 
the association of different clusters with each time period. 
It seems that while the same clusters were demonstrated in 
each phase, they had different levels of severity. On the 
average the pain clus~er received greater endorsement during 
the menstrual phase of the cycle and the negative affect 
cluster received greater endorsement during the premenstrual 
phase. Although menstrual and premenstrual discomfort may 
be characterized differently, women do not seem to suffer 
exclusively from one or the other; a variety of symptoms at 
a variety of times can occur in the same woman (Moos, 1969). 
The issue of primary concern in this study is 
premenstrual syndrome (PMS). The temporal distinction and 
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the symptoms most commonly associated with discomfort 
preceding the menstrual flow seem to provide an operational 
means of distinguishing the premenstrual syndrome from 
strictly menstrual complaints. 
Imnortanc~ of PMS 
It is difficult to estimate the prevalence of PMS 
(Calhoun & Sturgis, 1984). Reports of menstrual problem 
frequency often combine menstrual and premenstrual 
complaints. In addition, premenstrual complaints are often 
categorized as symptomatic of other disorders or traits. 
The estimates which have been made, however, range from 50% 
to 95% of the adult female population (Dalton, 1979; Hoes, 
1980; Reid & Yen, 1981; Widholm, 1979; Wood, Larsen, & 
Williams, 1979). Varying degrees of severity are used in 
computing frequency of the syndrome which may account for 
the discrepancy in estimates. Estimates of severe or 
debilitating premenstrual problems are usually restricted to 
5-10% of the adult female population (Dalton, 1979; Moos, 
1969). Unlike dysmenorrhea, PMS tends to increase with age 
(Gough, 1975; Hoes, 1980; Moos, 1968) and does not appear to 
respond to a popular treatment for dysmenorrhea: childbirth 
(Dalton, 1969; Kistner, 1971). 
Estimates of the impact of perceived premenstrual 
changes seem to be primarily based upon self-report. Women 
believe that they are less effective premenstrually (Brooks 
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et al., 1977; Parlee, 1973; Sommer, 1973). Studies using 
actual measures of overt behavior, however, do not support 
the co~clusion that performance is impaired in cognitive and 
academic tasks (Berstein, 1977; Dor-Shav, 
fluency and behavior changes (Silverman & 
Zimmerman & Parlee, 1973), and in other 
perceptual-motor behavior (Sommer, 1973). 
1976), speech 
Zimmer, 1976; 
cognitive and 
The detrimental 
impact of PMS, as it is perceived by women, however, should 
not be discounted. The belief that the premenstruum is 
responsible for lessened effectiveness and competence may 
lead women to be more anxious than usual which may impair 
their performance, or it may lead women to avoid particular 
activities in which they believe their performance will be 
impaired (Brooks et al., 1977). Thus, while the impact on 
performance may not have been demonstrated, the negative 
impact of the belief that performance is impaired is still 
possible. Woman hours, although not clearly documented, are 
surely lost due to premenstrual discomfort. 
Nature of Premenstrual Symptoms 
An important question related to the examination of PMS 
is: Are the nature and timing of premenstrual symptoms 
unique to the syndrome? The timing of symptoms has been 
used in the definition of the syndrome. This, however, is 
insufficient to demonstrate that the nature of these 
symptoms is exclusively premenstrual or cyclic. 
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Demonstrations that these particular symptoms occur 
consistently during the premenstruum are necessary to 
establish the periodic nature of the symptoms. 
First, research suggesting various explanations for the 
apparent periodic nature of these symptoms is discussed. 
Factors other than actual menstrual changes have been used 
to account for the apparent periodic nature of premenstrual 
symptoms including cultural stereotypes, expectation, social 
reinforcement, and methodological problems. Second, the 
literature dealing with the consistency of premenstrual 
symptoms is reviewed. Essentially the same symptom complex 
is consistently reported. 
premenstrual symptoms also 
Reports examining the nature of 
are discussed. Premenstrual 
symptoms have been compared to other responses to stress, 
characteristic response patterns, and major psychological 
disorders. 
Periodic Nature of Symptoms. Some researchers suggest 
the symptoms reported as premenstrual do not occur 
exclusively during the premenstruum. Similar symptomatology 
in response to periods of stress other than the premenstruum 
has been reported (Halbreich & Kas, 1977; Moos, 1969). 
Many studies using the MDQ report correlations between the 
menstrual, premenstrual, and intermenstrual time periods on 
the MDQ (Moos, 1969). These reports suggest the symptoms 
may not be unique to PMS. 
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Premenstrual symptoms have also been viewed as 
characteristic responses from the perspective of personality 
trait theory. Women with certain personalities are seen as 
more likely to show characteristic symptoms premenstrually, 
as well as at other times. Studies have been done which 
seek psychological patterns or personality characteristics 
to account for premenstrual complaints. The relationship 
between the severity of menstrual symptoms and personality 
traits has been examined with conflicting results. Gough 
(1975) reported menstrual distress was related to the 
California Personality Inventory measure of femininity; 
others have found no such relationship with similar measures 
of personality (Berry & McGuire, 1972; Slade & Jenner, 
1980). A relationship between high neuroticism on the 
Eysenck Personality Inventory and perimenstrual suffering 
has been found (Slade & Jenner, 1980), and greater menstrual 
symptom complaints have been reported among women considered 
to be neurotic (Coppen & Kessel, 1963). Others, however, 
have found no relationship between personality inventory 
measures of neuroticism and menstrual symptomatology 
(Awaritefe, Awaritefe, & Ebie, 1980). Higher state anxiety 
levels, however, among women instructed to imagine that they 
were in the perimenstrual time period have been reported 
(Awaritefe et al., 1980). 
Attempts 
symptoms to 
have also been made to relate 
other types of disor1ers. 
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pra~enstrual 
In general, 
pr~~enstrual negative affect and major psychologica.l 
disorders are considered to be different (Birtchnell ~ 
Floyd, 1975; Blechman & Galland, 1983; Diamond, Rubinstei~, 
Dunner, & Fieve, 1976). Many researchers, however, feel 
that premenstrual affective changes are related to more 
serious disorders. These affective changes have been 
characterized as related to affective disorders or 
depressive syndromes (Kashiwagi, McClure, & Wetzel, 1976; 
Wetzel, Reich, McClure, & Wald, 1975) and as mild forms of 
an affective disorder (Endicott, Halbreich, Schacht, & Nee, 
1981). More commonly, the menstrual cycle is seen as 
exacerbating an already existing disorder (Haskett et al., 
1980; Zola, Meyerson, Rezinoff, Thornton, & Concool, 1979). 
The view of premenstrual symptoms as characteristic 
responses or as related to major psychological disorders 
suggests the symptomatology is not unique to the 
premenstruum. The views also imply continuity between 
premenstrual affective symptoms and other affective changes. 
Researchers have also reported no cyclic pattern of 
symptoms (Golub & Harrington, 1981). Males and females 
completed symptom surveys: no differences between females 
in various phases or between males and any of the females 
were found. Koeske and Koeske (1975) have implied that 
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other factors might be responsible for the report of cyclic 
symptoms. There seems to be a tendency to attribute any 
behavioral changes occurring near the time of menstruation 
to PMS or menstrually related changes. 
Factors other than actual menstrual changes have been 
used to account for the apparent periodic nature of 
premenstrual symptoms. Cultural stereotypes, expectation, 
social reinforcement, and methodological pro~lems have been 
suggested (Brooks, Ruble, & Clark, 1977; Gannon, 1981; Woods 
et al., 1982). Researchers have suggested effects of 
cultural stereotypes on menstrual symptom ratings (Paige, 
1973). Koeske and Koeske (1975) suggested that negative 
mood, including depression, is likely to be attributed to 
menstruation. Parlee (1974) had both men and women rate 
symptoms 
complete 
of menstruation. Subjects were instructed to 
the MDQ as they believed most women would complete 
it for ~~e menstrual, premenstrual, and intermenstrual time 
periods. 
pervasive 
The similarity of their responses 
cultural beliefs about menstrual 
suggests 
symptom 
experience. In addition, using deception regarding cycle 
phase resulted in distinctly different symptom estimates. 
EEG measures were presented as evidence of a subject's 
actual menstrual cycle phase. In fact, all subjects were 
actually in the same phase of the menstrual cycle, six to 
seven days before menstruation. All reported that they 
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believed the EEG measure manipulation. Women who were led 
to believe that they were premenstrual reported increased 
incidence of physical symptoms such as water retention as 
compared to women who were led to believe they were not 
premenstrual (Ruble, 1977). Similarly, when the purpose of 
the study (examining menstrual changes) was disguised, no 
difference in mood state was reported by women whose 
retrospective reports of the premenstruum included increased 
negative affect (Vila & Beech, 1980). These studies support 
the prevalent influence of expectation in the experience of 
PMS. Women may actually be reporting culturally expected 
stereotypes rather than actual premenstrual symptoms. 
The behavior of others may also influence women's 
perception 
influence 
of and response to the premenstruum. The 
of others may be indirect through expectation of 
performance changes or direct through social reinforcement 
or consequation of "sick" behavior. If a woman is excused 
from activities and from expectations of mood control and 
"rational" behavior by those around her during the 
perimenstrual time, she may be less likely to participate in 
activities, or to display controlled mood or "rational" 
behavior. 
likely to 
If she is reinforced for "sick" behavior, she is 
display it. Examination of the impact of 
environmental factors on menstrually related behavior has 
been recommended (Devany & Leonard, 1979), but rarely 
22 
directly investigated. Environmental variables should not 
be minimized, however, as they are consistently demonstrated 
to be controlling factors in a variety of physiological 
disorders and processes (e.g., Melamed & Siegel, 1980). 
Treatment of menstrual distress has utilized environmental 
factors in at least one reported case: Mullen (1968) had a 
client's spouse ignore her pain-related behavior to help 
decrease it. Further research is needed into the impact of 
environmental variables on PMS. 
Methodological problems have also been noted in 
menstrual problem research (Gannon, 1981; Parlee, 1973). 
Large discrepancies between retrospective ratings and daily 
ratings have been demonstrated (Parlee, 1974; Rouse, 1977; 
Woods et al., 1982). These discrepancies suggest the effect 
of recall bias on premenstrual symptom reports. This bias 
may reflect a tendency among women to forget premenstrually 
related symptoms (Gannon, 1981) or to report them 
consistently with cultural stereotypes (Ruble, 1977). 
Sampson and Prescott (1981) recommend the use of daily 
ratings, in a review of PMS assessment and response to 
treatment, in order to demonstrate cyclicity of symptom 
occurrence. The assessments of personality traits and 
menstruation are consistently retrospective and have been 
criticised for possible confounding due to the similarity of 
instruments (Gannon, 1981). Measures of neuroticism and 
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measures of menstrual discomfort share specific items. 
Correlations between these measures may reflect these 
similar items, not actual relationships between neuroticism 
and PMS. Causal interpretations of correlational data are 
also common (Parlee, 1973), suggesting experimenter bias and 
misleading conclusions. 
Consistency of Symptom Clusters. PMS has been viewed 
as an ill-defined set of symptoms (Russell, 1972). Moos 
(1968) suggested that conflicting data exist regarding 
menstrual symptomatology. Despite the many differences 
among identified menstrual symptoms which may be attributed 
to individual (Moos, 1968) and methodological differences 
(Parlee, 1973), a review of the literature dealing 
specifically with premenstrual complaints suggests there is 
a certain amount of consistency in the symptom clusters 
associated with the complaint of PMS. There is no consensus 
regarding the essential symptoms of PMS, but there is a 
substantial amount of repetition of specific symptoms 
(Haskett, Steiner, Osmun, & Carroll, 1980). 
Behrman and Gosling (1966) identified premenstrual 
weight gain as diagnostic for PMS. Based upon later work, 
it appears to be neither necessary nor sufficient for the 
diagnosis, but seems to be fairly consistent (Chesney & 
Taste, 1975a; Moos, 1968; 1969; Stephenson· et al., 1983). 
Weight gain is frequently subsumed within a factor 
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independently identified as water retention (Moos, 1969; 
Stephenson et al., 1983; Webster et al., 1979). This factor 
or symptom category also includes breast tenderness and 
swelling, symptoms which are also fairly consistently 
reported (Chesney & Taste, 1975a; Moos, 1968; 1969; Russell, 
1972). Although these physical changes are not uni~ue to 
the premenstruum, they appear characteristic of that time 
period. 
In addition to these physical symptoms which have been 
consistently associated with PMS, similar psychological 
symptoms have also been independently identified. Symptoms 
of negative affect including mood swings, tension, 
depression, and irritability are common to the Chesney and 
Taste questionnaire (1975a) and the Moos questionnaire 
(1969). These same mood changes are reported by others 
attempting to delineate PMS {Golub, 1976; Haskett et al., 
1980; Kutner & Brown, 1972; Schuckit, Daly, Herrman, & 
Hineman, 1975). 
Depression is among the most common affective symptoms 
rated premenstrually on the MDQ (Woods, Most, & Dery, 1982). 
It has been estimated that one out of ten women experiences 
premenstrual depression (Kessel & Coppen, 1963). Depression 
is also among the most frequently cited premenstrual 
symptoms in gynecology textbooks (e.g., Behrman & G~sling, 
1966; Kistner, 1971; Novak, Jones, & Jones, 1975). Although 
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depression is not exclusive to the premenstruum, it appears 
characteristic of that phase of the menstrual cycle. 
In addition to the physical and affective symptoms 
reported during the premenstruum, behavior change complaints 
are also common. Symptoms of fatigue or lethargy and bed 
rest are common to the Moos questionnaire (1969) and to the 
Chesney and Taste questionnaire (1975a). Such changes in 
behavior or activity are not unique to the premenstruum. 
They have been reported during both the premenstrual and 
menstrual time periods. The Moos questionnaire (1969) is 
rated for both premenstrual and menstrual experience of 
symptoms and the Chesney and Tasto questionnaire (1975a) 
relates to all perimenstrual symptoms. In addition, 
specifically menstrually related changes in activity level 
or resting behavior have been reported (Amodei, 1983). 
Although behavior change is not exclusively symptomatic of 
the premenstruum, reports of it seem characteristic of that 
time period. 
PMS appears to consist of a complex assortment of 
symptoms. 
treatment 
Prior 
validity 
to 
of 
embarking on an examination of the 
matching treatment procedures to 
specific symptoms clusters (the present study), 
identification of orthogonal symptom clusters was deemed 
necessary. 
subsumed 
In order to identify orthogonal symptom clusters 
by the label PMS, and amenable to psychological 
intervention, a pilot study was conducted. 
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Identification of Clusters (Pilot Study) 
In order to identify specific symptom clusters for use 
in an exa~ination of the treatment validity of matching 
specific treatments to specific symptoms, the following 
pilot study was conducted .. A number of methodological 
issues in perimenstrual research were addressed in the 
design of this pilot study. 
Woods, Most, and Dery (1982) compared daily blind 
ratings of health with a Menstrual Distress Questionnaire 
(MDQ, Moos, 1969) that had been completed retrospectively. 
They found major differences between prospective and 
retrospective ratings of negative affect, pain, and water 
retention. Rouse (1978) found the same clusters to be rated 
differently prospectively and retrospectively in another 
comparison of daily and retrospective ratings of menstrually 
related symptomatology. She used the retrospective and "at 
present" forms of the MDQ, and her subjects were aware of 
the focus on menstrual distress prospectively as well as 
retrospectively. Neither of these studies factor analyzed 
in order to identify symptom clusters; they used the 
symptoms clusters originally identified by Moos {1969). 
These clusters of symptoms derived from the MDQ appear to be 
fairly consistent across analyses (Stephenson, Denney, & 
Aberger, 1983; Webster, Martin, Uchalik, & Gannon, 1979). 
Despite the apparent consistency of these clusters, it seems 
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necessary to derive symptom clusters empirically from a 
blind daily report of symptoms. "Blind" is used here to 
indicate that the subjects are not told that the study deals 
specifically with menstrual symptoms. The clusters have 
historically been derived from retrospective assessments of 
rnenstrually related symptoms. Such assessments have been 
demonstrated to be inconsistent with daily blind ratings 
which help to control the fairly clear impact of social 
expectation on the experience of perimenstrual complaints 
(Ruble, 1977; Vila & Beech, 1980). In order to derive 
empirically symptom clusters from blind daily ratings, the 
following three pilot study analyses were conducted. 
Subjects completed a Self- Assessment Questionnaire 
(Appendix A-1) daily for 40 days without the explicit 
knowledge that the purpose of the study was to collect 
information regarding their menstrual cycles. Of the 107 
Introductory Psychology students who signed up for the 
study, only four did not receive credit as they did not 
complete the study. Of the 103 subjects who received 
credit, the data from only 97 could be analyzed as six 
subjects recorded no menses within the 40 days of self 
assessment. A factor analysis using a varimax rotation 
resulted in 13 factors with eigenvalues greater than one. 
Although a perfect replication of Moos' original factors was 
not obtained in the first pilot study factor analysis, 
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similar factors were found. The similar or overlapping 
factors include Moos' factors: control, negative affect, 
behavioral change, arousal, and water retention (Appendix A-
2). The Moos factors are identified in the right hand 
column of Appendix A-2. 
The factors identified by this pilot study 
of all menstruating subjects were not used to 
analysis 
identify 
clusters to be targeted in the treatment validity study, 
the focus of this disseration project, in part, because of 
other aspects of the sample. Of the 97 subjects reporting 
menses during the 40 days of self-assessment, 24 were using 
oral contraceptives, a possible confounding variable, and 15 
rated themselves as aware of the purpose of the study all 
along. Awareness was rated on a 7-point Likert-type scale; 
1 = not at all aware of the experimenter's interest in 
menstrually related problems and 7 = very much aware. 
Subjects who rated themselves above 4 on the scale were not 
considered "blind." Four was an arbitrarily selected cut 
off (see Appendix A-3). 
Based upon this sample information, only 58 subjects 
were considered "pure," that is, not on oral contraceptives 
and unaware of the experimental focus on menstrually related 
complaints. A second factor analysis on just the 58 "pure" 
subjects using a varimax rotation also resulted in 13 
factors with eigenvalues greater than one. Again, although 
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a perfect replication of Moos' factors was not obtained, 
similar factors were revealed. These similar or overlapping 
factors include items on Moos' control, negative affect, 
arousal, water retention, and behavioral change factors 
(Appendix A-4). The Moos factors are identified in the 
right-hand col~~n of Appendix A-4. 
The clusters derived from the analyses of all 
menstruating subjects (Appendix A-2) and the subset of those 
subjects who were not taking oral contraceptives and not 
aware of the experimental focus on menstrually related 
issues (Appendix A-4), while not identical, did reveal 
substantial similarity. The analyses also reveal clusters 
similar to those reported by Moos. The similar clusters 
include: control items, arousal items, water retention 
items, negative affect items, and behavioral change items. 
The factors derived from the second pilot study 
analysis 
determine 
treatment 
project, 
The goal 
of the "pure" subjects also were not used to 
the symptom clusters to be targeted in the 
validity study, the focus of this dissertation 
in part, because of the goal of the pilot study. 
of the pilot study was to confirm through 
replication of Moos' factor analysis two prominent factors 
amenable to psychological intervention in a population 
complaining of PMS. The daily self assessment data were 
reanalyzed using only the data from the 33 subjects (out of 
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the 58 "pure" subjects) who reported that they suffered from 
premenstrual syndrome or premenstrual problems on the 
debriefing questionnaire (Appendix A-3). A varimax rotation 
was used and again resulted in 13 factors with eigenvalues 
greater than one. 
The factors derived from the final factor analysis of 
the responses of the subjects reporting PMS were similar to 
those revealed by the first two pilot study analyses. It is 
clear that while the variance accounted for differed, the 
items tend to cluster in a consistent manner particularly in 
relation to the factors derived by Moos. The three pilot 
study analyses revealed clusters similar to the Moos 
clusters. The similar clusters include: control items, 
arousal items, water retention items, negative affect items, 
and behavioral change items. 
The factors identified by the final pilot study 
analysis of subjects complaining of PMS were not directly 
used to identify clusters to be targeted in the treatment 
validity study, the focus of this dissertation project, 
because of the small sample size. The number of subjects 
did not exceed the number of items factored by a ratio of 4 
to 1 as considered necessary by Cattell (1952). Although 
Moos' factors were not prospectively derived from a "blind" 
population sample, his factor analysis did meet the criteria 
of a 4:1 ratio. Moos used 839 subjects and the 
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questionnaire includes 47 items. The pilot study factors do 
provide an indication and verification of which factors 
derived by Moos could serve as the basis of symptom cluster 
identification for a treatment validity study. 
Although a perfect replication of Moos' original eight 
factors was not obtained in the pilot study factor analyses, 
similar factors and factors which share a sizable proportion 
of the same items were found. The similar or overlapping 
factors specifically with the final analysis of the subjects 
reporting PMS include Moos' factors: control, arousal, 
water retention, negative affect, and behavioral change 
(Appendix A-5). The Moos factors are identified in the 
right hand column of Appendix A-5. The first three similar 
factors seem inappropriate to serve as target symptom 
clusters in a treatment validity study of psychological 
interventions. The control factor seems inappropriate as 
those items were originally included to account for general 
complaining, the arousal factor seems inappropriate as the 
items indicate positive affective events which do not 
require treatment, and the water retention factor seems 
inappropriate for a psychological intervention. In addition, 
arousal and water retention are not among the first two to 
three factors identified in the first factor analysis of all 
menstruating subjects (Appendix A-2) or in the final factor 
analysis of the PMS subjects in the pilot study (Appendix A-
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5); the first two to three factors account for most of the 
variability in factor analysis (e.g., Conte & Plutchick, 
1981). The other two similar factors are the second and 
third factor in the final pilot study analysis of subjects 
reporting PMS. They are similar to Moos' factors negative 
affect and behavioral change. A portion of the items which 
make up Moos' factor, negative affect, loaded on the second 
pilot study factor, depression. The shared items include 
3. crying, 38. mood swings, 40. depression, and 45. tension. 
These overlapping items appear amenable to a standard 
psychological intervention for depression. The last similar 
factor, Moos' behavioral change factor, overlaps with the 
third factor in the PMS subjects' pilot study. The shared 
items include 4. lowered work or school performance, 8. 
take naps; stay in bed, and 15. stay at home. This 
behavioral change factor appears amenable to a standard 
psychological intervention designed to alter activity level. 
Based upon the results of the pilot study and their 
interface with the factors originally derived by Moos, it 
appears reasonable to target Moos' factors, negative affect 
and behavioral change, in an evaluation of matching 
treatments to targetad symptom clusters. These factors are 
amenable to psychological intervention, and they have 
support from factor analyses of prospective, "blind" 
ratings of premenstrual symptoms. 
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Etiology and Treatment 
Physiological Intervention. A number of theories of 
the physiological etiology of the affective and behavioral 
symptoms of PMS have been proposed. No conclusive evidence 
implicating a particular physiological malfunction in 
individuals~ subjective experience of premenstrual distress 
is available, however (Steiner & Carroll, 1977). These 
theories are briefly reviewed. There is no necessary link 
between etiology and treatment from a monistic philosophical 
stance. Physically based treatment procedures, however, 
have been associated with physiological explanations of 
etiology. These physically based interventions are 
inconsistently effective or have undesirable side effects or 
both. These treatment procedures and demonstrations of 
their effectiveness are also discussed. 
At present a surgical procedure eliminating the 
presumed hormonal source of the physiological process is 
technically possible. Fluctuations in estrogen and 
progesterone levels would be terminated by bilateral 
oopherectomy, that is, removal of the ovaries. Even this 
invasive procedure has not been determined to be 
consistently effective (Novak et al., 1975). Even if it 
were, the side effects such as the complications of major 
surgeTy, infertility, and the systemic impact of estrogen 
loss may be deemed undesirable. 
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Oral contraceptives have been suggested as a means of 
controlling PMS as anovulatory cycles are frequently 
considered to have fewer and less 
symptoms (Clare, 1979; Novak et al., 
effects, again, 
increased risk 
may be undesirable, 
of cervical cancer, 
severe accompanying 
1975). The side 
e.g., infertility, 
pulmonary embolism, 
cerebral thrombosis, thrombophlebitis, and neuro-ocular 
lesions. Morris and Udry (1972), however, found no 
difference in perimenstrual symptom complaints between users 
and nonusers of oral contraceptives in a controlled double 
blind study. Others have also found a continuation of 
perimenstrual symptoms with the use of oral contraceptives 
(Cullberg, 1972; Herzberg, Draper, Johnson, & Nicol, 1971). 
Smith (1975) concluded there are four possible, nonexclusive 
results with the use of oral contraceptives: (a) cessation 
of perimenstrual symptoms, (b) decreased severity of 
perimenstrual symptoms, (c) side effects of the oral 
contraceptive, and (d) no change. Cullberg {1972) reported 
that a small number of women experience exacerbations of 
their symptoms from oral contraceptives. Oral 
contraceptives are not a highly reliable method of treating 
perimenstrual discomfort. In addition, premenstrual 
depression and dysphoria have been reported in anovulatory 
cycles (Adamopoulos, Loraine, Lunn, Coppen, & Daly, 1972), 
further disputing the role of ovulation in premenstrual 
distress. 
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Dalton (1969;. 1977) has been a great proponent of 
hormone imbalance theories. She advocates a 
deficiency theory and has promoted the use of 
progesterone 
supplemental 
progesterone in the treatment of PMS. There are, however, 
undesirable side effects, for example, the systemic effect 
of progesterone, inconvenience of injections and 
suppositories, unpleasantness, and expense (Clare, 1979). 
In addition, few controlled trials have been performed 
examining the effect of progesterone on menstrual symptoms. 
Those that have been done do not support the uncontrolled 
reports of effectiveness. Smith (1975) reported little 
difference in plasma progesterone levels and no improvement 
with progesterone injections in women with premenstrual 
depression. Taylor (1979) demonstrated no differences in 
absolute or relative progesterone levels between symptomatic 
and asymptomatic women. Sampson (1979; 1980) using double 
blind procedures demonstrated no difference between 
progesterone and placebo on a variety of premenstrual 
symptoms. 
Various dietary changes have been suggested for control 
of PMS. High protein and low carbohydrate diets have been 
suggested by Dalton (1977) to control mood swings believed 
to be caused by altered sugar metabolism during the 
premenstruum. No controlled studies have been done (Calhoun 
& Sturgis, 1984). Various vitamin deficiencies have been 
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implicated, most noticably pyridoxine (vitamin B6). 
Functional pyridoxine deficiency has been linked to 
depression associated with oral contraceptive use and to 
premenstrual depressed affect (Winston, 1973). The 
effectiveness of pyridoxine in alleviating premenstrual 
depression has not been confirmed in controlled studies 
(Stokes & Mendels, 1972). Dietary restriction and 
supplements may be undesirable for some women. 
Electrolytes and water retention have been implicated 
in PMS by Janowsky, Berens, and Davis (1973). They report 
that activation of the renin-angiotensin-aldosterone system 
causes premenstrual depression. They further suggest that 
premenstrual negative affect is caused by the impact of 
angiotensin on the nervous system. The activity of the 
renin-angiotensin-aldosterone system does not occur in 
anovulatory cycles (Steiner & Carroll, 1977); thus, the 
causal nature of angiotensin is unlikely since premenstrual 
symptoms may occur during anovulatory cycles (Adamopoulos et 
al., 1972). If the negative symptoms of PMS are viewed as a 
response to water retention and its associated discomfort, 
then diuretics become a reasonable symptomatic 
Salt restriction has also been suggested, 
treatment. 
but not 
experimentally assessed. These interventions also may have 
undesirable side effects, e.g., dehydration, sodium-
potassium imbalance, and possible teratogenic effects. The 
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use of diuretics is clinically reported to be 
idiosyncratically effective (Smith, 1975). In addition, no 
conclusive demonstration of a relationship between severity 
of premenstrual symptoms and weight gain or water retention 
is available (Bruce & Russell, 1962; Golub, Menduke, & 
Conley, 1965; Reeves, Garvin, & McElin, 1971; Russell, 
1972). 
Levels of prolactin (a pituitary hormone) have also 
been implicated in PMS (Carroll & Steiner, 1978). Serum 
prolactin have been found to be higher in women complaining 
of PMS (Halbreich, Ben-David, Assael, & Bornstein, 1976). 
Symptomatic women had higher prolactin levels in all phases 
of the cycle and proportionately greater increases at the 
time of the premenstruum. The reported effectiveness of 
bromocriptine (a prolactin secretion suppressor) in 
decreasing premenstrual symptoms provides much of the 
support for the prolactin hypothesis (Benedek-Jaszmann & 
Hearn-Sturtevant, 1976; Carroll & Steiner, 1978). Others, 
however, have demonstrated only partial effectiveness, that 
is, inconsistent effects across symptoms, and no more relief 
of symptoms than by use of a placebo (Andersen, Larsen, 
Sttenstrup, Svendstrup, & Nielson, 1977; Elsner, Buster, 
Schindler, Nessim, & Abraham, 1980). o'Brien and Symonds 
(1982) reported no consistent changes in serum prolactin 
level across the menstrual cycle, no difference in level in 
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symptomatic and asymptomatic women, and no correlation 
between mood changes and prolactin level. In addition, it 
has been found that prolactin secretion may be influenced by 
a variety of other factors including diet (Hill & Wynder, 
1976), stress, sleep (Frantz, 1978), and vitamin B6 (Foukas, 
1973; Mcintosh, 1976). The impact of these other substances 
and situations on prolactin levels is considered indirect 
evidence of the prolactin hypothesis (Carroll & Steiner, 
1978) • Any effects of these other factors on PMS is 
believed to be mediated by prolactin. The inconsistency of 
the data, however, suggests prolactin is not a primary 
mediator of PMS (Blechman & Galland, 1983). 
Uterine prostaglandins, in general, have been 
implicated in the etiology of dysmenorrhea, not PMS (Denney 
& Gerrard, 1981; Fraser, 1980; Gonzalez, 1980). Blechman 
and Galland (1983) propose a model which includes the role 
of excessive premenstrual pain sensitivity and ... . u ... erJ.ne 
prostaglandins in PMS. They propose a testable dual 
behavioral-biological mechanism for the acquisition and 
maintenance of PMS. Central to their proposal is the 
coexistence of excessive uterine protaglandin production and 
acute pain sensitivity in PMS sufferers. They proposed that 
pain sensitivity is centrally mediated with uterine 
prostaglandins or is acquired through interoceptive 
conditioning. They attribute acquisition of premenstrual 
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symptoms to amplification of routine physiological and 
psychological experiences, and maintainence of premenstrual 
symptoms to generalized anticipatory anxiety about the 
menstrual pain experience. This proposal provides an 
interesting attempt at incorporating current physiological 
hypotheses regarding PMS with psychological hypotheses 
regarding PMS. Much of this proposal lacks empirical 
support; and, unfortunately, while there is some evidence 
that heightened pain sensitivity is characteristic of 
dysmenorrheic women (Haman, 1944), there is also evidence 
which refutes this position. Aberger, Denney, and Hutchings 
(1983) report 
dysmenorrheic 
no 
women 
greater 
grouped 
Questionnaire into spasmodic, 
pain sensitivity 
using the Menstrual 
among 
Symptom 
nondysmenorrheic 
previous finding 
groups. They 
that women 
congestive, 
did, however, 
seem to have 
mixed, and 
support a 
higher pain 
~varren, Flynn, 
Blechman and 
thresholds during the premenstruum (Tedford, 
1977). There appears to be a problem in 
Galland's proposal with hypothesized pain 
well as some confusion regarding the 
sensitivity as 
role of uterine 
prostaglandins in PMS versus dysmenorrhea. 
Decreasing the production of uterine prostaglandins 
involves the use of pharmacological treatment which may have 
a number of side effects. Many of these side effects are 
the same as premenstrual symptoms, including mood 
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disturbances, edema, and gastrointestinal distress (Larkin, 
Van Order, Poulson, & Scott; 1979). All the more reason 
women with· premenstrual symptoms might choose not to try 
these prostaglandin inhibiting drugs. 
Psychological Intervention. Many of the interventions 
derived from theories of organic etiology are effective with 
some women who complain of PMS. None of the presently 
available interventions has been demonstrated to be 
consistently effective. Some women with PMS cannot or 
choose not to try these treatments because of side effects~ 
Psychological interventions provide an alternative, and they 
do not necessarily imply the absence of organic etiology. 
At this time, a clear pathophysiological basis for PMS is 
unknown. It is, however, known that psychological factors 
can influence physical conditions. While PMS does not 
strictly meet the DSM III criteria for psychological factors 
affecting physical conditions, a physiological, if not a 
pathophysiological, process appears to underlie the 
complaints of PMS. The presence or absence of organic 
etiology, or knowledge thereof, provides proof of neither 
the effectiveness nor ineffectiveness of psychologically 
based interventions. Effectiveness is an empirical 
question. 
The dearth of behavioral studies of PMS has been 
attributed to the vagueness of the complaint (Calhoun & 
Sturgis, 
make it 
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1984). The generality of the syndrome seems to 
a challenging issue from a behavioral perspective 
since PMS consists of a cluster of symptoms which occur 
frequently in the population, but are not consistent across 
individuals. One goal of behavioral studies would be to 
identify the variables controlling the PMS responses. 
Alteration of cultural expectation and stereotype is an 
option which has not yet been attempted (Calhoun & Sturgis, 
1984). Modification of the environmental consequences for 
the sick role has also been recommended (Devany & Leonard, 
1979). 
Another goal of behavioral studies might be to decrease 
symptomatic responses. Intervention through control of 
symptomatic responses is a reasonable intervention even if 
there is a physiological basis for the premenstrual mood and 
behavior changes. Interventions at the physiological level 
may be too invasive and have undesirable side effects. 
Distress, from cultural expectation or physiological 
process, and response to it, can be lessened through gaining 
a sense of control over the situation or pain. A sense of 
control has been reported to decrease subjective discomfort 
(Melzack & Wall, 1982). Pain management procedures are 
effectively being presented as self - control coping 
strategies (Denney, 1980; Turk & Genest, 1979). Quillen and 
Denney (1982) report effective management of perimenstrual 
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pain and discomfort using a self-control procedure similar 
to anxiety management training. Interventions which offer 
a means of controlling premenstrual symptoms 
what is culturally described as an 
(a response to 
uncontrollable 
physiological event) seem to have a high probability of 
success. 
Using techniques 
suggested (Clare, 
tailored for specific symptoms has 
1979). Chesney and Taste (1975b) been 
found a differential response to desensitization treatment 
between congestive and spasmodic dysmenorrheic women. They 
used hierarchies specifically directed at spasmodic 
symptoms. Spasmodic subjects decreased their experience of 
dysmenorrheic symptoms; congestive women did not. Duson 
(1976) replicated this differential effect with a 
desensitization procedure, but not with a cognitive 
restructuring procedure. Cox and Meyer (1978) did not 
replicate this differential effect with desensitization, nor 
did Rosenthal (1978). Rosenthal (1978), however, used 
hierarchies which were demonstrably different for congestive 
and spasmodic subjects. Although the desensitization 
procedure was not differentially effective, the hierarchies 
used appeared to address different dysmenorrheic symptoms. 
These different hierarchies functioned as different 
treatments which were equally 
dysmenorrheic symptoms. The 
effective 
importance 
with 
of 
different 
tailoring 
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treatments is suggested by both the differential impact of 
hierarchies addressing spasmodic symptoms (Chesney & Taste, 
, 1975b) and hierarchies addressing different symptoms for 
congestive and spasmodic women (Rosenthal, 1978). 
The present study utilized psychological, noninvasive 
interventions. The approach taken through the use of these 
treatments is one of symptomatic management of PMS. The 
expectation was that subjects would gain skills with which 
they could control the adverse symptoms they reported that 
they experienced during the premenstruum. The interventions 
used were modified versions of the Beck (1979) cognitive 
therapy of depression and the Fordyce (1976) operant 
treatment program for behavior control. These interventions 
were designed specifically for use with affective and 
behavioral ~hanges commonly 
premenstruum. The treatments 
demonstrated to be effective with 
associated with the 
have been previously 
nonmenstr~ally related 
depression and behavior changes, the target symptoms of this 
study. The cognitive therapy (depression treatment) 
involved identifying and disputing negative thoughts. 
Negative thoughts were considered to be characteristic of 
the experience of premenstrual affective symptoms, 
particularly depression. The operant intervention (behavior 
change treatment) involved planning contingent rewards for 
completion of scheduled activities. Avoidance of scheduled 
44 
or required activities were considered to be characteristic 
of premenstrual behavior changes. Differential impact of 
the two treatments was expected. The cognitive therapy of 
depression was expected to decrease affective symptoms, and 
the operant intervention for behavior changes was expected 
to decrease behavior change premenstrual symptoms. 
Proposed Management 
Symptomatic treatment for PMS was used in this study 
for three reasons. First, etiologically based treatments 
have been shown to have undesirable side effects and 
inconsistent effectiveness. The physiological treatment of 
PMS is based upon theories of etiology which have only 
sparse support in the literature. These treatments purport 
to treat the cause of a syndrome which has no clearly 
established physical basis. In addition, these treatments 
have undesirable nontherapeutic side effects. The second 
reason a symptomatic treatment was used is that symptomatic 
treatments have been shown in the past to be effective with 
other disorders. Symptomatic treatment has demonstrable 
positive effects, even in medicine. Aspirin, although not 
expected to alter the course of a bacterial infection, is 
frequently used to control the symptom of fever. In 
behavioral medicine, a popular example of symptomatic 
treatment is the use of temperature biofeedback for migraine 
headaches (Melamed & Siegel, 1980). Migraine sufferers are 
trained to 
periphery, 
biofeedback 
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increase the temperature of an area of their 
usually the hands, through the use of thermal 
techniques. The ability to increase hand 
temperature has resulted in decreases in migraines. Third, 
and finally, there is little evidence to suggest adverse 
effects of symptomatic treatment. The most commonly 
postulated negative effect of symptomatic treatment is 
symptom substitution. The fear of symptom substitution 
requires the belief that there are underlying causes, 
physiological or psychological, of premenstrual symptoms 
which must be behaviorally expressed. The critical 
question, when faced with the possibility of symptom 
substitution, is whether it is likely to occur. The 
evidence derived through reviews of empirical findings is 
against symptom substitution (Bandura, 1969; Lazarus, 1971; 
Sloane, Staples, Cristol, Yorkston, & Whipple, 1975). 
Symptomatic treatment is reasonable when dealing with a 
syndrome of unknown origin. 
The interventions used here sought to provide the 
individual with a means of controlling her behavior such 
that the targeted problem of depression or behavior change 
was resolved or became more managable. In selecting 
treatments to match the target behaviors of depression and 
behavior change, the assumption of continuity between 
premenstrual symptoms and other forms of negative affect or 
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behavior was made. If depression is viewed from a 
behavioral perspective as a complex of responses which can 
be subsumed by the label of depression, the heterogeneous 
cluster of depressed behaviors which constitutes the 
psychological diagnostic category of depression also 
constitutes the premenstrual symptom of depression. 
Similarly, if avoiding responsibilities or required 
activities is viewed from a behavioral perspective as a 
complex of responses subsumed by the label behavior change, 
the heterogeneous cluster of activities which constitutes 
the behavioral category of avoidance behaviors also 
constitutes the premenstrual symptoms of behavior change. 
Treatments which have been demonstrated to be effective with 
other forms of these two heterogeneous clusters of behavior 
have been selected and are discussed. Beck's cognitive 
therapy of depression (Beck, Rush, Shaw, & Emery, 1979) was 
modified for use with premenstrual depression, and Fordyce's 
operant treatment for behavior control (Fordyce, 1976) was 
modified for use with premenstrual behavior changes. 
Empirical support for the effectiveness of Beck's 
cognitive therapy of depression is available. The cognitive 
therapy of depression procedure involves three steps: (a} 
learning to identify negative thoughts or self-statements, 
{b) learning to dispute the negative thoughts, and (c) 
practice in disputing the negative thoughts. Shipley and 
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Fazio (1973) demonstrated the treatment procedure was more 
effective than a supportive treatment control. Morris 
(1975) demonstrated that a cognitive-behavioral treatment 
was more effective than an insight-oriented treatment or 
waiting list control. Shaw (1977) demonstrated cognitive 
modification was more effective than drug therapy, 
specifically imipramine (Rush, Beck, Kovacs, & Hollon, 
1977). 
Empirical support for Fordyce 
, 
s operant treatment 
program for chronic pain behavior is also available. The 
operant treatment program involves application of contingent 
positive consequences for increases in activity level or 
engaging in required activities and withdrawal of positive 
consequences for "sick" behavior or staying in bed and 
avoiding responsibilities. The goal of the treatment 
program is to increase activity level and simultaneously to 
decrease pain behaviors such as staying in bed. 
Essentially, patients are taught to make more adaptive or 
active responses which will elicit positive responses of 
others (Fordyce, 1976). One of the first operant-based 
treatment programs reported decreased reported pain, 
medication use, and time in bed, and increased activity 
levels in patients followed from five to 175 weeks after 
treatment (Fordyce, 
Trieschman, 1973). 
Fowler, Lehman, Delateur, Sand, & 
An eight-week learning theory-based 
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program reported that 74% of their patients were medication 
free and leading normal lives six months to seven years 
after treatment (Anderson, Cole, Gullickson, Hudgens, & 
Roberts, 1977). At a ten-month follow-up of another similar 
program, 75% of the patients reported decreased pain or 
increased activity level, and 58% reported being medication 
free (Cairns, Thomas, Mooney, & Pace, 1976). 
These demonstrations of the effectiveness of cognitive 
therapy of depression and operant treatment for behavior 
control, although not with menstrually related symptoms, 
suggested that these treatments would be effective in 
alleviating the premenstrual symptoms of depression and 
behavior change. The effectiveness of these treatments with 
premenstrual symptoms of negative affect and behavioral 
change 
change 
assumes continuity between depress~on and behavior 
under other circumstances and the clusters of 
behavior viewed as depression and behavior change during the 
premenstruum. 
Evaluation of Behavioral Assessment 
Behaviorists generally assume that correct 
identification of target behaviors leads to more effective 
intervention (Nelson & Hayes, 1981). There have been few 
empirical investigations, however, that demonstrate the 
importance of correct target behavior identification or of 
matching treatment to assessment results (Nelson & Hayes, 
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1979). The treatment validity of the selection of target 
behaviors (depression or behavior change) in PMS sufferers 
was assessed. 
Treatment Validity 
At present, there is some debate regarding the basis 
upon which to evaluate behavioral assessment. If the 
difference between traditional and behavioral assessment is 
seen primarily as conceptual, rather than methodological, 
then presumably the same methodology by which traditional 
assessment is evaluated should be sufficient and appropriate 
for behavioral assessment. Alternately, the conceptual 
differences may be seen as affecting methodology, requiring 
different evaluative criteria. 
Cone (1977) has suggested that the differences between 
behavioral 
conceptual. 
and traditional assessment are primarily 
The methodological criteria used to evaluate 
traditional assessment procedures, therefore, apply to 
behavioral assessment. The psychometric criteria used to 
evaluate traditional assessment procedures are the validity 
and reliability (consistency) of measurement. These 
criteria are believed to be important in behavioral 
assessment as well (Hartmann & Wood, 1982). Cone (1977) 
proposed recasting traditional validity and reliability in 
terms of generalizability theory. He suggested that 
evaluation of behavioral assessment devices across universes 
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of generalizabilty (e.g., items, time) provides sufficient 
criteria upon which to judge the devices. Others agree and 
believe these procedures will lead to more adequate 
assessment devices (Hartmann & Wood, 1982). These 
psychometric and generalizability theory approaches to the 
evaluation of assessment devices assume that people respond 
consistently across dimensions or universes. When dealing 
with a traditional approach to psychological functioning, 
this assumption is reasonable. A good assessment device 
would be expected to reflect the theoretically proposed 
consistency of responses emanating from a trait, conflict, 
or disorder. 
In traditional psychometric evaluations of assessment 
procedures, the consistency of responses measured by a 
traditional assessment device is examined: (a) across time 
by test-retest reliability and 
across situations by parallel 
predictive validity; 
forms reliability 
(b) 
and 
concurrent validity; and (c) across response systems by 
convergent validity. The assumptions of behavioral 
assessment are, however, different. They are that behavior 
is modifiable, situation-specific, and varies across 
response systems (Nelson, 1983). In behavioral assessment, 
inconsistent responding may indicate real changes in 
behavior, rather than a poor assessment device (Nelson, Hay, 
& Hay, 1977). Therefore, the psychometric criteria of 
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validity and reliability, alone, seem to be inappropriate or 
insufficient to evaluate behavioral assessment (Nelson & 
Hayes, 1979). Since the concepts of behavioral assessment 
differ from traditional assessment, perhaps the evaluative 
methodology should also differ. A functional approach to 
evaluation is more in keeping with a behavioral analysis. 
Nelson and Hayes (1979) recommended evaluating 
behavioral assessment functionally using the criteria of 
conceptual validity and treatment validity. These criteria 
are felt to better reflect the assumptions of behavioral 
assessment. Conceptual validity reflects one functional 
value of behavioral assessment: the long-term contributions 
to the understanding of behavior. This involves both 
descriptions of phenomena and consistent conceptual 
explanations of why the phenomena interact as they do. 
Conceptual validity comes with time. Treatment validity 
reflects another functional value of behavioral assessment: 
the contribution of assessment procedures to treatment 
effectiveness. Treatment validity is concerned with the 
impact of assessment decisions on treatment effectiveness; 
for example, targeting one specific behavior may be more 
parsimonious in attaining the treatment goals than targeting 
another behavior. To demonstrate, Hay, Hay, and Nelson 
(1977) showed that reward of academic performance increased 
both academic accuracy and on-task behavior, while reward of 
• 
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on-task behavior increased on-task behavior, but had no 
impact on academic performance. Treatment validity of all 
stages of the assessment procedure may be evaluated, 
including selection of assessment device, choice of target 
behavior, classification or diagnosis of clients, the use of 
functional analysis, and choice of treatment procedure. 
Demonstrations that particular assessment decisions lead to 
more effective treatment are needed at all stages of 
behavioral assessment to establish treatment validity. The 
evaluation of treatment validity of various stages of 
behavioral assessment procedures with various populations 
can lead to a greater understanding of behavior and, thus, 
to greater conceptual validity (Nelson & Hayes, 1979; 1981). 
Recently, treatment validity studies have been 
recategorized into three general types of studies (Hayes, 
Nelson, & Jarrett, in press). These types of studies are: 
post hoc, a priori single dimension, and a priori 
multiple dimension. 
study addresses 
characteristics and 
The post hoc type of treatment validity 
the relationship between 
outcome of treatment. This 
patient 
type of 
study usually addresses this relationship subsequent to the 
actual experimental procedure, perhaps in an attempt to 
explain the pattern of results. Hayes and his colleagues 
consider this to be appropriate primarily as a means of 
generating treatment validity hypotheses. 
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The a priori, single-dimension type of study is 
divided into three subcategories indicating the dimension or 
the portion of the assessment process which is 
experimentally varied. These subcategories are manipulated 
assessment, manipulated match, and observed differences. 
single-dimension, manipulated-assessment type 
validity study addresses the effect of 
The a priori, 
of treatment 
assessment devices, strategies, and methods on outcome of 
treatment. Essential to this subcategory is that subjects 
be randomly divided into groups and one aspect of assessment 
be systematically varied. The a priori, single-dimension, 
manipulated-match type of treatment validity study addresses 
the effects of different use of available assessment data on 
outcome of treatment. What is varied in this subcategory is 
the "correspondence" between the assessment data and the 
chosen treatment procedure. The a priori, single-dimension, 
observed-differences type of treatment validity study 
addresses the relationship between patient types and outcome 
of treatment. Subjects are divided into groups based upon 
assessment differences {nonrandomly), and the impact of 
treatment, if differential, demonstrates the treatment 
validity of the assessment differences. This is considered 
a more common approach than the preceding a priori, single-
dimension subcategories {Hayes et al., in press). 
The a priori, multiple-dimension type of study is 
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divided into five subcategories indicating the two or more 
dimensions or the portions of the assessment procedure which 
are experimentally varied. These subcategories are 
manipulated assessment-manipulated match, manipulated 
assessment-observed differences, manipulated match-observed 
differences, manipulated assessment-manipulated match-
observed differences, and observed differences with two or 
more treatments. The manipulated 
match combination addresses the 
assessment-manipulated 
effect of assessment 
procedures on the impact of different uses of assessment 
information on outcome of treatment. Essentially it is a 
design allowing each of the two single-dimension questions 
to be asked along with the question of their impact on each 
other. The manipulated assessment-observed differences 
combination addresses the effect of assessment procedures on 
the outcome for distinct subject types. Again, studies 
which fall in this subcategory address the single-dimension 
questions and their interaction. The manipulated match-
observed differences combination addresses the effect of the 
use of assessment information on outcome of treatment for 
distinct subject types. The triple combination addresses 
the effect of assessment procedures on the impact of 
different uses of assessment information on outcome of 
treatment for distinct subject types. 
of the a priori, multiple-dimension 
The final subcategory 
type of treatment 
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validity study is observed differences using two or more 
treatment procedures. This subcategory addresses the effect 
of different treatment procedures on the outcome for 
distinct subject types. 
According to Hayes and his colleagues, all of the above 
types of treatment validity studies can be performed through 
within-subject designs with the exception of the single-
dimension, observed-differences subcategory as treatment 
does not vary and no differences can be manipulated. 
One additional type of study is discussed in this 
delineation of types of treatment validity studies; it is 
termed the manipulated target (Hayes et al., in press). 
Hayes and his colleagues suggest that this type of study 
does not evaluate an assessment procedure, but rather 
explores the nature of a disorder which contains a number of 
possible target behaviors. The essential feature casting the 
manipulated target type of study from the treatment validity 
subtypes seems to be that any type of assessment may be used 
in the exploration of the nature of a disorder (Hayes et 
al., in press). Since the role of treatment validity 
studies is the evaluation of the various aspects of 
behavioral assessment, the view that manipulated target 
studies offer no information regarding the value of the 
assessment procedure clearly rules this type of study from 
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the classification of treatment validity studies. An 
alternate view considers the choice of target behavior a 
part of the assessment process essential to the 
effectiveness of treatment. While this particular type of 
study may not permit direct assessment of the quality of 
behavioral assessment, 
theories of disorders 
behavior over another. 
"it may evaluate the quality of our 
which may lead us to target one 
This could be called a kind of 
'treatment 
Perhaps, 
permitted 
studies, 
included 
validity.'" (Hayes et al., in press, p. 32). 
in the same way that the post hoc type of study is 
in the classification of treatment validity 
the manipulated target type of study could be 
for its value in generating treatment validity 
hypotheses. 
Two pragmatic considerations deserve attention in 
discussing the use of the manipulated target type of 
treatment validity methodology for the present study. 
First, while it is experimentally ideal to identify "pure 
types," the ability to do so may differ for different 
disorders. In some disorders, they may not be readily 
available as an experimental population, they may not exist 
at all, and the results obtained through the study of such 
pure types may not actually offer clinically useful 
information, particularly if they are sufficiently uncommon 
in the naturally occurring population. The treatment 
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validity of the spasmodic versus congestive dysmenorrhea 
distinction demonstrated by Chesney and Taste (1975a) is an 
example. The ease with which one can find women who readily 
assign themselves to one category or the other and the 
actual distinction between the categories, per se, has been 
repeatedly questioned (Cox, 1977; Stephenson et al., 1983; 
Webster et al., 1979). In addition, in the initial 
screening for the present study, all of the first 20 
volunteers demonstrated experience of a combination of the 
two symptom clusters (depression and behavior change), 
despite their statistically orthogonal nature. That is, 
they all experienced both clusters at least mildly rather 
than displaying only one of the clusters. The second 
pragmatic issue is the unexplored nature of the disorder 
studied here, PMS. This issue fits nicely with the view of 
Hayes and his colleagues (in press) that the manipulated 
target type of study is useful for the exploration of the 
nature of the disorder. When the symptom pattern of a 
disorder is unclear, and the patient population is 
undefined, as in PMS, it may be more valuable to use the 
manipulated target-procedure. With this type of study, it 
is possible to evaluate the effectiveness of treatment, to 
get a preliminary picture of the course and symptoms of 
disorder, and to generate other treatment validity 
hypotheses for future research. Based upon these concerns, 
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the manipulated target appears to be the most appropriate 
design for the present study despite its step-sibling status 
to the other types of treatment validity studies. 
A number of studies have been done which may be 
classified as treatment validity studies. These studies 
assess the impact of the use of behavioral assessment on 
treatment effectiveness. These treatment validity 
are reviewed and presented by problem area to 
characterize the contribution of treatment validity 
to conceptual validity. 
Treatment Validity Literature Review 
studies 
better 
studies 
There are select studies within particular topic areas 
which demonstrate the impact of behavioral assessment on 
enhancing treatment outcome. Various components of the 
assessment procedure have been examined by these studies. 
For example, the importance of subject characteristics or 
classification in enhancing treatment outcome has been 
demonstrated through the differential treatment effects of 
relaxation training in idiopathic and pseudoinsornniacs as 
classified by EEG measures {Borkovec, Grayson, O'Brien, & 
Weerts, 1979). As subjects were categorized as idiopathic 
and pseudoinsomniacs after completion of the study, this 
would fit in the post hoc type of treatment validity study 
delineated by Hayes and his colleagues {in press). The 
treatment validity of target behavior selection has also 
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been assessed. Aggressive behavior was shown to decrease 
more in response to contingency contracting for solitary as 
opposed to social play (Wahler & Fox, 1980). This study 
appears to be a manipulated target type of study as 
treatments directed at 
applied in the same 
specific target behaviors were 
individuals. The assessment of 
depression also has 
validity question: 
been examined using the treatment 
does the selection of target behavior 
enhance treatment outcome? Depressed women were classified 
as those with irrational cognitive responses and those with 
overt skills deficits in a manipulated match type of study 
(McKnight, Nelson, Hayes, & Jarrett, 1984). Cognitive 
therapy and social-skills training were used with both 
groups and were found to have differential treatment 
effectiveness. Not surprisingly from a logical perspective, 
cognitive therapy was more effective with irrational 
cognitive responders, not only in altering irrational 
cognitions but also in ameliorating depression. Social-
skills training was more effective with those with overt 
skills deficits, in improving both social skills and 
depression. These are select examples within different 
areas. Treatment validity studies, in general, need to be 
done for different disorders, different phases of the 
assessment process, and different assessment techniques. 
Treatment validity studies within the areas of (a) social 
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behavior and (b) perimenstrual distress are discussed with 
an eye to the component of the assessment procedure being 
evaluated and the type of study performed. 
Social 
behaviors. 
attributed 
behavior is a complex cluster of complaints and 
Problems in social behavior have commonly been 
to social anxiety and/or skills deficits. 
Trower, Yardley, Bryant, and Shaw (1978) compared the impact 
of social skills training and systematic desensitization on 
individuals classified as deficient in social skills or as 
socially anxious. This study appears to fit into the 
treatment validity category of observed differences with two 
treatments. Distinct subject types are crossed with two 
distinct treatment approaches, testing the treatment 
validity of the subject types and the theories which 
distinguished 
surprisingly, 
them and their implied treatments. Not 
skills individuals deficient in social 
improved more with social skills training. Socially anxious 
individuals, however, improved with either intervention in a 
comparable manner. It seems more important to successful 
treatment selection to identify social-skills deficits than 
social anxiety. Within social-skills deficits, the 
treatment of target behaviors has been demonstrated. 
Calhoun, and Hobbs (1979), in what is likely 
classified as a manipulated target type of study, 
higher ratings of female attraction resulted from 
Kupke, 
to be 
showed 
training 
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males in personal attention skills (e.g., use of the pronoun 
"you") over minimal encouragement skills (e.g., brief 
statements like "Oh, really?"). 
Others have found differential effects of treatment 
within social anxiety. Ost, Jerremalm, and Johansson (1981) 
assessed the impact of matching treatment to individual 
response patterns in social phobics. They classified their 
subjects as behavioral or physiological responders and 
evaluated the effect of social skills versus relaxation 
training on the response patterns. In general, social 
skills training was better for behavioral responders (six of 
ten measures were significantly different), while relaxation 
training was better for physiological responders (three of 
ten measures were significantly different). Specifically, 
on the overall change score measure, there was no 
significant difference between treatments for behavioral 
responders, but the physiological responders improved 
significantly more (p<.025) with the relaxation treatment 
than with the social skills treatment. This study 
demonstrated the treatment validity of the behavioral-
physiological differentiation among social phobics using an 
observed differences with two types of treatment type study. 
Socially anxious individuals have also been sabdivided into 
those with increased autonomic perceptions plus increased 
physiological reactivity and those with increased autonomic 
perceptions 
(Shaher & 
and no increase 
Merbaum, 1981). 
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in physiological reactivity 
This is similar to the 
behavioral-physiological distinction used by Ost and 
colleagues 
focus more 
Individuals 
(1981). Shaher and Merbaum (1981), however, 
on a physiological-cognitive distinction. 
in these classifications or subdivisions of 
social anxiety responded differentially to desensitization 
and cognitive restructuring procedures; those with increased 
physiological reactivity improved more with desensitization 
and those with no increase in physiological reactivity 
improved more with cognitive restructuring. This study 
demonstrated the treatment validity of the physiological-
cognitive differentiation a~ong socially anxious subjects 
using an observed differences with two types of treatment 
type study. 
Another study which may be retrospectively classified 
as a treatment validity study further clarifies the value of 
specifying social behavior problems through assessment 
procedures. Meichenbaum, Gilmore, and Fedoravicius (1971) 
demonstrated differential responding to treatment by 
individuals with generalized social anxiety and those with 
specific speech anxiety. Cognitively oriented insight 
treatment 
anxiety, 
was more effective with generalized 
and desensitization was more effective 
social 
with 
specific speech anxiety. This suggests the treatment 
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validity of distinguishing general from specific anxiety 
using what appears to have been a post hoc type of treatment 
validity study. Similar to sr.aher and Merbaum's (1981) 
treatment of social anxiety, others have examined the 
differential responding of speech anxious individuals 
divided into cognitive and somatic responders (Altmaier et 
al., 1982). These researchers examined the impact of 
components of stress inoculation on these two types of 
anxiety responders using an observed differences with two or 
more treatments type study. They found the relaxation 
component and the complete stress inoculation treatment to 
be significantly better (p<.OOl) than the coping statement 
component or no treatment for somatic responders, but only 
on the cognitive indices of anxiety. The behavioral indices 
of anxiety showed no differential effects; all three 
components were significantly better than no treatment 
(p<.OO&). There was no significant differential treatment 
effect for the cognitive responders. This study supports 
the importance of assessing the impact of assessment 
decisions on different response modes when performing 
treatment validity studies (Nelson & Hayes, 1979). 
In general these treatment validity studies of social 
problems stress the importance of differentiating skills 
deficits versus anxiety excesses and then identifying the 
specific pattern of anxiety (e.g., general or specific, and 
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cognitive, behavioral, or physiological) in order to 
maximize treatment impact. In terms of general 
understanding of behavior referred to as social anxiety and 
social problems, we have gained a relatively clear picture 
through these studies that social problems constitute a 
class of complex response patterns which benefit 
differentially from specified treatment. The use of 
alternative types of treatment validity studies could help 
to provide an even clearer picture of the value of 
behavioral assessment procedures in the study of social 
problems and their treatments. 
Another 
perspective 
area which has been examined 
of the treatment validity of 
from the 
behavioral 
assessment 
primarily 
Symptom 
is dysmenorrhea. 
on the treatment 
Questionnaire in 
These studies 
validity of 
classifying 
have focused 
the Menstrual 
subjects as 
experiencing congestive versus spasmodic dysmenorrhea. 
Using the classification of congestive versus spasmodic 
dysmenorrhea, Chesney and Tasto (1975b) demonstrated a 
differential response to desensitization using an observed 
differences with two or more treatments type study. Women 
classified as 
significantly 
spasmodic dysmenorrhea sufferers improved 
more (p<.OOl) from desensitization than from 
placebo-discussion or no treatments; there were no 
differential treatment effects for congestive dysmenorrhea 
sufferers. 
responding 
Duson (1976) found similar 
to desensitization, but not to 
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differential 
a cognitive 
restructuring procedure. The trea~~ent validity of the 
congestive-spasmodic distinction, however, has not been 
upheld in other studies. Cox and Meyer (1978) found 
systematic desensitization effective with fourteen women 
with primary dysmenorrhea, but found no significant 
difference between congestive and spasmodic groups using 
what appears to be a post hoc type of treatment validity 
study; they consider it an arbitrary dichotomy. Rosenthal 
(1978) also reported no significant treatment effect and no 
interaction between congestive and spasmodic dysmenorrhea 
classifications and treatment. Quillen and Denney (1982), 
using essentially a single-dimension, observed-differences 
type of study with a no-treatment control group, found pain 
management training to be effective in treating 
dysmenorrhea, but found no differential reponse to treatment 
based upon the subject classification of congestive and 
spasmodic dysmenorrhea. Amodei (1983) also found little 
support for a differential effect of treatment on congestive 
and spasmodic responders using an observed differences with 
two or more treatments type treatment validity study. These 
results suggest the congestive-spasmodic distinction 
proposed by Dalton (1969), in general, is not predictive of 
treatment effectiveness. The treatment validity of the 
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congestive-spasmodic classification based on the Menstrual 
Symptom Questionnaire has not been clearly demonstrated. 
The effectiveness of desensitization using hierarchies and 
images specifically matched to the subjects' symptoms 
(Rosenthal, 1978; Quillen & Denney, 1982), however, suggests 
the importance of matching treatment to specific target 
behaviors in order to enhance treatment outcome. Research 
examining all components of the assessment procedure and a 
variety of the types of treatment validity studies are 
needed in the area of perimenstrual distress. 
Statement of Purpose 
The purpose of this study was to evaluate the treatment 
validity of identifying specific target behaviors within the 
premenstrual syndrome. This 
concerned with the question: 
treatment validity issue is 
does selection of specific 
target behaviors and matching treatment to them enhance 
treatment outcome? 
Selection of specific target behaviors is considered 
a manipulated target type study which is not considered to 
have direct bearing on the quality of assessment (Hayes et 
al., in press). Therefore, there is a potential controversy 
in calling the present study a treatment validity study 
without qualification. The qualification of applying the 
label treatment validity study may be reasonably reiterated 
here. Hayes and his colleagues (in press) suggest that the 
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selection of target behaviors when evaluated in a 
manipulated target type study does not offer information 
directly related to the evaluation of behavioral assessment 
and, therefore, does not clearly fit within the 
classification of treatment validity study. They do offer, 
however, that such a study may evaluate the quality of our 
theories of disorders which may lead us to select specific 
target behaviors and, thus, may be viewed as a kind of 
treatment validity. In addition, in the same way that the 
post hoc type of study is permitted in the classification of 
treatment validity studies, the manipulated target type of 
study could be included for its value in 
treatment validity hypotheses and in 
generating 
addressing 
other 
issues 
related to treatment validity. 
is referred to here as a 
targeting specific symptoms. 
Therefore, the present study 
treatment validity study of 
Treatment Validitv of Tarcretincr Soecific PMS Svmotoms 
The central question posed here is: does the selection 
of a specific target behavior from among the many symptoms 
associated with PMS and matching it to a treatment enhance 
treatment outcome? This is a question of the treatment 
validity of identifying specific target behaviors within the 
general classification of PMS. Within an individual woman 
with symptoms of depression and behavior change, is it 
.important to the outcome of treatment to use a treatment 
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directed at her depression symptoms? or is it important to 
the outcome of treatment to use a treatment directed at her 
behavior change symptoms? More generally, is it important 
to treatment effectiveness to target specific symptoms 
within PMS? It may not be important to treatment 
effectiveness; this is an empirical question (Nelson & 
Hayes, 1979). 
The prediction regarding this issue is that symptoms 
will change only if they have been targeted by the specific 
treatment procedure matched to them. Thus, in this study, 
the cognitive therapy of depression was expected to decrease 
complaints of the symptoms associated with depression, and 
the operant intervention for behavior control was expected 
to decrease complaints of the symptoms associated with 
behavior change. The interventions used were expected to be 
effective in treating only the symptoms for whch they were 
intended as they have been demonstrated to be effective, 
previously, with similar, although nonmenstrually related 
problems (Becket al., 1979; Fordyce et al., 1973). These 
procedures are noninvasive and provide the subject with a 
means of controlling the discomfort she experiences 
premenstrually. 
These predictions have treatment validity implications. 
If the cognitive therapy of depression is effective with 
depression symptoms and the operant intervention for 
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behavior control is effective with behavior change symptoms, 
then, in the future, a woman with predominant depression 
symptoms would be better helped by the depression treatment 
than by the behavior change treatment. Similarly, 
with predominant behavior change symptoms would be 
helped by the behavior change treatment than 
depression treatment. These implications for the 
management of PMS symptoms actually offer 
a woman 
better 
by the 
future 
testable 
hypotheses regarding the treatment validity of targeting 
specific symptom clusters. 
An additional question is addressed by this study: 
will changing one specific symptom (depression or behavior 
change) have more impact than changing the other on changing 
PMS as a whole, as measured by the Menstrual Symptom 
Questionnaire? This question also has treatment validity 
implications. If the overall measure, the MSQ, responds 
differentially to the depression treatment, then the 
depression symptom cluster may be more central to the 
disorder of PMS. It may be more effective to target 
depression symptoms than behavior change symptoms. 
Alternately, if the overall measure responds differentially 
to the behavior change treatment, then the behavior change 
symptom cluster may be more central to the disorder of PMS. 
It may be more effective to target behavior change symptoms. 
These implications also provide testable hypotheses 
regarding the nature of PMS. If over time and trials, 
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treatments that target depression are consistently superior 
to those that target behavior change, then selecting 
depression as a target behavior within PMS may be said to 
have "treatment validity." Or if treatments that target 
behavior change are consistently superior to those that 
target depression, then selecting behavior change as a 
target behavior within PMS may be said to have "treatment 
validity." While this does not provide a direct evaluation 
of assessment, it would provide information on the nature of 
the disorder (Hayes et al., in press). 
In summary, this study asks the questions: (a) does 
the selection of a specific target behavior (depression or 
behavior change) from among the many symptoms associated 
with PMS and matching it to treatment (cognitive therapy of 
depression or operant intervention for behavior control) 
enhance treatment outcome? and (b) will changing a specific 
symptom (depression or behavior change) have more impact on 
changing PMS as a whole, as measured by the MSQ? Although 
this study may b~ c0nsidered a manipulated target type which 
does not directly evaluate behavioral assessment (Hayes et 
al., in press), it is considered a kind of treatment 
validity study here as the answers it provides may generate 
further treatment validity hypotheses and information 
regarding the nature of the disorder (PMS) against which our 
theories may be tested. 
CHAPTER II 
~£THOD 
Subjects 
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Thirty-six postpubescent female volunteers, complaining 
of premenstrual discomfort, and solicited from the local 
community, served as subjects. The subjects (age range 21-
41 years, mean 31.9) were not oral contraceptive users. 
They denied use of physician-prescribed medication for their 
premenstrual 
psychological 
reported at 
discomfort. 
discomfort, and were not experiencing severe 
or psychiatric disturbances. All subjects 
least a one-year history of premenstrual 
Hoes (1980) suggested that a four-cycle history 
of symptoms is necessary for a diagnosis. Subjects were 
solicited by newspaper, radio, or television public service 
announcements. Any volunteer determined to be ineligible 
during the screening assessment phase of the study was 
offered a list of referral sources including local 
physicians and psychologists. 
Screening Assessment 
One hundred and two women responded to the 
advertisements for subjects. Of these, 27 were deemed 
inappropriate for participation in the study during the 
initial telephone contact; of these, 10 were taking oral 
contraceptives, 9 were taking prescription medication for 
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premenstrual syndrome, and 8 had other medical conditions 
(e.g., previous hysterectomy). The remaining 75 women from 
the community scheduled screening assessment appointments 
with the principal investigator. They all reported that 
they were at least 18 years old and denied use of oral 
contraceptives and physician-prescribed medication for 
premenstrual symptoms. Nineteen of the women who initially 
scheduled appointments either cancelled or failed to come in 
for their appointments. The remaining 56 volunteers met 
with the principal investigator for their screening 
assessment appointments. Two of these were determined 
ineligible by virtue of psychological/psychiatric 
disturbances. Another eleven were determined to be 
ineligible by their scores on the Menstrual Distress 
Questionnaire which was used to assess severity of symptoms. 
Five subjects withdrew following the screening assessment 
and prior to the first (baseline) menses; three had been 
assigned to the control group, one to the depression 
treatment group, and one to the behavior change treatment 
group. Two additional subjects withdrew after completing 
their participation in the treatment sessions: one in the 
depression treatment group and one in the behavior change 
treatment group. Thus, thirty-six subjects completed the 
study, twelve in each group. 
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Volunteers were interviewed by the principal 
investigator to ascertain the presence of premenstrual 
discomfort and the absence of serious psychological 
disturbance (see Appendix B). Each subject complained of at 
least a one-year history of premenstrual discomfort, 
including depression and behavior change. The duration of 
discomfort ranged from 4 to 14 days prior to the onset of a 
menstrual period. Sutherland and Stewart (1965) consider 
the diagnosis of premenstrual syndrome to be based upon the 
report of physical or psychological symptoms beginning at 
least four days before menstruation. 
Following the interview, volunteers still eligible then 
completed the Menstrual Distress Questionnaire (MDQ) (Moos, 
1969). The MDQ (see Appendix C) consists of 47 items 
presented as symptoms which women experience. For the 
screening assessment, each item was rated regarding a 
typical week preceding the subject's menstrual flow onset. 
The items are rated on a 6-point Likert-type scale ranging 
from no experience of the symptom to acute or partially 
disabling 
of the 
experience of the symptom. 
MDQ rates the most recent 
The original version 
menstrual cycle and 
includes two additional ratings of each symptom: the period 
of the actual menstrual flow and the intermenstrual time 
period. The intermenstrual time refers to the rest of the 
subject's cycle excluding her days of flow and the preceding 
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week. These ratings of the menstrual and intermenstrual 
time periods were considered unnecessary for the present 
study. The focus here was on the the premenstruum and 
associated symptomatology·. The 47 items on the MDQ are 
divided into eight factors by Moos' original analyses 
(1969}. Each of the eight factors reflects an 
intercorrelated group of symptoms associated with phases of 
the menstrual cycle. The factors are pain, concentration, 
behavioral change, autonomic reactions, water retention, 
negative affect, arousal, and a control scale. The control 
scale includes six items which are not considered to be 
symptoms of menstrual distress, but are included as a 
measure of complaining. 
Eligibility for participation required a score of 15 or 
greater on the Moos Behavioral Change cluster (items: 4, 8, 
15, 20, and 41}, an average rating of at least 3 on each of 
five items; and a score of 24 or greater on the Moos 
Negative Affect cluster (items: 3, 11, 21, 27, 36, 38, 40, 
and 45}, an average rating of at least 3 on each of eight 
items. The score of 3 was an arbitrary cut-off chosen 
because it indicates the symptom is present and noticable 
although mild. The Moos Behavioral Change and Negative 
Affect clusters were chosen because they appear to be 
consistent clusters based upon Moos (1969} findings and are 
supported by the pilot data reported in the first chapter 
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(the Introduction); they also appeared to be amenable to 
psychological intervention. If the individual met these 
criteria, she was eligible to participate in the study. 
The mean score on the screening assessment MDQ 
Behavioral Change cluster for the 36 subjects who completed 
the study was 19.1 and the range was 15 to 26. Their mean 
score on the Negative Affect cluster was 35.6 and the range 
was 25 to 48 (Table 1; Table 1 and all subsequent tables are 
located in Appendix D). 
After eligibility had been determined through the 
interview and the MDQ, during the screening session, a data 
deposit of $20.00 was collected. Refundable deposits have 
been shown to result in fewer absences and more consistent 
data (Ersner-Hershfield, Connors, & Maisto, 1981). Each 
subject was asked to make out four checks for $5.00 each to 
the principal investigator and her supervisor. One of the 
four checks was returned to the subject at each of the four 
previously agreed upon times; these times were explicitly 
stated in the initial consent form (Appendix El). Subjects 
signed an additional consent form which 
referred to the treatment group to which 
assigned (Appendix E2). 
Design 
specifically 
each had been 
A 3 (treatment) X 3 (measurement occasions) 
experimental design was used. The between-groups factor was 
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treatment. The treatments were cognitive therapy of 
depression, operant interventior. for behavioral change, and 
a no treatment data collection only control. Subjects were 
·randomly assigned to treatment within the constraint that 
one third of the subjects were in each treatment group. 
Twelve of the subjects participated in the cognitive therapy 
of depression, 12 participated in the operant intervention 
for behavioral control, and 12 served as a no-treatment 
control group. The two experimental treatment procedures 
(cognitive therapy of depression and operant intervention 
for behavioral control) were administered in four sessions 
which occurred between the baseline menses and the 
posttreatment menses. The control group members were 
offered a choice between the two treatment procedures after 
three cycles of data collection. The within-subjects factor 
(measurement occasions) refers to the time periods for which 
the collected dependent measures were analyzed. All 
dependent measures were analyzed for the baseline 
premenstruum (the four days preceding each subject's first 
menstrual period), the posttreatment premenstruum (the four 
days preceding each subject's second menstrual period, the 
first following intervention), and the follow-up 
premenstruum (the four days preceding each subject's third 
menstrual period). 
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Dependent Measures 
Each subject completed a daily self-assessment every 
evening at bedtime throughout her participation in the study 
(three menstrual cycles). The daily rating included self-
reports of subjective and objective measures of the two 
targeted behaviors (depression and behavioral change). Both 
subjective measures (depression and behavior change) used 
Likert-type scales with 0 = no experience of the symptom and 
6 = extreme experience of the symptom. Although subjects 
completed daily self-assessments throughout their 
participation in the study (three menstrual cycles), only 
the four days prior to the onset of menses were used in the 
data analyses. The objective measures used a frequency 
count of discrete episodes of crying for depression and 
duration of time resting, not engaged in required activities 
for behavior change. The sum of each of the ratings 
(subjective Likert-type and objective frequency count or 
amount of time) for the four days immediately preceding the 
onset of menstrual flow served as the dependent variable 
scores for the analyses. Thus, each subject had four daily 
self-rating scores for each premenstruum (Appendix F). Each 
subject received instructions regarding the completion of 
the daily self-assessment as needed from the principal 
investigator. 
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In order to provide an additional means of assessing 
the impact of treatment on the two targeted symptom 
clusters, each subject also completed an viDQ for each 
premenstruum included in the study. Each subject completed 
the MDQ three times following the screening assessment; the 
items were rated regarding the week prior to the most recent 
menstrual flow onset. The MDQ was completed within one week 
after the onset of each subject's first (baseline) menstrual 
period; then within one week after the onset of each 
subject's second menstrual period; and, finally, within one 
week after the onset of each subject's third (follow-up) 
menstrual period. The assessments were administered after 
the onset of each subject's menstrual period as the onset of 
menstrual flow is considered to be symptom free for 
premenstrual syndrome (Dalton, 1977). In 
onset of menstrual flow is more easily 
addition, the 
equated across 
subjects than is the premenstruum, and it is close in time 
to the experience of premenstrual symptoms which aids in 
reliability of ratings. The MDQ provided a score for the 
Behavioral Change symptom cluster and a score for the 
Negative Affect symptom cluster. 
In addition to the daily self-assessment and the MDQ 
measures which specifically assessed the targeted symptoms, 
each subject also completed the MSQ (Chesney & Taste, 1975) 
three times to provide a global measure of change which is 
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not directly tied to the criteria for inclusion in the 
study. The MSQ consists of 24 statements which describe 
symptoms associated with the menstrual period. Twelve of 
the statements are associated with congestive dysmenorrhea 
(premenstrual symptoms), and 12 are associated with 
spasmodic dysmenorrhea (menstrual symptoms). The MSQ, 
usually scored for frequency of symptom occurrence, was 
scored for the purpose of this study for severity of 
symptoms during the present/most recent premenstruum. 
Severity was rated on a Likert-type scale ranging from 1 = 
not at all to 5 = severe experience of the symptom (Appendix 
G). Sums of the subject's severity ratings on the 
congestive (premenstrual) items were compared in order to 
have a general measure of change in symptom severity across 
the three menstrual cycles included in the study. The MSQ 
was completed with the MDQ within one week after the onset 
of each of each subject's three menstrual periods. 
Therefore, each subject had a total of seven scores for 
each premenstruum; four daily self-assessment scores, two 
MDQ targeted symptom cluster scores, and one MSQ congestive 
symptom global score (Table 2). 
Each 
programs 
designed 
Treatment 
subject participated in one of two treatment 
(or was in the control group): One program was 
to address the symptom of depressed mood and the 
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other was designed to address the symptom of behavior change 
or decreased activity level. A modified version of Beck's 
(1979) depression trea~~ent (see Appendix H) was used as the 
depression intervention. A modified version of Fordyce's 
(1976) operant program for behavior control (see Appendix I) 
was used as the behavior change/activity level intervention. 
Beck's cognitive therapy of depression (Beck, Rush, 
Shaw, & Emery, 1979) was modified for application within 
four treatment sessions (see Appendix H). The treatment 
procedure involved restructuring of negative thought 
patterns. This method of restructuring negative thought 
patterns takes two forms: (a) demonstrating the falsity of 
the beliefs through empirical hypothesis testing and (b) 
disputing the negative beliefs through logical arguments. 
Both forms of restructuring negative thoughts were 
explained, demonstrated and, practiced within the treatment 
sessions. Subjects received instructions to practice the 
technique daily and to apply it during the premenstruum. 
Fordyce's operant intervention for pain behavior 
control (Fordyce, 1976) was modified for use with decreased 
activity level and behavior change during the premenstruum 
and for application within four sessions (see Appendix I). 
The treatment procedure involved learning to increase 
desired/required activity level through the application of 
operant principles and the use of scheduling. Increased 
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required activity level is accomplished through 
identification of potential rewards and scheduling these 
rewards contingent upon completion of the re~~ired activity 
(see Appendix I-4). Both parts of this operant program for 
behavior control were explained, demonstrated, and practiced 
within the treatment sessions. Subjects received 
instructions to practice the technique daily and to apply it 
during the premenstruum. 
The subjects who had been randomly assigned to the 
control group were told that they needed to collect daily 
assessment data for three cycles. After completing the data 
collection, they would then have the opportunity to 
participate in four experimental treatment sessions 
conducted by the principal investigator. Following data 
collection, control subjects were debriefed. The debriefing 
involved an explanation of the experimental hypothesis and 
the use of and need for control groups (see Appendix J). 
Subjects were then presented with the rationales for both 
treatments and were given the opportunity to choose the 
treatment procedure they would prefer. Eight control 
subjects chose to terminate their involvement prior to 
participating in one of the treatments; two chose the 
cognitive therapy of depression; and two chose the operant 
intervention for behavior control. 
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Each of the interventions was administered within 14 to 
20 days of the onset of the first menstrual flow in four 
sessions. The final session occurred at least one week 
prior to the onset of the subjects' second menstrual flow. 
The interventions were individually administered by the 
principal investigator and one other female graduate student 
in psychology who served as therapists. The principal 
investigator served as a therapist to five of the subjects 
of the in the behavior change treatment group and seven 
subjects in the depression treatment group; the 
therapist saw seven subjects in the behavior 
treatment group 
treatment group. 
other 
change 
and five subjects in the depression 
The assignment of subjects to therapists 
was based upon compatibility of schedules and balance across 
therapists of the two treatment groups. The principal 
investigator provided the interventions to all of the 
control subjects who participated in treatment. The 
therapists were trained in the administration of the 
treatment packages. 
Therapist Training and Monitoring 
Each therapist participated in four hours of training 
with the two treatment packages. The training involved 
review of the components of each treatment package and 
rehearsal of administration of each of the eight treatment 
sessions (see Appendices H & I). The training also involved 
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clarification and rehearsal of any aspect of the sessions 
that the therapists felt they needed to practice further. 
Each therapist 
tapes were reviewed 
ensure consistency 
interventions. As a 
was periodically audiotaped. These 
by the author and her supervisor to 
in the administration of the 
check on the independent variable, 
tapes of 11 percent of the sessions were reviewed by both 
the principal investigator and her supervisor. Each 
identified each taped session as the "behavior change" or 
"depression" treatment. One hundred percent agreement was 
demonstrated suggesting the interventions were identifiably 
different. 
Procedure 
Each subject participated in a screening interview 
during which she completed the MDQ, was determined to be 
eligible for treatment, and was randomly assigned to a 
treatment group. At that time, she made her data deposit, 
received instructions regarding data collection, and began 
data collection. She completed daily rating sheets for at 
least four days prior to the onset of her first (baseline) 
menstrual period. She continued to self-record daily 
throughout the duration of her participation in the study. 
Within one week after the onset of her baseline menstrual 
period, each subject contacted the principal investigator 
and completed the MDQ and the MSQ. All subjects except the 
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twelve control subjects were then assigned to a therapist 
and participated in four treatment sessions within the next 
14 to 20 days. Within one week after the onset of her 
second menstrual period, each subject again contacted the 
principal investigator and completed the MDQ and the MSQ. 
Within one week after the onset of her third (follow-up) 
period, each subject completed her last MDQ and MSQ for this 
study. At that time, each subject also received a list of 
referrals for further treatment, if she so desired. 
CHAPTER III 
RESULTS 
Exoerimental Design 
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A 3 (treatments) by 3 (measurement occasions) 
experimental design was used. The between-subjects factor 
was treatments (cognitive therapy of depression, operant 
techniques for behavioral control, and no treatment 
control). Subjects were nested in treatment. The within-
subjects factor was measurement occasions or time. 
Data were collected for three premenstrual time 
periods: pretreatment or baseline, posttreatment, and 
follow-up. Discrete scores for the three premenstrual time 
periods assessed in the study were derived by summing each 
subject's daily ratings across the four days immediately 
preceding the onset of menses. The sums of the ratings for 
the four days prior to the onset of the baseline menstrual 
period, the sums of the ratings for the four days prior to 
the onset of the posttreatment menstrual period, and the 
sums of the ratings for the four days prior to the onset of 
the third (follow-up) menstrual period provided the scores 
for the measures of depression and behavior change: 
subjective depression rating, crying episode frequency, 
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subjective behavior change rating, and amount of time 
resting. An additional measure of each targeted symptom 
cluster was provided by the negative affect and behavioral 
change symptom cluster scores derived from the Menstrual 
Distress Questionnaire (MDQ) completed by each subject for 
each premenstruum during the study. A seventh dependent 
measure 
Symptom 
measure 
consisted of a score derived from the 
Questionnaire (MSQ) which provided an 
of change not directly related to the 
symptom clusters. Decreasing scores on all 
Menstrual 
overall 
targeted 
measures 
indicate improvement, i.e., lower scores reflect endorsement 
of less symptom severity or fewer symptoms. 
The results of the analyses are presented in the 
context of the experimental questions to which they pertain. 
The central question was "did the treatments differentially 
affect the types of symptoms?" This question is further 
divided into the specific differential effects of treatment 
on the depression symptom measures and on the behavior 
change symptom measures. The second question was "did the 
treatments differentially affect overall PMS complaints?" 
Did Treatments Differentially Affect 
Types of Symotoms? 
Insofar as the experimental hypothesis was concerned 
with the differential effect of the treatments on the 
specific targeted symptom clusters, it was necessary to 
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analyze the impact of the treatments on the specific symptom 
clusters separately. Therefore, two separate analyses were 
conducted; 
depression 
one on the dependent variables used to measure 
and one on the dependent variables used to 
measure behavior change. Thus, one multivariate analysis of 
variance (MANOVA) with Groups as the between-subjects 
factor, Time as the within-subjects factor, and three 
·dependent measures (the MDQ negative affect symptom cluster 
measure, the subjective daily depression rating, and crying 
episode frequency) was used to assess the impact of the 
treatments on the depression symptom cluster; and one MANOVA 
with Groups as the between-subjects factor, Time as the 
within-subjects factor, and three dependent measures (the 
MDQ behavioral change symptom cluster measure, the 
subjective daily behavior change rating, and time resting) 
was used to assess the impact of treatments on the behavior 
change symptom cluster. These results are discussed in 
relation to the specific experimental questions to which 
they pertain. 
Did the Treatments Differentially Affect the 
Depression Measures? 
The depression measures included the MDQ negative 
affect cluster measure, the daily depression rating measure, 
and the crying frequency measure. The depression symptom 
cluster MANOVA revealed no significant effects for Group, 
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Wilks Lambda = • 91' which is equivalent to £:(6,62)= .53, 
£>.05; Time, Wilks Lambda = .71, which is equivalent to 
f(6,28)= 1. 93' E.>-05; or the interaction of Group by Time, 
Wilks Lambda = .55, which is equivalent to £:_(12,56)= 1. 61' 
£>.05 (Table 3). 
Consistent with the MANOVA results, none of the ANOVAs 
on these measures showed the predicted significant group by 
time interaction. Only the ANOVA on the MDQ negative affect 
symptom cluster showed any significant effect. There was a 
significant main effect for Time, £:_(2,66)=4.79, E,<.05. There 
was no significant effect for Group, £:(2,33)= .41, £>.05, 
and no significant effect for the interaction of Group by 
Time, £:_(4,66)=1.32, E,>.05 (Table 4; Figure 1; Figure 1 and 
all subsequent figures are in Appendix K). The Newman-Keuls 
post hoc comparison among the means comprising the 
significant effect for Time (Table 5) revealed significant 
differences between the baseline time period and the post-
treatment time period and between the baseline time period 
and the follow-up time period. The difference between the 
means of the posttreatment and follow-up time periods were 
not significant. 
There were no significant effects demonstrated in the 
analyses of the daily depression rating measure (Table 6; 
Figure 2). 
f(2,33)=.39, 
There were no significant effects for Group, 
_E>.05, Time, £(2,66)=.69, £>.05, or the 
interaction, f(4,66)=.89, £>.05. 
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There were no significant effects demonstrated in the 
analyses of the crying frequency measure (Table 7; Figure 
3) • There were no significant effects for Group, 
f_(2,33)=1.06, £>.05, Time, ~(2,66)=.38, £>.05, or the 
interaction, ~(4,66)=2.02, £>.05. 
These results offer no support for the prediction that 
the treatments would differentially affect the depression 
measures. 
Did the Treatments Differentially Affect the Behavior 
Change Measures? 
The behavior change measures included the 
behavioral change symptom cluster measure, the 
MDQ 
daily 
behavior 
measure. 
change rating 
Similarly to 
measure, and 
the MANOVA 
the time 
performed 
resting 
on the 
depression symptom measures, the behavior change symptom 
cluster MANOVA also revealed no significant effects for 
Group, Wilks Lambda = .95, which is equivalent to 
f(6,62)= .28, £>.05 or the interaction of Group by Time, 
Wilks Lambda= .66, which is equivalent to f(l2,56)= 1.10, 
£>.05. The behavior change symptom cluster MANOVA, however, 
did reveal a significant effect for Time, Wilks Lambda 
= .59, which is equivalent to ~(6,28)= 3.21, £<.05 (Table 
8) • 
Similar to the findings ~n the depression measure 
analyses, none of the ANOVAs performed on the behavior 
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change measures showed the predicted significant group by 
time interaction. There was, however, a significant effect 
on the MDQ behavioral change symptom cluster measure, 
consistent with the results of the MANOVA on the behavior 
change symptom measures. This was a main effect for Time, 
K(2,66)=4.25, E<-05. There was no significant effect for 
Group, K(2,33)=.71, £>.05, and no significant effect for the 
interaction of Group by Time, K(4,66)=.68, £>.05 (Table 9; 
Figure 4). The Newman-Keuls post hoc comparison among the 
means comprising the significant effect for Time (Table 10) 
revealed significant differences between the baseline time 
period and the posttreatment time period and between the 
baseline time period and the follow-up time period. The 
difference between the means of the posttreatment and 
follow-up time periods were not significant. 
There was also a significant effect on the daily 
behavior change rating measure, a main effect for Time, 
f(2,66)=6.43, £<.01. There was no significant effect for 
Group, K(2,33)=.39, £>.05, and no significant effect for the 
interaction of Group by Time, f(4,66)=2.27, £>.05 (Table 11; 
Figure 5). The Newman-Keuls post hoc comparison among the 
means comprising the significant effect for Time (Table 12) 
revealed significant differences between the baseline time 
period and the posttreatment time period and between the 
baseline time period and the follow-up time period. The 
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difference between the means of the posttreatment and 
follow-up time periods were not significant. 
There were no significant effects demonstrated in the 
analyses of the time resting measure (Table 13; Figure 6). 
There were no significant effects for Group, f(2,33)= .11, 
£>.05, Time, f(2,66)= 1.00, £>.05, or the interaction, 
f(4,66)= .02, £>.05. 
These results offer no support for the prediction that 
the behavior change treatment would differentially affect 
the behavior change measures. 
In general, the multivariate analyses and the 
univariate analyses demonstrate no support for the treatment 
validity hypothesis that the treatments would differentially 
affect the type of symptoms. 
Did the Treatments Differentially Affect 
Overall PMS Complaints? 
The congestive scores on the MSQ were included as an 
overall measure of PMS symptom complaints. The congestive 
items on the MSQ are those items which pertain to symptoms 
occurring prior to the onset of the·menstrual flow and, 
thus, are analogous to premenstrual symptoms. The ANOVA 
performed on the MSQ measure showed no differential effect 
by treatment group. 
There was one significant finding on the MSQ measure. 
It was a significant main effect for Time, f(2,66)=7.52, 
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£<.01. There was no significant effect for Group, 
f(2,33)=.06, £>.05, and no significant effect for the 
interaction of Group by Time, f(4,66)=1.77, £>.05 (Table 14; 
Figure 7). The Newman~Keuls post hoc comparison among the 
means comprising the significant effect for Time (Table 15) 
revealed significant differences between the baseline 
period and the posttreatment time period and between 
baseline time period and the follow-up time period. 
difference between the means of the posttreatment 
follow-up time periods were not significant. 
time 
the 
The 
and 
In general, these results offer no support for the 
hypothesis that the treatments would differentially affect 
an overall measure of PMS complaints. 
In summary, there was no indication in the multivariate 
or univariate analyses of a differential effect by 
treatments on either type of symptom or the overall measure 
of PMS complaints. The only significant effects were for 
Time on the MDQ measure of depression and behavior change, 
on the daily behavior change rating, and on the MSQ overall 
measure of PMS symptom complaints. 
Correlation Among Dependent Measures 
The ·degree of correlation among the seven dependent 
measures is of interest for a number of reasons. The 
measures were concomitantly collected and are presumed to be 
measuring various aspects of the sa~e problem, PMS. Pearson 
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correlation coefficients were computed for the pretreatment 
or baseline scores on all seven measures. The degree of 
correlation among the measures is discussed in relation to 
the aspects of PMS (depression symptom cluster, behavior 
change symptom cluster, overall PMS complaints) they were 
presumed to be assessing. The correlation matrix for all 
measures is presented in Table 16. 
Correlation Among Depression Measures 
The three measures used to assess the depression 
symptoms were the MDQ negative affect symptom cluster, the 
daily depression rating, and crying frequency. The MDQ 
negative affect symptom cluster measure showed a significant 
correlation with the daily depression rating, r= .42, and 
with the crying frequency measure, r= .47, for both £<.01. 
The daily depression rating and crying frequency measures 
also showed a significant correlation, r= .46, £<.01. 
Correlation Among Behavior Chanqe Measures 
The three measures used to assess behavior change were 
the MDQ behavioral change symptom cluster measure, the daily 
behavior change rating, and time resting. The MDQ 
behavioral change symptom cluster measure showed no 
significant correlation with the daily behavior change 
rating, r= .23, or time resting, r= -.06, for both £>.05. 
The daily behavior change rating and time resting measures, 
however, showed a significant correlation, r= .32, £<.05. 
Correlation Between Depression and Behavior 
Change Measures 
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The MDQ negative affect and behavioral change symptom 
cluster measures showed a significant correlation, r= .55, 
£<.01. The daily depression and behavior change ratings 
also showed a significant correlation, r= .62, £<.01. The 
objective measures, crying frequency and time resting, 
however, showed no significant correlation, r= .00, £>.05. 
The preceding three comparisons are the logical associations 
which might be expected among the measures; the two measures 
taken from the MDQ questionnaire were compared, the two 
subjective measures taken from the daily rating form were 
compared, and the two measures considered to be the 
objective measures were compared. There was only one other 
significant correlation among the measures compared across 
targeted symptom clusters: the MDQ negative affect measure 
showed a significant correlation with the daily behavior 
change rating, r= .34, £<.05. There was no significant 
correlation between the MDQ negative affect measure and the 
time resting measure, r= -.10, £>.05. The MDQ behavioral 
change measure showed no significant correlation with the 
daily depression rating, r= .24, or with the crying 
frequency measure, r= .23, for both £>.05. 
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Correlation Between the Overall Measure of PMS -- ---
and the Symptom Cluster Measures 
The MSQ was the overall measure of PMS. It showed 
significant correlations with both the MDQ negative affect 
measure, r= .37, £<.05, and the MDQ behavioral change 
measure, r= .43, £<.01. The MSQ also showed a significant 
correlation with the daily depression rating, r= .33, £<.05. 
There were no other significant correlations~ daily behavior 
change rating, r= .19, crying frequency measure, r= .14, and 
time resting measure, r= .24, for all £>.05. 
Individual Subject Data and 
Nonparametric Sign Tests 
To examine the influence of individual subjects' 
responses on the apparent change over time and to assess 
the relative number of subjects improved in each group, 
nonparametric sign tests (Siegel, 1956) were performed on 
the frequency of subjects improving or worsening from 
baseline. Improving or worsening were defined as a change 
of at least plus or minus one unit of measurement relative 
to the baseline score. The analyses pertaining to the 
overall change (change over time) are presented first, and 
then the analyses reflecting changes within individual 
treatment groups are presented. 
Change ~ Time Sign Tests 
Nonparametric sign tests were performed on the number 
of subjects who changed from baseline to posttreatment and 
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from baseline to follow-up for each dependent measure (Table 
17). Consistent with the results of the ANOVAs, the sign 
tests on the MSQ overall measure of PMS were significant. 
From baseline to posttreatment, 35 subjects' scores changed: 
eleven subjects worsened and 24 subjects improved (£<.05). 
From baseline to follow-up, 33 subjects' scores changed: 8 
subjects worsened, and 25 improved (£<.01) (Figures 8-10). 
On the MDQ negative affect symptom cluster measure, the 
sign test effects were weak at best. Weak, throughout this 
discussion, refers to significance levels greater than 
E>-05. From baseline to posttreatment, 34 subjects' scores 
changed: 11 subjects worsened, and 23 improved (E<.lO). 
From baseline to follow-up, 33 subjects' scores changed: 13 
subjects worsened, and 20 improved (E>-25) (Figures 11-13). 
On the MDQ behavioral change symptom cluster, the sign 
test effects were also relatively weak. From baseline to 
posttreatment, 35 subjects' scores changed: 13 subjects 
worsened, and 22 improved (£<.25). From baseline to follow-
up, 32 subjects' scores changed: 9 worsened, and 23 improved 
(£<.05) (Figures 14-16). 
The daily behavior change rating showed effects on the 
sign tests consistent with the ANOVAs. From baseline to 
posttreatment, 36 subjects' scores changed: 11 worsened, and 
25 improved (£<.05). From baseline to follow-up, 36 
subjects' scores changed: 11 worsened, and 25 improved 
97 
(£<.05) (Figures 17-19). The sign tests on the measures 
which did not show the significant change over time on the 
ANOVAs (the daily depression measure, crying frequency, and 
time resting) were consistent with those analyses; none of 
the sign tests showed a significant effect (Table 17). 
Individual Treatment Group Sign Tests 
Nonparametric sign tests were performed on the number 
of subjects in each treatment group (depression treatment, 
behavior change treatment, and control) who changed from 
baseline to posttreatment and from baseline to follow-up for 
each dependent measure (Table 17). Only two dependent 
measures showed significant effects on the sign test in 
individual treatment groups; these are the MSQ overall 
measure of PMS (Figures 8-10) and the daily behavior change 
rating (Figures 17-19). Both showed significant effects at 
posttreatment for the behavior change treatment group and 
significant effects at follow-up for the depression 
treatment group; for all four effects, 12 subjects' scores 
changed: two worsened, and 10 improved (£<.05). 
Weaker effects were evident in four dependent measures: 
the MSQ overall measure, the MDQ negative affect symptom 
cluster, the MDQ behavioral change symptom cluster, and the 
daily depression rating. In addition to the significant 
effects on the MSQ overall measure, weaker effects were 
revealed at posttreatment for the depression treatment group 
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and at follow-up for the behavior change treatment group; 
for both, three subjects worsened, and nine improved 
(£<.25). The MDQ negative affect cluster and the daily 
depression rating cluster show the same pattern for the weak 
effect as demonstrated for the significant sign test 
effects. The effect was for the behavior change treatment 
group at posttreatment and for the depression treatment 
group at follow-up; in each case, three subjects worsened 
(£<.25). The same pattern of effects was evident on the MDQ 
behavioral change symptom cluster with the addition of an 
effect for the behavior change treatment group at follow-up, 
in which only nine subjects' scores changed, with one 
worsening (£<.25). 
Thus, the depression treatment group showed significant 
or weak effects on five dependent measures at follow-up and 
the behavior change treatment group showed significant or 
weak effects on five dependent measures at posttreatment. 
In contrast, the control group showed essentially equal 
numbers of subjects' scores worsening and improving on all 
measures at posttreatment and follow-up (£>.25) (Table 17). 
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CHAPTER IV 
DISCUSSION 
The main goal of the present study was to test the 
hypothesis that matching specific treatments to the symptom 
clusters of depression and behavior change within 
premenstrual syndrome (PMS) would enhance the effectiveness 
of treatment. This is the treatment validity hypothesis 
that targeting specific symptom clusters within a disorder 
will improve treatment effectiveness. Thus, this study 
assessed the treatment validity of identifying depression 
and behavior change symptoms within the general 
classification of PMS. 
was that symptoms 
The prediction regarding this issue 
matched to the specific treatment 
procedure used would change. A modified version of Beck's 
cognitive therapy for depression was expected to decrease 
scores on the three measures of depression: (a) ratings of 
symptoms included on the negative affect symptom cluster of 
the Menstrual Distress Questionnaire (MDQ), (b) premenstrual 
daily ratings of depression, and (c) reported premenstrual 
frequency of crying. A modified version of Fordyce's 
operant 
expected 
behavior 
intervention for control of pain behavior was 
to decrease scores on the three measures of 
change: (a) ratings of symptoms included on the 
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MDQ behavior-al change symptom cluster, {b) premenstrual 
daily ratings of behavior change, and {c) reported 
premenstrual time resting. The results of the multivariate 
and univariate analyses did not support this prediction. 
This study also addressed the question: does targeting 
a specific symptom {depression or behavior change) have more 
impact on changing PMS as a whole, as measured by the 
Menstrual Symptom Questionnaire {MSQ)? In other words, in 
comparison to a no-treatment control group, on a general 
measure of premenstrual symptoms, is it more effective to 
target depression symptoms of PMS or behavior change 
symptoms? The prediction regarding this question was that 
one treatment {Beck~s cognitive therapy of depression or 
Fordyce~s operant intervention for behavior control) and its 
associated target symptom {depression or behavior change) 
would be more effective than both targeting the other 
symptom and the control procedure, in reducing the scores on 
the MSQ overall measure of PMS. The univariate analysis of 
the MSQ overall measure revealed no such differential 
treatment effect. 
The results of the analyses pertaining to both 
questions are discussed below. The implications of the 
various analyses for the treatment validity hypothesis are 
addressed, followed by a discussion of the overall treatment 
effects on PMS. Subsequently, the limitations of the 
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present study are summarized, directions for future research 
are suggested, and conclusions are offered. 
Treatment Validity Hypothesis 
The treatment validity hypothesis in this study was that 
identifying the specific target behaviors of depression and 
behavior change and matching the the cognitive therapy of 
depression and operant intervention for behavior control to 
them, respectively, would enhance treatment outcome. This 
hypothesis was tested using two MANOVA's, one on the three 
depression measures and one on the three behavior change 
measures. Differential effects for treatment group by time 
period were expected in support of the hypothesis. The 
outcome of these analyses are reviewed below, 
discussion of the potential impact of the 
followed by a 
choice of 
treatment and the choice of symptom cluster on the findings. 
Outcome 
The treatment validity hypothesis predicted that the 
MANOVA's would show significant effects for the treatment 
group by time period interactions. Specifically, the MANOVA 
on the three depression measures was expected to reveal 
significantly greater improvement by the depression 
treatment group. The depression treatment group was 
expected to improve over time relative to the no-treatment 
control group and the behavior change treatment group. 
There was no significant interaction effect. Thus, there 
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was no evidence of the treatment validity of targeting the 
depression symptom cluster within PMS and matching a 
cognitive therapy of depression to it. Similarly, the 
MANOVA on the three behavior change measures was expected to 
reveal significantly greater improvement by the behavior 
change treatment group. The behavior change treatment group 
was expected to improve over time relative to the no-
treatment control group and the depression treatment group. 
There was no significant interaction effect. Thus, there 
was no evidence of the treatment validity of targeting the 
behavior change symptom cluster within PMS and matching an 
operant intervention for behavior control to it. 
The nonparametric analyses of the number of subjects in 
each individual treatment group who changed from baseline to 
posttreatment and from baseline to follow-up may suggest a 
different conclusion. There were differential significant 
effects by the treatment groups on two of the dependent 
measures (the MSQ and the daily behavior change rating). At 
posttreatment, the behavior change treatment group shows 
significantly more subjects improved than worsened; the 
depression treatment group and the control group do not show 
this significant effect. At follow-up, however, the 
depression treatment group shows significantly more subjects 
improved than worsened; the behavior change treatment group 
and the control group do not show this significant effect. 
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These differential effects do not show a clear relationship 
between specific treatment procedures and specific symptom 
clusters, but do suggest differential effects of the two 
interventions. These differential effects seem to be 
related to how quickly or how long the intervention will be 
effective. It appears that while the behavior change 
intervention results in significantly more subjects 
improving at posttreatment, this improvement does not last 
through follow-up; and it appears that while the depression 
treatment does not result in significantly more subjects 
improving at posttreatment, it does at follow-up. These are 
weaker findings than the parametric statistics offer, but 
they do suggest differential effects of the two 
interventions on two of the dependent measures. These 
effects, however, do not seem to differentiate in terms of 
the specific symptom clusters. It appears, therefore, that 
there is little empirical support for the experimental 
hypothesis that the treatments would differentially effect 
the symptom clusters to which they were matched. 
There are three potentially confounding factors which 
may have bearing on the nonsignificant findings. The 
experimental hypothesis states that the identification of a 
specific symptom cluster and matching a treatment to it will 
enhance treatment outcome. The factors which may result in 
nonsignificant findings are the treatment procedures chosen, 
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the target behaviors chosen, and the match between the 
treatments and the targets. The assessment of the 
appropriateness of the match requires that the 
appropriateness of the treatments and targets be previously 
established. Discussions of the choice of treatment and the 
choice of the cluster, in the present study, follow. 
Choice of Treatment 
The effectiveness of the chosen treatment procedures 
with premenstrual symptoms has not been directly 
demonstrated. The modified form of Fordyce's (1976) operant 
intervention for pain behavior control was assumed to be 
effective with PMS symptoms based upon research with other 
physical disorders that limited activity. Similarly, the 
modified form of Beck and his colleagues' (1979) cognitive 
therapy of depression was assumed to be effective with PMS 
symptoms based upon research with depression in general. It 
may be that these assumptions were incorrect, and that the 
treatment procedures were ineffective with premenstrual 
symptoms. The problem, then, may lie with the specific 
treatments selected, rather than in the match between 
specific 
Targeting 
symptom clusters and specific 
the specific symptom clusters with 
treatments. 
treatments 
that have been demonstrated to be effective for premenstrual 
symptoms of behavior change or depression may well enhance 
treatment outcome. 
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Treatment validity is considered to be "based upon a 
nexus of assessment devices, theoretical distinctions, and 
treatment approaches" (Hayes et al., in press, page 19). 
Each of these three aspects is necessary in order to 
demonstrate treatment validity. The absence or 
incorrectness of any one aspect prevents treatment validity 
from being established. It is, therefore, inherent in the 
treatment validity methodologies that the treatment 
procedures used be effective with the disorder in question. 
Correct assessment and effective treatment are both required 
in order to address the question of the match between the 
two. Treatment validity demonstrations are always dependent 
upon the effectiveness of the treatments. 
It cannot be said based upon the results of the 
parametric statistical analyses tha~ the treatments were any 
more effective than the control procedure. There were 
significant improvements across time on four of the seven 
dependent measures; there was no significant difference 
among the three treatment groups: depression treatment, 
behavior change treatment, and control procedure. 
Nonparametric analyses of the number of individuals 
whose scores changed from baseline to posttreatment and 
from baseline to follow-up, however, suggest that there may 
indeed have been a greater effect by the experimental 
treatment procedures than the control procedure. A nuober 
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of the dependent measures showed significantly more treated 
subjects (at various levels of significance) improved than 
worsened in the depression and behavior change treatment 
groups. The 
significant 
the number 
control group subjects, however, showed no 
differences between the number who improved and 
who worsened. These data do suggest greater 
effectiveness (more subjects improved) in the experimental 
treatment groups than in the control group. Unfortunately, 
these differences appear to have been too weak to result in 
demonstrable significance on parametric statistical 
analyses. The issue of power is discussed later. In light 
of the relative weakness of these findings, ineffectiveness 
of the treatment procedures still warrants discussion. 
If the treatment procedures were ineffective (that is, 
no more effective than a control procedure) with 
premenstrual symptoms, reasons for their ineffectiveness 
merit discussion. The extension of the Fordyce (1976) 
operant intervention, usually used to control pain behavior, 
to the inactivity associated with premenstrual complaints 
appears logically consistent, as does the extension of the 
Beck et al. (1979) cognitive therapy for depression to the 
negative affective changes 
complaints. It is clear, 
associated with premenstrual 
however, that logic does not 
guarantee effectiveness. The effectiveness of a treatment 
procedure is a matter for experimental demonstration. The 
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present study may provide one instance of the experimental 
ineffectiveness of the treatment procedures for PMS 
symptoms, despite the nonparametric findings. 
In addition, there are points of logic which may be 
argued. The effectiveness of Fordyce-like procedures has 
been primarily demonstrated with chronic pain patients 
(Anderson et al., 1977; Cairns et al., 1976; Fordyce et al., 
1973). While the decreased activity level reported by women 
who complain of PMS appears to be the same as the inactivity 
reported in chronic pain patients, it may well be different 
in a variety of ways essential to treatment effectiveness. 
Similarly, the effectiveness of Beck-like procedures has 
primarily been demonstrated with pervasive, chronic, and 
endogenous depression (Beck et al., 1979). While the 
depression reported by women with PMS appears to be the same 
as the depression reported by individuals suffering with 
more pervasive depression, it may well be different in a 
variety of ways essential to treatment effectiveness. 
An additional issue pertaining to treatment 
effectiveness warrants attention. In order for a treatment 
procedure to be effective, it must be implemented. When the 
procedure is patient applied, the compliance and cooperation 
of the patient are required. If the women in the present 
study did not implement the procedures, they had little 
chance of being effective. In the present study, it is 
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likely that the subjects were implementing the procedures 
during their posttreatment premenstrual days as the post-
treatment premenstruum usually occurred within one week of 
the completion of the treatment program. During the 
treatment program (four visits within two weeks), subjects 
in the behavior change treatment group completed practice 
activity schedules, and subjects in the depression treatment 
group used homework forms for daily practice of the 
procedure. These practice sheets were reviewed by the 
therapist during the treatment sessions. It is, of course, 
possible that the subjects lied regarding practice, but it 
would have required more effort in filling out the homework 
sheets. 
There is less certainty that subjects actually 
implemented the treatment procedures for the follow-up 
premenstrual days; subjects were merely instructed to 
continue daily practice of their procedure throughout the 
remainder of their participation in the study. There is, in 
fact, anecdotal evidence suggesting that subjects in the 
behavior change treatment group were not applying the 
treatment technique during the follow-up premenstruum. A 
number of women in the behavior change treatment group 
voluntarily reported noncompliance to the author. At the 
final data collection visit, they admitted that during 
their most recent premenstruum they had not implemented the 
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procedure they had been taught. This would essentially 
result in a return to baseline for an effective treatment 
technique. In comparison, none of the women in depression 
treatment group made such reports. There was, however, no 
parametric statistical evidence of such a return to baseline 
distinguishing the behavior change treatment group from the 
other groups. The nonparametric sign tests performed on the 
individual treatment group data, however, show a pattern of 
results which may support this return to baseline evidence 
of noncompliance. The two dependent measures showing 
significant effects on the sign tests (the MSQ and the daily 
behavior change rating) both showed a significant effect at 
posttreatment for the behavior change treatment group, but 
no significant effect at follow-up. This may be interpreted 
as a return to baseline. 
The variety of factors which may play into 
noncompliance (divulged or not) were not elucidated by the 
present study, but certainly merit further investigation. 
Methodologically, it would be better to ensure through some 
form of check on homework compliance that the treatment 
procedures were indeed implemented during the posttreatment 
and follow-up premenstruum. 
The behavior change treatment group showed improvement 
at posttreatment and not follow-up on the nonparametric 
analyses. It appears that the lack of effectiveness of the 
behavior change 
noncompliance. 
sign tests for 
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treatment may be accounted for by 
The pattern of results on the nonparametric 
the depression treatment group show the 
reverse of the behavior change treatment group results. The 
depression treatment group data show significant improvement 
at follow-up, and not at post-treatment. This may be 
accounted for by the amount of practice required for 
effective application of the procedure. It may take time 
(more than one menstrual cycle) for subjects to learn how to 
effectively apply the cognitive therapy for depression. The 
length of practice and assessment may influence the apparent 
effectiveness of the depression treatment procedure. An 
investigation of the amount of practice necessary to 
effectively utilize the procedure would elucidate this 
suggested interpretation of these findings. 
One alternative explanation of the ineffectiveness of 
previously effective treatment procedures concerns 
timing of administration of the treatment procedures. 
the 
Both 
treatments in the present study were administered within two 
weeks following the onset of each subject's baseline menses. 
This is technically considered an asymptomatic time period 
(Dalton, 1979). Therefore, treatment was administered 
during a symptom-free time period, and depended upon 
generalization of the intervention techniques to a 
symptomatic time period. It could be argued that it is 
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ineffective to teach a skill designed to cope with symptoms 
during an asymptomatic time period. 
Other effective treatment procedures, however, also 
teach skills during asymptomatic time periods for 
application when symptoms arise. For example, systematic 
desensitization is taught and practiced before the phobic 
scene or object is actually encountered. In systematic 
desensitization, the encounter with phobic scene is 
rehearsed imaginally; similarly, application of the coping 
skills taught in the present study were practiced while 
imagining that it was the premenstruum (Appendices Hand I). 
Relaxation training provides another example of training of 
a coping technique prior to actual experience of a symptom. 
Relaxation exercises are taught prior to facing a painful or 
stressful experience in order to prepare for it. 
Similarly, Lamaze breathing exercises for childbirth are 
taught and practiced prior to delivery in order to prepare 
the woman with the skills to handle that situation. The 
intervention techniques taught in the present study were 
also taught prior to the premenstrual symptoms in order to 
prepare for them. 
In addition, with all these interventions it would seem 
that training might be less effective if it were to occur 
initially when the symptoms were in full force. The 
theoretical underpinnings of systematic desensitization as 
well as the 
suggest that 
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clinical experience with phobic responses 
training in the face of the phobic stimulus 
will not be particularly effective. Certainly, the 
introduction to Lamaze breathing exercises during labor is 
less effective than having learned the skills prior to that 
time. With PMS, the decreased activity level and depression 
experienced during the premenstruum are antithetical to the 
skills necessary for acquisition of a new coping response 
(Cassara, 1984). 
It may be that practice in applying the techniques in 
response to the symptoms in question may enhance their 
effectiveness, but the initial training appears to require 
training prior to the symptomatic time period. The relative 
merits of training during symptom flare-ups versus prior to 
them could certainly be empirically investigated. Despite 
the evidence generalized from other treatments and other 
disorders, it may be necessary with PMS to learn and/or 
practice the application of treatment procedures during the 
experience of symptoms. 
Choice of Cluster 
In addition to the choice of the treatments that may 
have been no more effective than the no-treatment control, 
the choice of the specific cluster may have contributed to 
nonsignificant findings. It is possible that the specific 
clusters identified, depression and behavior change, are 
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nonessential in the treatment of PMS. The symptom clusters 
targeted in the present study were chosen for experimentally 
pragmatic reasons: (a) consi3tency with previously 
identified clusters in PMS, and (b) potential 
responsiveness to noninvasive psychological interventions. 
Guidelines for selecting from among alternative 
socially acceptable target behaviors have been proposed and 
summarized by Nelson and her colleagues (Nelson & Barlow, 
1981; Nelson & Hayes, 1979). These guidelines are, by no 
means, rigid rules; they do, however, offer a point of 
departure for subsequent empirical demonstrations of the 
treatment validity of target behavior selection. Some of 
these guidelines may have been violated by the selection of 
the specific symptom clusters for targeting within the 
present study. While the present study provides no 
empirical evidence for such violations, they may have 
bearing on nonsignificant or nonsupportive findings for the 
treatment validity hypothesis. 
The first guideline recommends targeting the most 
irritating symptom first (Tharp & Wetzel, 1969); it is 
likely that the behavior change symptoms were not the most 
irritating for the women in the present study. Targeting 
the behavioral change symptom cluster may have violated 
this guideline. All of the participants reported both 
negative affect and behavior change symptoms of at least 
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mild severity. In addition, only eight of the 36 subjects 
reported that behavior change symptoms were more bothersome 
than negative affect symptoms, based upon percentage of the 
total possible symptom severity score on each symptom 
cluster (Table 18). Each subject's screening assessment 
scores on the MDQ negative affect and behavioral change 
symptom clusters were calculated as percentages of the total 
possible score on each cluster (negative affect: 48, and 
behavioral change: 30). These percentages make up Table 18. 
Most subjects have higher negative affect percentage scores 
than behavioral change percentage scores. 
Another guideline which may have been violated suggests 
targeting responses at the beginning of a response chain 
(Angle, Hay, Hay, & Ellinwood, 1977); it is possible that 
either the negative affect or behavior change symptoms 
endorsed by women complaining of PMS may be part of longer 
response chains. If there are other behaviors which precede 
symptoms in a response chain, targeting the first behaviors 
is assumed to be more effective than targeting the 
s~=sequent symptoms. 
Two other guidelines were summarized by Nelson and her 
colleagues (Nelson & Barlow, 1981; Nelson & Hayes, 1979) 
which could also be empirically investigated prior to target 
behavior selection. One is targeting behaviors which will 
result in beneficial response generalization (Hay et al., 
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1977). This is done in order to maximize the effect of the 
intervention procedure, thereby reducing the overall amount 
of treatment time and enhancing the therapeutic gains. The 
other guideline suggests targeting a behavior which is easy 
to change first (O'Leary, 1972) in order to lay a groundwork 
of successful change upon which to build further changes. 
The use of such guidelines is assumed to enhance 
treatment effectiveness. This is clearly an empirical . 
question for each specific disorder and each choice of 
target behavior. Attention to these guidelines prior to 
empirical investigations of the relationship between the 
assessment of target behaviors and treatment outcome, 
however, may be helpful in confirming or disconfirming a 
particular treatment validity hypothesis. 
The particular choice of treatment procedures and 
symptom clusters makes it difficult to reject the tested 
treatment validity hypothesis. Further investigation is 
needed to clarify the role of these two factors in the 
treatment validity of targeting behavior change symptoms in 
PMS. The results of the present study suggest overall that 
treatment outcome may not be enhanced by targeting negative 
affect or behavior change symptoms and matching them to the 
specific treatment procedures used. 
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Overall Treatment Effects on PMS -- ---
Two general classes of findings pertain to the overall 
treatment effects on PMS: (a) the differences between the 
number of subjects who improved as compared to the number 
who worsened within each treatment group, and (b) the 
differences between the entire groups. 
The nonparametric sign tests on the individual 
treatment groups provide analyses of the relative 
improvement of subjects within treatment groups. These 
analyses demonstrate that significantly more subjects 
improved than worsened in both treatment groups on at least 
two dependent measures. There was no significant difference 
between the number of subjects in the control group who 
improved and the number who worsened. This suggests that 
while subjects in the control may have improved, the change 
was random compared to subjects in the treatment groups of 
whom significantly more improved than worsened. This is an 
interesting finding and it does suggest that the 
interventions warrant further investigation with PMS 
symptoms. 
The more conservative approach would be to examine and 
focus on the differences between the groups, rather than the 
differences within the groups. The parametric analyses 
addressed the relationship between the groups and revealed 
no significant differences between the groups. On the 
average, all three appear to have improved over time. 
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From this conservative perspective, the discussion of 
overall treatment effects on PMS may address three general 
concerns: (a) why there was change across time, (b) why 
there was no statistical difference between the experimental 
treatments and the control group, and (c) why there was 
change on only four of the seven dependent measures. These 
concerns are discussed following a summary of the 
significant main effects for time. 
Sig:nificant Main Effects for Time 
There were significant main .::ffects for time on four 
dependent variables: the MDQ negative affect symptom 
cluster, the MDQ behavioral change symptom cluster, the 
daily behavior change rating, and the MSQ overall measure. 
The significant effect for time simply reflects a decrease 
in symptom severity over time regardless of treatment. The 
experimental treatment procedures were not statistically 
more effective than the record keeping of the control group. 
Chang:e over Time 
The improvements over time may reflect the most 
consistent finding demonstrated in other studies of the 
treatment of PMS: improvement attributable to a placebo 
effect. A high placebo response in the treatment of PMS has 
been reported in controlled double blind trials (Clare, 
1979). Simple acknowledgement of the existence of 
menstrually related behavior and mood changes has been 
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reported to be essential in the effective management of PMS 
(Cassara, 1984). Simply seeking help through participation 
in a research project, attending systematically to the 
symptoms, and having one's concerns professionally heard may 
be the "placebo" causing the decline of symptom severity and 
complaints over time. 
Classically, placebos have been considered inert 
pharmacological products~ this restrictive definition has 
been extended, however, to include nonspecific treatment 
effects in various forms of psychotherapy (Critelli & 
Neumann, 1984~ Shapiro & Morris, 1978). Explanation of 
"placebo" responses may be given at various levels: 
cognitive, behavioral, and physiological. 
One common cognitive explantion of placebo responding 
is expectancy. A number of different specific explanations 
for the expectancy mechanism in placebogenesis have been 
preferred (Shapiro & Morris, 1978). Among them are 
cognitive dissonance and feelings of control. 
The theory of cognitive dissonance (Festinger, 1957), 
suggests that a generalized drive state is established when 
two beliefs are dissonant (logical opposites). This drive 
state will lead the individual to alter the weaker belief in 
order to achieve a state of cognitive consonance. In the 
case of placebogenesis, dissonance will result if the belief 
that the therapy will be effective is confronted with the 
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experience of no improvement. If the belief in therapeutic 
effectiveness is strong, the belief regarding lack of 
improvement will be changed in order to achieve consonance. 
A dissonance-induced placebo effect may have occurred in the 
present study. The belief that participation would help PMS 
symptoms when confronted with lack of improvement may have 
resulted in a state of cognitive dissonance. If beliefs 
that could restore consonance (e.g., the treatment is 
ineffective, the researcher is wrong) were not acceptable in 
the subject's value system, then the belief regarding 
improvement could have changed in order to achieve 
consonance. 
Feelings of control may also serve as an expectancy 
mechanism of placebogenesis. The expectation that therapy 
will be effective may give people a feeling of control over 
their lives (Gatchel, 1980). Such a sense of control may 
reduce perceived discomfort (Melzack & Wall, 1982). A 
common complaint among women reporting PMS symptoms is that 
they feel out of control (Dalton, 1969). Entering into the 
present research project may have offered the expectancy of 
a means of control to the subjects, and thus the experience 
of symptom improvement. 
Behavioral explanations of placebogenesis have also 
been offered (Shapiro & Morris, 1978). Classical and 
operant conditioning both offer viable explanations of 
improvement in response to nonspecific effects. 
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In a classical conditioning model, a neutral stimulus 
may come to serve as a conditioned stimulus for the response 
of improvement due to previous temporal association with 
unconditioned stimuli that produced improvement. Classical 
conditioning accounts have been used for physiological 
reactions to drugs occurring faster than they can be 
pharmacologically induced (Shapiro & Morris, 1978; Stanley & 
Schrosberg, 1953). In the present study, subjects may have 
experienced improvement during their previous experiences 
with psychological professionals, in research projects, or 
at universities. 
Intentionally or not, operant conditioning principles 
may control the responses of experimental subjects and 
patients (Frank, 1968; Shapiro & Morris, 1978). 
Reinforcement has been implicated in independently and 
incrementally increasing placebo effects (Buckalew, 1972). 
Subjects in the present study may have been differentially 
reinforced for improvement by subtle experimenter cues. The 
situation of the study (i.e., a therapeutic setting) also 
may have served as a discriminative stimulus for positive 
regard or other reward for symptom improvement. 
A physiological mediator in placebo responses has 
also been suggested. A system of endogenous opiates, 
including the analgesia-inducing beta-endorphin sequence of 
the beta-lipotrophin amino acid chain, may account for 
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placebo analgesia (Houston, 
Gordon, and Fields (1978) 
Bee, & Rimm, 
demonstrated, 
1985). 
in 
Levine, 
patients 
displaying a placebo effect, an increase in reported pain 
due to injection of an opiate receptor-blocking drug. Thus, 
mediation of the placebo effect by an endogenous opiate 
system was inferred. Such a mechanism may be generalized to 
a psychotherapy placebo effect. Decreased ratings of pain 
or discomfort may be the result of increased production of 
endogenous opiates in response to the experimental or 
therapeutic situation. Increased beta-endorphin levels in 
response to social settings have been reported, albeit in 
animal research (Houston et al., 1985). By virtue of 
participation in the present 
cognitive or behavioral events, 
study and accompanying 
subjects may have produced 
greater quantities of endogenous opiates and, thus, reported 
the experience of improvement. 
One additional influence on placebo effects deserves 
mention: it is the impact of evaluation (Shapiro & Morris, 
1978). The assessment procedure,~~' may cause reactive 
changes in the participants. Simple pretesting has been 
found to sensitize respondents and result in alteration of 
responses (Haase & Ivey, 1970; Mungus & Walters, 1979). 
Experimental designs have been created to account for such 
effects; the main purpose of the Solomon four-group design 
is to evaluate the effect of pretesting on the impact of a 
122 
specific treatment (Solomon, 1949). This has been called an 
"ideal design for social scientists" (Campbell, 
303) suggesting the importance of attending to 
routine measures may have on what they assess. 
1957, p. 
the impact 
The simple 
use of pretests and repeated measures may have altered 
subjects' responding. 
In the present study, it is possible that the daily 
self recording resulted in a decrease in reported symptom 
severity. Self-recording has been shown to be reactive, 
with desireable behaviors increasing in frequency, and 
undesireable behaviors decreasing in frequency (Nelson, 
19 77) . It is believed that reactivity is due to either 
positive or negative self-evaluation (Kanfer, 1974) or to 
positive or negative naturally occurring 
consequences (Rachlin, 1974). 
environmental 
Lack of Differential Treatment Effects. 
There 
demonstrated 
study. This 
were no significant group by time effects 
by the statistical analyses in the present 
lack of treatment procedure effectiveness 
compared to a no-treatment control raises, again, the issues 
of placebo factors and treatment effectiveness. 
The "control group" in the present study has been 
referred to as a "no-treatment" group. In actuality, this 
control group may be considered a "placebo" control group. 
An effect sufficient to result in significant changes across 
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time occurred in the control group to the extent that it 
could not be distinguished from the "treatment" groups. 
Some common events may have been causing the common effects. 
In order to consider the control group a placebo 
control group, a definition of placebo 
research must be established. A 
within psychotherapy 
number of different 
positions exist regarding the appropriate definition of 
placebo within psychotherapy research. These definitions 
range from treatments considered theoretically inert from 
the perspective being tested (Rosenthal & Frank, 1956), to 
treatments without theoretical support in general (O'Leary & 
Borkovec, 1978), to the view that all treatments may be 
theoretically explained via Bandura's (1977) self-efficacy 
theory. Critelli and Neumann (1984) provide a review of 
these and alternative positions which define placebo based 
upon the concept of nonspecific treatment effects. They 
conclude that the concept of common factors offers the most 
useful definition of placebo for psychotherapy research. 
Common factors means those factors that are common to most 
forms of therapy (Kazdin, 1979; Wilkens, 1979). 
In the present study, this common-factors definition 
of placebo offers a workable explanation of the apparent 
lack of differential treatment effects. It may be that 
improvement over time in all groups resulted from those 
factors which are common to all three groups (e.g., data 
collection, expectancy, experimenter contact). 
Treatment 
appparent lack 
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effectiveness is another issue raised by the 
of differential treatment effects. The 
treatment procedures were not statistically more effective 
than the control procedure. The reasons for this apparent 
lack of treatment effectiveness are discussed previously and 
include possible lack of compliance and inappropriateness of 
the procedures for PMS-related symptoms. Most simply, 
however, the present study may provide one instance of the 
experimental ineffectiveness of the treatment procedures 
with PMS symptoms. 
Differential Responsiveness of Measures. 
Only four of the seven dependent variables showed any 
significant effect on the parametric analyses. These four 
measures were the MSQ overall measure, both MDQ symptom 
clusters (negative affect and behavioral change), and the 
daily behavior change rating. They showed significant 
improvement over time regardless of intervention. The three 
measures which showed no significant effects were the daily 
depression rating and the two "objective" daily measures 
(reported crying frequency and reported time resting). In 
the face of consistent effects among the three treatment 
groups (the two treatments and the control procedure), the 
inconsistency in responsiveness of the dependent measures 
merits discussion. 
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Only two of the seven dependent variables showed a 
significant effect for time on the nonparametric analyses. 
These two measures were the MSQ overall measure and the 
daily behavior change rating. The two MDQ symptom clusters 
(negative affect and behavioral change) showed weaker 
effects (Table 17). There were no significant effects on 
the daily depression rating and the two "objective" daily 
measures (reported crying frequency and reported time 
resting). These results are consistent with those of the 
parametric analyses. Thus, the nonparametric analyses 
regarding change over time are consistent with the more 
conservative parametric analyses. Ther~fore, the parametric 
analyses will be specifically addressed in the discussion of 
the differential responsiveness of the dependent measures. 
Two general issues are apparent in evaluating the 
differential responsiveness of measures: the validity of 
the MSQ as an overall measure of PMS, and the relationship 
between 
addition 
prospective and 
to the general 
retrospective measures. In 
retrospective measures 
topic of prospective versus 
are the specific problems of 
inconsistency of the measures within and between symptom 
clusters. 
Validity of the MSQ as an Overall Measure of PMS. The 
MSQ was devised as a measure of dysmenorrhea. It was 
designed to distinguish between spasmodic and congestive 
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dysmenorrhea (Chesney & Tasto, 1975a). While this 
distinction has been questioned (Cox, 1977; Stephenson et 
al., 1983; Webster et al., 1979), the use of the congestive 
measure on the MSQ as an overall measure of PMS in the 
present study seemed appropriate. In the original 
distinction, spasmodic dysmenorrhea referred to menstrual 
cramping and discomfort accompanying menses; congestive 
dysmenorrhea referred to bloating and discomfort preceding 
the onset of menses (Dalton, 1969; 1979). Congestive 
dysmenorrhea, therefore, had been likened to PMS. 
If the MSQ is a valid overall measure of PMS, 
conceptually there should be a relationship among the 
results of the MSQ analyses and the results of the analyses 
of the other measures of PMS. If the MSQ is an overall 
measure of PMS and the specific symptom clusters targeted 
account for a large proportion of the variance within PMS, 
then it would be expected that the results of treatment on 
the three measures would be similar. The results on the MSQ 
and on the MDQ specific symptom clusters all showed a 
significant effect for time and no differential effect by 
treatment group. In addition, both MDQ symptom clusters 
were significantly correlated with the MSQ overall measure, 
although each accounted for less than 20 percent of the 
variance. 
measures 
This similarity and correlation among these 
suggest that the MSQ does provide an overall 
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measure of PMS and reflects the targeted symptom clusters, 
at least, retrospectively. 
The retrospective measures, the MSQ and the MDQ 
measures, appear to be consistent among themselves. The 
differential responsiveness of measures, therefore, may be 
due to general differences between prospective (daily 
ratings) and retrospective (MSQ and MDQ measures) measures. 
Prospective Versus Retrospective Ratinqs. The 
relationship of prospective and retrospective ratings for 
PMS, in general, is discussed. Possible explanations for 
the inconsistency of the measures within and between symptom 
clusters also are discussed. Because the inconsistencies 
among the measures are different for the two symptom 
clusters 
context, 
they are discussed separately. Within this 
issues of definition, interpretation, and 
differences in the time periods assessed are addressed. 
The only prospective dependent measure which showed the 
significant effect for time was the daily behavior change 
rating. The other three prospective measures (daily 
depression rating, crying frequency, and time resting) 
showed no significant effects. The other three measures 
which showed the significant effect for time (the MSQ 
overall measure, and both MDQ symptom cluster measures) were 
all retrospective measures. The method of measurement may 
account for the differential responsiveness of the measures. 
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The inconsistent findings between most of the 
prospective daily ratings and the retrospective measures may 
reflect the general inconsistency between prospective and 
retrospective measures of premenstrual symptoms. Woods and 
her colleagues (1982) suggest that report of perimenstrual 
symptoms is influenced by the method of data collection. 
They compared a prospective daily health diary with a 
retrospective MDQ for 73 women. Their analyses revealed 
that the women were much more likely to report negative 
affect symptoms and water retention symptoms on the 
retrospective device. Among the symptoms these researchers 
found reported on the MDQ, but never on the daily health 
diary, were crying and avoiding social activities. The 
items crying and avoiding social activities are included in 
the symptom clusters targeted in the present study. Crying 
was also the objective daily measure of the depression 
cluster and avoiding social activities may be related to the 
objective daily measure of behavior change, time resting. 
It is possible that even when specifically solicited in 
daily ratings these behaviors are not of sufficient 
frequency or importance to warrant notice or reflect change. 
One 
colleagues 
nature of 
problem in comparing the findings of Woods and her 
(1982) with those of the present study is the 
the prospective ratings. In the Woods study, 
blind prospective ratings were used, whereas in the present 
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study the subjects were aware that premenstrual symptoms 
were of interest. The discrepancy between prospective and 
retrospective ratings, however, still seems relevant. 
Others have also reported that retrospective self-report 
measurement devices ·maximize the reporting of negative moods 
and minimize the reporting of positive moods during the 
premenstrual time period (Englander-Golden, Whitmore, & 
Dienstbier, 1978). Even when using the same questionnaire 
prospectively and retrospectively, differences between the 
ratings on various symptom clusters have been reported 
(Rouse, 1978). Differences attributable to prospective 
versus retrospective methodology may well have had an impact 
on the results of the present study. 
Differential Responsiveness of Depression Measures. 
If taken at face value, it certainly seems reasonable to 
assume that daily ratings of depression and crying frequency 
would be related to retrospective ratings of depression. In 
fact, the three measures are significantly correlated. In 
terms of content, both the objective measure, crying 
frequency, and the subjective daily depression rating were 
items included in the retrospective MDQ negative affect 
symptom cluster (item numbers 3. crying and 40. depression). 
The similarity of the items on the prospective and 
retrospective measures may account for the intercorrelation 
among the three depression measures. While all three 
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depression measures were significantly correlated, only the 
retrospective MDQ negative affect symptom cluster measure 
showed the significant change across time. This 
discrepancy may be due to the prospective-retrospective 
measurement distinction (Woods et al., 1982). As previously 
mentioned, the daily ratings of these behaviors may not be 
of sufficient frequency or strength to reflect change. 
Differential Responsiveness of Behavior Change 
Measures. It seems reasonable to assume that daily ratings 
of behavior change and time resting would be related to 
retrospective ratings of behavior change. On one hand, 
consistent with the prospective-retrospective distinction, 
only the two daily measures of behavior change were 
significantly correlated. On the other hand, both the MDQ 
behavioral change symptom cluster measure (retrospective) 
and the daily behavior change measure (prospective) showed 
the significant change over time. 
The time resting measure showed no significant effects. 
It was the only measure of the behavior change cluster which 
did not change significantly over time. The time resting 
measure was significantly correlated with the other 
prospective measure of the behavior change cluster: the 
daily behavior change measure (accounting for ten percent of 
the variance). This similarity among the prospective 
measures and concomitant dissimilarity to the retrospective 
measures suggests some 
retrospective distinction. 
support for a 
It seems most 
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prospective-
parsimonious, 
however, to ascribe the lack of significant change over time 
on the time resting measure to insufficient strength or 
importance to reflect change, an explanation consonant with 
that applied to the daily depression ratings. 
The lack of significant correlation between the daily 
behavior change rating and the retrospective MDQ behavioral 
change symptom cluster measure is complicated by the 
concomitant significant change over time on both measures. 
Three possible differences between these measures are 
described. The first is concerned with time, the second 
with interpretation, and the third with definition. 
Time may account for differences between the daily and 
retrospective measures. On the retrospective questionnaire, 
the subjects were instructed to rate the symptoms for the 
week prior to their most recent menstrual period. The 
prospective daily ratings were analyzed only for the four 
days immediately preceding the onset of the subjects' 
menstrual periods. This discrepancy could have resulted in 
inconsistent findings. Severe behavior changes may have 
occurred five or six days prior to menstrual onset resulting 
in a retrospective rating of severe lowered school or work 
performance. As only the four days preceding the onset of 
menses were included in the daily rating score, the 
prospective rating 
differences may be 
between the daily 
measures. 
may have been only mild. 
of 
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Thus, time 
differences an artifactual cause 
and retrospective behavior change 
Interpretation of the measures also may account for 
differences between 
Interpretations may 
the daily and retrospective measures. 
vary between the prospective and 
retrospective measures. They may also vary between subjects; 
one woman's severe behavior change may be only mild to 
another, and one's moderate decreased efficiency may be 
debilitating to another. The repeated measures design 
hopefully helped to account for such individual differences. 
Other inconsistencies in the interpretation of the rating 
scales may not be accounted for by design. On one 
measurement occasion, a woman may have retrospectively 
reported "avoids social activities" as severe in response to 
only mild prospectively reported behavior change. On 
another measurement occasion, the same woman may have 
retrospectively reported "avoids social activities" as mild 
in response to severe prospectively reported behavior 
changes. The former time period may have been the occasion 
of avoiding only one, but an important social activity (a 
business lunch), while the latter time period may have 
included avoiding multiple social gatherings, none of which 
were recalled as a great loss. Similarly, one day of 
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prospectively rated severe behavior change could be 
retrospectively rated as moderate decreased efficiency on 
one occasion while five days of prospectively rated mild 
behavior change could be retrospectively rated as moderate 
decreased efficiency on another occasion. These types of 
inconsistency in the interpretation of the rating scales 
were not accounted for in the present study and could play a 
part in the lack of correlation between the daily and 
retrospective behavior change measures. 
Similar to interpretation, differences in definition 
may account for the differences between the daily and 
retrospective behavior change measures. Unlike the 
depression symptom cluster, the items which make up the 
daily behavior change ratings actually may not be part of 
the identified MDQ behavioral change symptom cluster. The 
identified cluster actually included specific types of 
behavior change, as opposed to a global rating of how 
different one's behavior appeared compared to "normal." The 
retrospective MDQ cluster included lowered school or work 
performance, take naps and stay in bed, stay at horne, avoid 
social activities, and decreased activity; did not 
include a rating of behavior change, per se. It may well be 
that the global term "behavior change" reflects a different 
set of behaviors than are assessed by the retrospective MDQ 
behavioral change symptom cluster measure. 
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While there is no significant correlation between the 
daily behavior change rating and the MDQ behavioral change 
symptom cluster measure, there is a significant correlation 
between the daily behavior change rating and the MDQ 
negative affect symptom cluster measure. It appears that 
the daily behavior change rating accounts for 12 percent 
of the variance on the MDQ negative affect symptom cluster 
measure. This across cluster correlation is consistent with 
previously demonstrated significant correlations between 
depressed mood and a low frequency of pleasant events 
(Lewinsohn & Graf, 1973; Lewinsohn & Libet, 1972). This 
suggests that the daily rating of behavior change has a 
different definition than the MDQ behavioral change symptom 
cluster. Subjects may have defined the daily behavior 
change rating as decreases in pleasant events (relating to 
items on the MDQ negative affect cluster) rather than as a 
global rating of the specific behavior changes delineated by 
the items on the MDQ behavioral change symptom cluster. 
Different 
lack of 
definitions of the measures may account for 
correlation between the prospective 
retrospective behavior change measures. 
the 
and 
The lack of correlation between the behavior change 
prospective and retrospective measures may be accounted for 
by differences in time, interpretation, and definition of 
the measures. The issue is, then, why only the daily 
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behavior change rating showed the significant change over 
time. The other measures, which were significantly 
correlated with the MDQ negative affect cluster, did not 
show the significant change over time. As previously 
discussed, the other prospective measures may not have been 
of sufficient importance or sensitivity to reflect the 
change, whereas the daily behavior change rating was 
interpreted consistently with the retrospective measures. 
The measures which did not show the significant change over 
time (daily depression rating, crying frequency, and time 
resting) may have been defined or interpreted as similar to 
comparable single items on the retrospective devices. 
Single items may be relatively weak or insensitive to change 
compared to the clusters. Similarly, the behavior change 
daily rating may have been interpreted or defined in a more 
global manner reflecting mood or affective changes in 
general. Measures which incorporate a number of specific 
items do appear sensitive to change (e.g., the MSQ overall 
measure, both MDQ symptom cluster measures). Differential 
strength of measures may account for their differential 
responsiveness. 
One additional point concerning the "objective" daily 
measures (crying frequency and time resting) relates to this 
issue of strength. The baseline frequency of both of these 
measures was extremely low. They appear to be irrelevant 
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behaviors and are subject to floor effects. This decreases 
their utility as measures of change and may account for the 
differential responsiveness of, at least, these measures. 
The overall treatment effects on PMS demonstrated in 
the present study do not support the experimental 
hypotheses. No differential effect on symptom clusters for 
treatment group by time period was revealed and no 
enhancement of outcome resulted from targeting a specific 
symptom cluster. The results demonstrate a significant 
change over time on four out of seven dependent measures 
regardless of specific intervention. These effects are 
interpreted as placebo effects or the effects of common 
therapeutic factors seen specifically on retrospective 
general-concept measures as oppose~ to prospective single-
item measures. Because of the potential impact of other 
variables on the present study, the inability to rule out 
treatment ineffectiveness, and the differential (although 
relatively weak) effects demonstrated by the nonparametric 
analyses, it can only be stated that the present findings 
are inconclusive. The treatment procedures, in light of the 
nonparametric findings, certainly warrant further 
investigation, as do treatment validity hypotheses which 
have been neither confirmed nor belied. No definitive 
statement regarding the effectiveness of targeting 
depression or behavior change symptom clusters in enhancing 
treatment outcome has been made. 
Limitations of the Present Study 
Possible explanations and- interpretations of 
results of the present study were discussed previously. 
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the 
It 
remains important to address the limitations of the present 
design in answering the experimental questions proposed. 
Limitations within the rubric of treatment validity research 
as well as design issues in the study of premenstrual 
symptoms and in general are discussed. 
The purpose of this study was to evaluate the 
treatment validity of identifying specific target behaviors 
within PMS. This treatment validity issue is concerned with 
the question: does selection of specific target behaviors 
and matching treatment to them enhance treatment outcome? 
One limitation of the present study may be that it does not 
offer direct evidence regarding the evaluation of behavioral 
assessment as is expected of treatment validity studies. 
As previously discussed, selection of specific target 
behaviors is considered a manipulated-target type of study 
which is not considered to have direct bearing on the 
quality of assessment (Hayes et al., in press). The 
controversy in calling the present manipulated-target type 
of study a treatment validity study is that such studies do 
not offer information directly related to the evaluation of 
behavioral assessment. Such studies may be included as 
treatment validity studies, however, as they evaluate the 
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quality of our theories of disorders which may lead us to 
select specific target behaviors and have value in 
generating other treatment validity hypotheses (Hayes et 
al., in press). The role of the present study in evaluating 
the quality of a theory of PMS as a whole and in generating 
other treatment validity hypotheses is discussed. 
A major limitation of the present study is that two 
unknowns were addressed simultaneously. In addressing two 
unknowns simultaneously the results are equivocal and, 
thus, the interpretation difficult. In addition to the 
treatment validity question (were the correct symptom 
clusters targeted?), the present study was also asking 
outcome questions. The outcome questions were also being 
asked as no previous work has been done addressing the 
effectiveness of the treatment procedures with premenstrual 
symptoms. For example, the lack of a differential treatment 
effect in the present study is difficult to interpret. 
Whether identifying the specific symptom clusters offers 
little to enhance treatment outcome or the treatment 
procedures were ineffective is unclear. Treatment validity 
questions may be answered clearly only if outcome questions 
pertaining 
specific 
questions 
impact of 
to the effectiveness of specific treatments with 
disorders are answered first. When outcome 
have been answered, treatment validity or the 
various aspects of assessment may be clearly 
demonstrated. 
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An implication of the equivocal findings in the present 
study is that it may be too early in our empirical knowledge 
of premenstrual disorders to use them to assess the impact 
of assessment on treatment outcome. So little is known of 
the disorder in general and its treatment in particular 
that the present attempt to evaluate the quality of 
behavioral assessment using the disorder of PMS is clearly 
premature. Treatment validity studies need to be done, but 
will provide useful information about the value of various 
aspects of behavioral assessment only with fairly well-known 
disorders with already established treatment procedures. 
The present study rests upon the theory that PMS is a 
multisyrnptom disorder which may respond to symptom specific 
intervention procedures (Clare, 1979; Moos, 1969). Two 
psychologically relevant symptom clusters were chosen for 
targeting and logically matched to two intervention 
procedures. The consistency of findings among the 
retrospective measures and their intercorrelation suggest 
that the MDQ negative affect and behavioral change symptom 
clusters are related to the MSQ overall measure of 
congestive dysmenorrhea or PMS. This finding provides a 
connection between the specific type and timing of 
premenstrual symptoms. Thus, in a small way, this study 
provides support for the theory that PMS is a multisymptom 
disorder. It provides only limited support, however, for the 
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responsiveness of the symptom clusters to the selected 
treatment. 
In terms of generating other treatment validity 
hypotheses for testing, the questions raised by the present 
study may be addressed from a treatment validity 
perspective. For example, a manipulated assessment type of 
treatment validity study could address the value of 
assessing 
particular 
specific symptoms of PMS at all, regardless of 
cluster. The placebo effect explanation that 
record keeping in general and a sympathetic professional ear 
are sufficient to result in decreased ~everity of symptoms 
suggests that assessing specific symptoms may not enhance 
outcome; all women complaining of PMS will respond to record 
keeping and serious attention. Women complaining of PMS 
could be randomly assigned to two groups. The single aspect 
of assessment to be varied in this example would be the 
formulation of specific treatment plans based upon specific 
symptoms endorsed. One group would see therapists who have 
access to an assessment device upon which they specify 
symptoms and would receive treatment based upon the 
assessment of those specific complaints, and the other group 
would see therapists who do not have access to the 
assessment device upon which the subjects specified their 
symptoms and would receive treatment which does not account 
for the specific complaints assessed. Differential outcomes 
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for the two groups would delineate the treatment validity of 
assessing specific symptoms within PMS. This is an empirical 
question within the rubric of treatment validity research. 
Additional treatment validity hypotheses generated by the 
present study are presented later (in Directions for Future 
Research). 
Additional limitations of the present study include 
assumptions which in retrospect appear to be faulty. One 
faulty assumption relates to the equivocal findings of the 
present study and their relationship to the lack of 
effectiveness of the treatment p=ocedures. The treatment 
procedures were chosen based upon the assumptions that 
premenstrual depression was the same as other depression and 
that premenstrual behavior change was the same as other 
illness-induced behavior change. The treatment procedures 
have been demonstrated to be effective with nonmenstrually 
related depression and behavior change. Their lack of 
effectiveness in the present study calls into question the 
assumption of equivalence between premenstrual and 
nonmenstrually related depression and behavior change. 
A second faulty assumption relates to factors derived 
in the pilot study which were statistically established as 
orthogonal. The choice of negative affect and behavioral 
change clusters was based in part upon their orthogonal 
nature. This orthogonality, however, was statistically 
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established by a factor analysis varimax rotation. It was 
not a reflection of "real" orthogonality or actually 
independent symptom clusters. Moos' (1968; 1969) original 
reports of these factors suggests that they are, in fact, 
highly correlated particularly within subjects. Thus, it 
appears that any subject experiencing both negative affect 
and behavioral change symptoms does not experience them as 
independent symptoms, but experiences them as related 
symptoms unlikely to respond differentially. This is in 
direct contradiction to the experimental hypothesis which 
assumes the symptom clusters were independent and predicts 
differential responding. 
Lack of information about the disorder results in 
additional limitations of the present study. The subjects 
used in the present study were self-diagnosed volunteers. 
Any woman who believed that she had PMS and who met the 
experimental criteria was eligible to participate. Post hoc 
examination of the daily depression and behavior change 
ratings do demonstrate that subjects showed an elevation of 
symptoms during the premenstruum compared to the 
postmenstruum (Figure 20). The postmenstruum is considered 
to be symptom free in women with PMS (Dalton, 1979). 
Many of the researchers working with menstrual 
disorders feel that much more stringent criteria are needed. 
These criteria include assessment of multiple menstrual 
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cycles and professional rather than self-diagnosis. The 
specific subject eligibility criteria recommendations range 
from two to six menstrual cycles of specific records 
demonstrating symptom occurrence premenstrually (Dalton, 
1979; Sampson & Prescott, 1981). The value and importance 
of prospective and retrospective assessment of specific 
symptom clusters in PMS cannot be ruled out on the basis of 
the present study, in part, because it is possible that the 
women participating in this study were not actually 
suffering from PMS. The use of more stringent criteria in 
future research is recommended. 
In addition, in the present study only one baseline 
assessment and two posttreatment assessments were used. 
Calhoun and Sturgis (1984) recommend multiple pre- and post-
treatment measures due to the fluctuation in menstrually 
related symptoms across cycles. Others also support the use 
of multiple pre- and posttreatment measures in order to 
provide a greater sample of behavior upon which to base 
experimental conclusions (Dalton, 1979; Sampson & Prescott, 
1981}. 
The issue of power as related to sample size is another 
limitation of the present study. Power is the probability 
of rejecting the null hypothesis appropriately and is 
determined by the interaction of sample size, effect size, 
and significance level (Cohen, 1977). In the present 
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study, using the treatment group sample size (12), a medium 
effect size (.25), and the arbitrary standard significance 
level (.05), the power of the ANOVA's used was only .23-.28 
depending upon the degrees of freedom (Cohen, 1977). That 
is, the rate of Type II error, or failing to reject a false 
null hypothesis, is between 72 and 77 percent. This rate of 
Type II error suggests that failure to reject a false null 
hypothesis is likely. Sample size may also be determined by 
the other three variables: effect size, significance level, 
and power. Using the same effect size (.25, medium), the 
standard significance level (.05), and the proposed standard 
power level (.80), the necessary sample size to demonstrate 
significant effects would be 52 subjects per treatment group 
(Cohen, 1977). It is apparent that the power level and 
sample size in the present study were insufficient to reveal 
even medium size effects; to reveal small effects a sample 
size of 322 per treatment group would be necessary and even 
large effects (unlikely in psychological treatment 
evaluation research) would require a sample size of 21 
subjects per treatment group (Cohen, 1977). Thus, the 
sample size in the present study is clearly a limitation. 
overall, the limitations of the present study serve to 
temper the tendency to reject the experimental hypothesis. 
At the same time, it is clear that the treatment validity of 
targeting specific symptom clusters within PMS has not been 
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demonstrated in the present study. The results, however, 
may be viewed as intriguing and may serve to spur further 
treatment validity and PMS research. Attention to these 
limitations in future research is advised. 
Directions for Future Research 
In light of the limitations of the present study, 
directions for future research must be carefully considered. 
It is clear that studies examining both treatment validity 
and PMS are needed. Prior to embarking on another research 
project which addresses treatment validity questions in the 
assessment of PMS, more research on PMS is necessary. In 
general, future directions for research include a) 
examination of 
known disorders 
treatment 
which 
validity questions 
have treatments 
with better 
empirically 
demonstrated to be effective, and b) descriptive and simple 
outcome research on PMS. 
Various issues have been raised in the interpretation 
of the results of the present study. A number of these 
issues lend themselves to treatment validity studies, 
assuming the limitations of the present study and the state 
of empirical knowledge of PMS can be overcome. These and 
other directions for future research are discussed. 
The present study was concerned wir~ the importance of 
matching treatment to identified symptom clusters. An 
alternative design which could be used to examine the 
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correspondence between identifying specific symptom clusters 
and outcome is the manipulated match type of treatment 
validity study. Hayes and his colleagues (in press) suggest 
that this may be more powerful in revealing such 
relationships between assessment and treatment than other 
designs. In such a design, individuals would be randomly 
assigned to groups based upon the method of matching 
assessment to treatment. Those whose symptoms are matched 
to treatment would be compared with those whose symptoms 
are mismatched. Differences in outcome would be interpreted 
to reflect the treatment validity of different use of 
available assessment data. Such a design answers the 
question: is outcome enhanced by matching treatment to 
symptoms or is assessment of those symptoms irrelevant? 
Such a design could offer a more powerful evaluation of 
the value of targeting the depression and behavior change 
symptom clusters within PMS. Subjects would be randomly 
assigned to one of the three treatment groups: depression 
treatment, behavior change treatment, and control. Half of 
the subjects in each group would have been determined to 
have depression symptoms, but no behavior change symptoms; 
and the other half would have been determined to have 
behavior change symptoms, but no depression symptoms. This 
design would address the same question as the present study 
through the more powerful treatment validity design: 
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manipulated match. One difficulty with such a design is the 
availability of such "pure" types of subjects. In addition, 
in light of the limited information on PMS in general and 
its response to various treatments in particular, even this 
more powerful design would be premature. 
An alternatiye treatment validity approach might side-
step the limited information on the-characteristics of PMS. 
This approach would compare an idiographic and a yoked 
approach to treatment of PMS. This would require that 
subjects be randomly assigned to one of two groups: 
idiographic and yoked. The idiographic group would be 
individually assessed and symptomatically treated based upon 
the specific symptoms complained of by each subject. The 
yoked group would receive specific symptomatic treatment 
which was mismatched with her specific symptomatic 
complaints. This would meet the criteria of a manipulated 
match type of treatment validity study; the value of 
behavioral 
symptoms 
assessment in matching versus 
to treatment would be evaluated. The 
mismatching 
difficulty 
inherent in the absence of empirically effective treatments, 
however, remains. 
In light of the potential differences on prospective 
and retrospective assessments, an evaluation of the 
treatment validity of these two forms of assessment would be 
valuable. A manipulated assessment type of treatment 
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validity study could be used. All subjects could be 
assessed using both prospective and retrospective devices, 
and randomly assigned to a prospective or retrospective 
group. Those in the prospective group would receive a 
treatment based upon only the prospective assessment and 
those in the retrospective group would receive a treatment 
based upon only the retrospective assessment. Differential 
outcomes between the groups would confirm the treatment 
validity of the prospective versus retrospective aspect of 
assessment. Such a design would answer the question: is 
outcome enhanced by the prospective or retrcspective method 
of assessment? 
An additional issue related to the prospective 
assessment of PMS lends itself to a treatment validity 
question. Insofar as it has been recommended that three 
months of prospective assessment are required to establish 
the diagnosis of PMS (Calhoun & Sturgis, 1984; Dalton, 
1979), it would be interesting to examine the treatment 
validity of such assessment. A simple observed-differences 
type of treatment validity study could be used. Subjects 
whose PMS had been confirmed by three months of prospective 
ratings could be compared to subjects whose PMS had not been 
confirmed by the three months of prospective rating. 
Pragmatically speaking, one would need to use subjects all 
of whom retrospectively report PMS. Any differential 
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response to the same treatment procedure would demonstrate 
the treatment validity of three months of prospective 
ratings to confirm PMS. This is a treatment validity study . 
in that the impact of prospective·assessment on treatment 
would be evaluated. Again, this study may be premature in 
the face of no empirically effective treatment procedures. 
Although it does not directly lend itself to a 
treatment validity question, another direction for future 
research was suggested by the results of the present study. 
It was suggested that the lack of treatment effect could 
have been due to noncompliance. In light of the potential 
effect of noncompliance, assessing the impact of the 
treatment procedures when compliance is ensured would be 
helpful in clarifying both present and future results. One 
way to address the question of the impact of compliance is 
to ensure compliance through a variety of measures in future 
research. Alternatively, the the impact of compliance could 
be directly evaluated. Most simply, although not a 
treatment validity study, a group in which compliance is 
ensured could be compared to a group in which compliance is 
not ensured. Such a treatment outcome study could clarify 
the impact of compliance on the outcome of the behavior 
change treatment. 
Although the results of the present study were not 
supportive of the experimental hypothesis, the issues 
raised by the findings offer multiple directions for 
research. Primary among those directions are the 
different types of treatment validity study which 
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future 
many 
could 
elucidate the present findings and further the evaluation of 
behavioral assessment. 
Conclusions 
The main goal of the present study was to test the 
hypothesis 
within PMS 
treatment 
that the selection of a specific target behavior 
and matching it to a treatment would enhance 
outcome. Overall, the results did not support 
this treatment validity hypothesis. 
This study also addressed the question: in terms of a 
general measure of premenstrual symptoms, is it more 
effective to target depression symptoms of PMS or behavioral 
change symptoms? The results of the parametric statistical 
analyses of this study suggest that neither experimental 
treatment was significantly more effective than a control 
procedure on the overall measure of PMS. 
The major difficulty in comfortably rejecting the 
experimental hypothesis is the confound of the importance 
of identifying the specific symptom clusters and the 
effectiveness of the treatment procedures used. If the 
treatment procedures were ineffective in ameliorating or 
managing the symptoms of PMS, then there is no way to 
determine whether targeting the specific symptom clusters 
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would enhance treatment outcome. It would be necessary to 
use proven treatment procedures and ensure their application 
in order to effectively evaluate the contribution of 
identifying specific symptom clusters to treatment 
effectiveness. The treatment procedures used in the present 
study had been effective with similar symptoms of other 
disorders, but had not previously been established as 
effective with PMS symptoms. The lack of significant 
findings may reflect ineffective treatment procedures rather 
than a lack of treatment validity for identifying specific 
symptom clusters. Alternatively, it may be that identifying 
the depression and behavioral change symptom clusters within 
PMS is irrelevant in treatment effectiveness. Further 
investigation regarding the impact of the treatment 
procedures and the treatment validity of targeting specific 
symptoms is needed to clarify these issues. 
Due to the limitations of the present study, the 
findings are essentially equivocal. The experimental 
hypothesis was not supported, but cannot be discarded or 
ruled out. The major contribution of the present study 
appears to be two-fold. First, the present study provides 
an example of the necessity of using treatments whose 
effectiveness has been previously empirically demonstrated 
in a treatment validity study. Second, the present study 
demonstrates the need for descriptive and outcome research 
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with PMS prior to its use as a vehicle for the elaboration 
of treatment validity issues. 
Due to the present state of empirical knowledge of PMS 
it is clear that research focusing on treatment validity 
questions are premature with this disorder. When more has 
been demonstrated regarding effective interventions for PMS, 
treatment validity questions could be better addressed 
through investigations of the disorder. For the present, 
treatment validity questions are best addressed through 
research using disorders which are better known and have 
tried and true treatment procedures available. Treatment 
validity studies address higher order research questions: 
thus, they require basic knowledge of treatment 
effectiveness and a firm theoretical base in order to 
provide useful or meaningful results as Hayes and his 
colleagues have suggested (in press). 
In summary, the most salient results suggest only that 
PMS symptom severity does not respond differentially to an 
operant intervention for behavior control, a cognitive 
therapy of depression, or record keeping only. While there 
was no substantial support for the experimental hypothesis, 
it cannot be rejected outright. The confound of treatment 
effectiveness and symptom cluster choice requires 
clarification. The only firm statement that can be made is 
that there were no significant differences among groups and 
there was an general decline in symptom severity 
baseline to posttreatment and follow-up. Overall, 
study serves as a demonstration of the necessity of 
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from 
this 
using 
disorders with known effective treatments in examining the 
treatment validity of specific aspects of behavioral 
assessment. 
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Appendix A-1 
ID# ____ _ Day ___ _ Date ----
Self Assessment Questionnaire 
The following is a list of symptoms which women sometimes 
experience. Please describe your experience of these 
symptoms today. Rate each item on the following scale: 
l=no experience of the symptom; 2=barely noticable; 
3=present, mild; 4=present, moderate; S=present, strong; 
6=acute or partially disabling. 
Weight Gain 
Insomnia 
Crying 
Lowered school or 
work performance 
Muscle stiffness 
Forgetfulness 
Confusion 
Take naps; stay in 
bed 
Headache 
Skin disorders 
Loneliness 
Feeling of 
suffocation 
Affectionate 
Orderliness 
Stay at home 
Cramps 
Lowered judgement 
Fatigue 
Nausea, vomiting 
Restlessness 
Hot flashes 
Difficulty concentrating 
Painful breasts 
Feelings of well being 
Ringing in the ears 
Distractible 
Swelling 
Accidents 
Irritability 
General aches and pains 
Mood swings 
Heart pounding 
Depression 
Decreased efficiency 
Dizziness, faintness 
Excitement 
Chest pains 
Avoid social 
activities 
Anxiety 
Backache 
Cold sweats 
Menstrual bleeding 
Allergies 
Appendix A-1, page 2 
--- Lowered motor coordination 
Numbness, tingling 
Change in eating habits 
Tension 
Blind spots, fuzzy 
vision 
Bursts of energy, 
activity 
Cold 
Flu 
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Factor 1: 
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Appendix A-2 
Prospective Rating Factors 
(N=97; all menstruating subjects) 
5. muscle stiffness 
8. take naps; stay in bed 
17. dizziness 
19. chest pains 
23. cold sweats 
32. ringing in the ears 
39. heart pounding 
43. numbness, tingling 
44. change in eating habits 
46. blind spots, fuzzy 
vision 
MOOS FACTORS 
pain 
behavioral change 
autonomic reactions 
control 
autonomic reactions 
control 
control 
control 
n/a 
control 
Factor 2: Depression 
Factor 3: 
Factor 4: 
Factor 5: 
3. crying 
7. confusion 
38. mood swings 
40. depression 
45. tension 
4. lowered school or 
work performance 
15. stay at home 
25. fatigue 
29. difficulty concentrating 
33. distractible 
Positive Affect 
14. orderliness 
18. excitement 
31. feeling of well being 
47. bursts of energy 
24. lowered judgement 
26. nausea, vomiting 
37. general aches and pains 
41. decreased efficiency 
42. lowered motor 
coordination 
negative affect 
concentration 
negative affect 
negative affect 
negative affect 
behavioral change 
behavioral change 
pain 
concentration 
concentration 
arousal 
arousal 
arousal 
arousal 
concentration 
autonomic reactions 
pain 
behavioral change 
concentration 
Factor 6: 
1. 
30. 
34. 
Factor 7: 
6. 
28. 
35. 
Factor 8: 
22. 
36. 
Factor 9: 
2. 
Factor 10: 
16. 
20. 
Factor 11: 
13. 
Factor 12: 
10. 
12. 
Factor 13: 
27. 
Appendix A-2, page 2 
Water retention 
weight gain 
painful breats 
swelling 
forgetfulness 
hot flashes 
accidents 
backache 
irritability 
insomnia 
cramps 
avoid social activities 
affectionate 
skin disorders 
feeling of suffocation 
restlessness 
MOOS FACTORS 
water retention 
water retention 
water retention 
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concentration 
autonomic reactions 
concentration 
pain 
negative affect 
concentration 
pain 
behavioral change 
arousal 
water retention 
control 
negative affect 
Items with no correlation weight over 0.50 
highest weight on 
Factor 
2 
13 
4 
9. headache 
11. loneliness 
21. anxiety 
pain 
negative affect 
negative affect 
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Appendix A-3 
Consistency/Inconsistency of Self Assessment 
Debriefing Questionnaire 
ID# SS# ---------------------------
To what extent were you aware of the experiementer's 
interest in menstrually related problems during your 40 days 
of self assessment? 
NOT AT ALL 
1 2 3 4 
VERY MUCH 
5 6 7 
Are you or were you pregnant during the 40 days of self 
assessment? 
1. Yes 2. No 
Did you take birth control pills during your 40 days of self 
assessment? 
1. Yes 2. No 
Do you suffer from premenstrual syndrome or premenstrual 
problems? 
1. Yes 2. No 
please describe: 
Were you taking any medication for cramps or premenstrual 
discomfort during your 40 days of self assessment? 
1. Yes 2. No 
what kinds of medication? 
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Appendix A-4 
"Pure" Subjects Factors 
(N=58; all unaware, no oral contraceptive use subjects) 
Factor 1: General complaints 
5. muscle stiffness 
17. dizziness 
19. chest pains 
23. cold sweats 
32. ringing in the ears 
39. heart pounding 
42. lowered motor 
coordination 
43. numbness, tingling 
46. blind spots, fuzzy 
vision 
Factor 2: Depression 
3. crying 
7. confusion 
11. loneliness 
38. mood swings 
40. depression 
45. tension 
Factor 3: Positive Affect 
Factor 4: 
Factor 5: 
14. orderliness 
18. excitement 
31. feeling of well being 
47. bursts of energy 
6. forgetfulness 
26. nausea, vomiting 
28. hot flashes 
35. accidents 
9. headache 
36. irritability 
41. decreased efficiency 
Factor 6: tva ter retention 
1. weight gain 
30. painful breats 
34. swelling 
MOOS FACTORS 
pain 
autonomic reactions 
control 
autonomic reactions 
control 
control 
concentration 
control 
control 
negative affect 
concentration 
negative affect 
negative affect 
negative affect 
negative affect 
arousal 
arousal 
arousal 
arousal 
concentration 
autonomic reactions 
autonomic reactions 
concentration 
pain 
negative affect 
behavioral change 
water retention 
water retention 
water retention 
Factor 7: 
Factor 8: 
Factor 9: 
Factor 10: 
Factor 11: 
Factor 12: 
Factor 13: 
Appendix A-4, page 2 
4. lowered school or 
work performance 
29. difficulty concentrating 
33. distractible 
Behavior Change 
8. take naps; stay in bed 
15. stay at home 
20. avoid social activities 
10. skin disorders 
2. insomnia 
27. restlessness 
16. cramps 
13. affectionate 
MOOS FACTORS 
behavioral change 
concentration 
concentration 
behavioral change 
behavioral change 
behavioral change 
water retention 
concentration 
negative affect 
pain 
arousal 
Items with no correlation weight over 0.50 
highest weight on 
Factor 
4 21. 
6 22. 
1 24. 
5 25. 
5 37. 
1 44. 
anxiety negative affect 
backache pain 
lowered judgement concentration 
fatigue pain 
general aches and 
pains pain 
change in eating 
habits n/a 
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Appendix A-5 
PMS Subjects Factors 
(N=33; "pure" subjects 
complaining of premenstrual symptoms) 
Factor 1: General complaints 
5. muscle stiffness 
17. dizziness 
19. chestpain 
23. cold sweats 
32. ringing in the ears 
39. heart pounding 
43. numbness, tingling 
44. change in eating habits 
46. blind spots, fuzzy 
vision 
Factor 2: Depression 
3. crying 
7. confusion 
38. mood swings 
40. depression 
45. tension 
Factor 3: Behavior Change 
4. lowered school or 
work performance 
8. take naps; stay in bed 
15. stay at home 
25. fatigue 
29. difficulty concentrating 
33. distractible 
Factor 4: Positive Affect 
Factor 5: 
14. orderliness 
18. excitement 
31. feeling of well being 
47. bursts of energy 
24. lowered judgement 
26. nausea, vomiting 
37. general aches and pains 
41. decreased efficiency 
42. lowered motor 
coordination 
MOOS FACTORS 
pain 
autonomic reactions 
control 
autonomic reactions 
control 
control 
control 
n/a 
control 
negative affect 
concentration 
negative affect 
negative affect 
negative affect 
behavioral change 
behavioral change 
behavioral change 
pain 
concentration 
concentration 
arousal 
arousal 
arousal 
arousal 
concentration 
autonomic reactions 
pain 
behavioral change 
concentration 
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Factor 6: 
1. 
30. 
34. 
Factor 7: 
6. 
28. 
35. 
Factor 8: 
22. 
36. 
Factor 9: 
2. 
Factor 10: 
16. 
20. 
Factor 11: 
13. 
Factor 12: 
10. 
Factor 13: 
Water retention 
weight gain 
painful breasts 
swelling 
forgetfulness 
hot flashes 
accidents 
backache 
irritability 
insomnia 
cramps 
avoid social activities 
affectionate 
skin disorders 
MOOS FACTORS 
water retention 
water retention 
water retention 
concentration 
autonomic reactions 
concentration 
pain 
negative affect 
concentration 
pain 
behavioral change 
arousal 
water retention 
no item correlation weight greater than 0.50 
Items with no correlation weight over 0.50 
highest weight on 
Factor 
8 9. 
2 11. 
12 12. 
4 21. 
6 27. 
headache pain 
loneliness negative 
feeling of 
suffocation control 
anxiety negative 
restlessness negative 
affect 
affect 
affect 
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Screening Interview 
The prinicipal investigator presents, 
subject sign consent form I, and 
signature. She asks the subject: 
explains, ana nas the 
then witnesses her 
her name: 
address: 
telephone number: 
age: marital status: 
today's date: month: day: year: 
any pregnancies? 
using birth control pills? 
other physician prescribed medication? for what? 
to describe her premenstrual symptoms and problems: 
behavior changes? time resting? 
depression? crying episodes? 
physical symptoms or changes? 
symptoms and problems start how many days before menstrual 
onset? 
how long has she had these symptoms and problems? 
history of psychological problems? family history? 
hospitalized? hallucinations/delusions? 
suicidal ideation? plan? medications? 
currently under psychological/psychiatric care? 
180 
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If eligible, have subject complete MDQ. 
If eligible, explain data collection procedure and treatment 
program. 
have subject sign consent form II, witness her 
signature. 
collect data deposit. 
If not eligible, offer subject alternative referral sources. 
principal investigator signature 
date 
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Menstrual Distress Questionnaire 
The following is a list of symptoms which women sometimes 
experience. Please describe your experience of these 
symptoms during the week before a typical menstrual flow 
(for screening) or your most recent menstrual flow (for 
baseline, post-treatment, and follow-up measurement 
occasions). Rate each item on the following scale: 1 =no 
experience of the symptom; 2 = barely noticable; 3 = 
present, mild; 4 = present, moderate; 5 = present, strong; 
and 6 = acute or partially disabling. 
Weight Gain 
Insomnia 
Crying 
Lowered school or 
work performance 
Muscle stiffness 
Forgetfulness 
Confusion 
Take naps; stay in 
bed 
Headache 
Skin disorders 
Loneliness 
Feeling of 
suffocation 
Affectionate 
Orderliness 
Stay at home 
Cramps 
Lowered judgement 
Fatigue 
Nausea, vomiting 
Restlessness 
Hot flashes 
Difficulty concentrating 
Painful breasts 
Feelings of well being 
Ringing in the ears 
Distractible 
Swelling 
Accidents 
Irritability 
General aches and pains 
Mood swings 
Heart pounding 
Depression 
Decreased efficiency 
Dizziness, faintness 
Excitement 
Chest pains 
Avoid social 
activities 
Anxiety 
Backache 
Cold sweats 
Appendix C, page 2 
--- Lowered motor coordination 
Numbness, tingling 
Change in eating habits 
Tension 
Blind spots, fuzzy 
vision 
Bursts of energy, 
activity 
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Tables 
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Table 1 
Subject Data 
Screening Assessment Scores 
Subject .II. Age Marital MDQ 'It 
Status neg beh 
affect change 
Depression Treatment Group 
101 41 m 45 22 
102 35 m 31 15 
103 23 m 47 26 
104 31 m 35 23 
105 40 d 35 21 
106 24 s 40 16 
107 41 m 48 25 
108 38 m 32 19 
109 41 d 43 20 
110 43 sep 33 16 
111 24 m 35 15 
112 23 s 26 15 
mean 33.7 37.5 19.4 
range 23-41 26-48 15-26 
Behavior Change Treatment Group 
201 24 s 46 20 
202 28 s 33 18 
203 38 m 39 23 
204 27 m 39 19 
205 38 m 26 15 
206 33 m 37 22 
207 29 m 27 23 
208 27 m 36 24 
209 34 m 29 25 
210 36 m 34 20 
211 40 m 35 19 
212 27 m 37 17 
mean 31.8 34.8 20.4 
range 24-40 27-46 15-25 
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Table 1 continued 
Subject .u. Age Marital MDQ 1T 
Status neg beh 
affect change 
Control Group 
301 32 m 25 15 
302 21 s 42 23 
303 31 m 38 18 
304 23 m 31 23 
305 38 m 34 15 
306 31 m 27 16 
307 33 m 33 22 
308 30 m 42 19 
309 38 m 27 23 
310 23 s 43 23 
311 38 m 28 15 
312 24 s 46 21 
mean 30.2 34.7 17.8 
range 21-38 25-46 15-23 
Overall (all groups) N = 36 
mean 31.9 35.6 19.1 
range 21-41 25-48 15-26 
minimum 
for inclusion 24 15 
1'1·et rea tmunt ( ha se I i ne) Scores 
Subject M 1 0 I 102 103 
llcai 1 y Ua li ll'JS 
dcf•1"t:.~~ i Ull 1 5 I 2 1 1 
bt:l1dViur chilll'JU 16 I 1 I 1 
t:l y i lliJ upi tiOdes 00 OJ 0] 
wi 1111 Lus a· est i n•J 0000 01100 0750 
I·IIJI.! 
IIL:IJdliVt! affect P.J 411 46 
IJch<l vi or <1 I ch<~IIIJU 16 1 u 24 
l·l~il.! 
l:IJIIIJl!::il j VU !iCOn.! IJj 45 46 
'l'ablt! 2 
Jndiviclual Suhjuct Data 
Depression 'l'reatment Group 
1 04 105 106 I 07 100 
09 10 OJ 00 00 
I 0 00 1 4 00 1 1 
00 01 01 01 00 
0000 0000 1200 03]0 0660 
27 3!.1 ]2 ]] 29 
1!.1 1!.1 10 24 26 
47 54 39 59 30 
109 110 Ill 
10 00 1 3 
07 00 15 
01 00 01 
0000 0000 00]0 
24 1 3 34 
09 07 14 
39 ]0 37 
1 1 2 
00 
03 
no 
0100 
]5 
10 
40 
Group 
Means 
0. 1 
9.5 
• 8 
262.5 
32.6 
16.] 
43.8 
,_... 
00 
0\ 
'&'able 2, pa~Je 2 
lluprossion 'l'reatment Group 
Post-tl·eatmunt scores 
Subject I ) 0) 102 )0] I 04 105 106 107 1 00 
l>di ly Hatinys 
dcpt·ession 1 7 ()] 04 06 04 04 12 12 
lwllavior chanye 20 05 04 07 06 12 12 16 
cayiny episodes 00 01 ()() 0) 02 06 02 01 
mi nultH> rest i ny (}()()() 0400 0420 00011 0000 1200 0150 0720 
l·lllU 
••o..:CJetl i ve a f feet •15 ) 'J 2'J 23 29 31 25 ]} 
bo..:hav i ot·a 1 change :a 1 ) 17 13 25 20 07 O'J 
I·Hic.J 
CCJII<JUSt j Vl! score 52 35 JO 40 46 27 57 3!) 
1 09 1) 0 1 1 1 
19 01 03 
1 7 02 03 
00 00 00 
0000 0000 01100 
36 15 12 
10 00 06 
4] 20 21 
1 12 
06 
01 
00 
0060 
)6 
00 
31 
Group 
Means 
7.6 
0.8 
1 • 0 
252.5 
25.9 
13.8 
30. 1 
1-' 
co 
--I 
'l'al> 1 e 2, page 3 
Depression Treatment Group 
Fo 11 ow-up Scores 
Subject I I 0 I 102 103 104 105 106 107 100 
Daily llatings 
depression 1 0 05 03 02 10 00 04 1 4 
belaav iot· change 21 04 03 04 05 05 04 07 
crying episodes Ill 00 00 01 01 01 00 01 
uai nu tes resting 0000 0000 0360 000() 0400 1440 0100 0720 
HllQ 
negative affect 4 ) I 4 19 1 1 )) 09 27 31 
lwhaviora I change I •I 00 10 05 23 09 1 4 17 
HSQ 
congestive scor·e 411 25 34 24 51 20 51 40 
109 II 0 I 1 1 
07 06 I 0 
()) 04 05 
00 05 OJ 
0000 0450 0000 
22 32 I 7 
1 1 1 6 00 
37 29 34 
1 1 2 
OJ 
00 
OJ 
0000 
26 
07 
45 
Group 
Heans 
6.8 
5. J 
I . 2 
302.5 
24.0 
11.0 
]J.) 
1-' 
co 
co 
'l'<tble 2, palJe 4 
Uehavior Chan'.)e 'l'reatment Group 
l'rE:treatment (haseline) Scores 
Sui• ject I <!Ill 202 203 204 205 206 207 200 
IJil i I y Hat i III.JH 
dcJH-e~s i <•II I 3 10 )} 07 10 1 3 00 05 
IJl.:IJdviot- chan'.)e 1 4 09 1 1 05 16 1 4 05 10 
cryiiH.J episodes ()j 05 00 02 00 OJ 00 00 
ud1111tcu n~stiiH.J 0 I :Hl 0060 0060 0000 0000 0000 0090 0240 
HIJ'.} 
llt..:•Jd t i ve affect JJ ]7 34 39 24 34 1 4 36 
bulldviot-it 1 chun<.Jt.! 21 1 2 10 17 11 15 1 0 25 
I·WI.J 
,;IJII<Jl!til j Vt.! l:iGOI"l! 4~ 34 ]6 40 35 44 44 49 
209 210 21 I 
10 04 10 
16 05 12 
00 00 00 
1660 0060 0540 
1 0 26 26 
05 23 10 
46 30 44 
212 
1 2 
11 
01 
035 
37 
17 
40 
Group 
f.!Cilllfi 
10. 1 
10.8 
1 • 2 
266.7 
29.3 
16. 7 
41 . 6 
t-' 
00 
~0 
'l'ttble 2, puye 5 
Uchttvior Chani.Je 'l'reatmcnt Group 
l'o::;t-ll·eatrnent Scores 
t.iuh)ucl I 2UI 202 20] 2U4 205 206 207 200 
U<1i ly HnlilllJS 
tlu('rCS~J!nn J 1 03 1 1 10 09 15 04 01 
hdwv i or c..·h;· 00 04 10 Oll 10 15 00 05 
cryinlj epi ..:!~ no 00 00 01 00 no 00 00 
ud lllll~S 1· .: i Ill] ()1)!)0 0120 0030 0]6() 0000 0060 0075 0060 
I· IDO 
IIUI.Jdlive nffcct j() 2) 32 H I 3 32 I 7 36 
l.d•<•vional dailii'JC I ./ I 0 I 5 15 07 10 I 4 26 
l-l!iiJ 
Cllii'.Jutilivu score 44 J5 )5 ]!) 24 46 37 38 
2U~ 210 21 I 
00 03 05 
00 04 00 
on 00 00 
1920 0030 0060 
I 6 20 31 
06 15 1 4 
30 35 40 
212 
14 
09 
00 
0155 
]] 
15 
)4 
Group 
f.leans 
7.2 
6. I 
. I 
246.7 
26.4 
I 4. 3 
36.4 
t-' 
\.0 
0 
'l'ah1e 2, pai.Je 6 
Uulwvior Clmnqo 'l'reatmont Group 
l·'u 11 uw-up Scores 
:_iubjcel • :.!Ill :.!02 201 20'1 205 206 207 20U 
l~<d ly natiiHJS 
dt..:JIH!Sti i Oil ll 1 ] ) 2 14 ) 6 )6 06 00 
bdaav i or change l l 12 10 09 1 2 ) 7 02 06 
eryiuq episode::; 04 04 00 04 00 Ol 00 0) 
ani 1ualcti rusl i nq ().12 II 0240 01160 0425 0000 0000 0000 nooo 
I·IIJQ 
III!'J<Ilive affcet 15 J4 13 46 23 29 17 ]9 
a,chaviot·ul Glmnqc 15 12 1 5 16 09 1U 1 2 22 
I·ISIJ 
t.;unqestivc scores 42 44 34 51 35 46 40 36 
209 210 211 
00 01 OJ 
03 0] 03 
00 00 00 
2200 00]0 0000 
10 1 4 ]2 
05 09 1 1 
25 2U ]9 
212 
1 3 
1 l 
05 
0195 
H 
1 7 
35 
Grou1' 
Heans 
9.4 
0.3 
1 • 6 
304.2 
2U.O 
l 3. 4 
J7. 9 
....... 
\.0 
....... 
'l'ahle 2, page 7 
Control Gt·oup 
l'cet a·ea tment (base I j ne) Scores 
!:iu!Jject I ]()) 302 303 304 305 306 307 
ll<d ly Hc1linyti 
depression no 10 16 01 00 (I} 21 
J,L:J.dv i oc chanCJe 05 ou 10 03 ) 4 04 I 9 
ca·yiaHJ epi~odes 0() 00 05 00 02 01 OJ 
111i11utes n~stiny OIUO 1740 0)00 0000 0150 0000 05)0 
NIJI.} 
au~tJ<l t i ve a f f uct 17 31 37 31 29 24 37 
bclw vi oc a I claauye 07 I 7 22 14 ) 5 12 25 
t·l!:i!J 
CIJIItJel:ll j Vt! tiCOf(! J() 47 37 4] 37 30 45 
308 309 310 
06 06 I 7 
09 I I I 0 
00 00 1 1 
0000 0060 0320 
41 26 42 
10 lU 21 
4 1 27 40 
3 II 312 
1 3 I 7 
06 10 
01 04 
0120 (1900 
20 42 
15 17 
39 43 
Group 
Neans 
9.0 
10.4 
2. 3 
340.0 
]2.1 
16.8 
30.9 
f-' 
\0 
N 
'l'abl e 2, pa9e 8 
ContL·ol Group 
l'ust-treatmunt Scores 
SuiJjuct I 301 302 303 304 305 306 307 
lldily ltatinql:i 
d~.::pcu!o>sion 02 l4 06 00 00 1 4 20 
t~~.:hi\V i or ch<Hl<Jl! 04 l4 02 00 1 l 12 1 5 
cryiuy episodes 110 01 02 00 OJ 06 02 
wi IHI tes rust i IHJ 11120 1620 0020 0000 0240 0360 0690 
f.IIHj 
lll:tJdlive affect I y 36 20 10 38 25 32 
iH:II<IV j Ol'iJ 1 cllulliJt! I l 20 09 10 21 14 16 
I·JtjiJ 
ClJIHJl!:it i Vl! SCOH! 40 44 34 36 31 30 50 
300 309 310 
15 09 09 
l 1 00 14 
00 02 01 
0060 0000 0300 
38 2) 29 
20 1 1 16 
43 28 36 
])} 312 
08 10 
10 1 3 
00 02 
0020 0600 
28 41 
15 1 ] 
39 44 
Group 
Muauu 
9.6 
8.0 
1.4 
3J5. 8 
20.9 
14.8 
30.6 
1-' 
\.0 
w 
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Control Group 
Follow-up .Scon..!s 
.Subject I 3111 302 303 304 305 306 307 
U.c~i ly UatiiH.JS 
dcpre~H;ion Ol 14 05 06 05 09 1 1 
IH.:!!Iav i or change 04 14 06 07 15 05 1 2 
cryiiiiJ episudcl:i ()() 01 01 00 03 01 01 
111i1111les resliniJ 11120 1620 0020 0100 0240 0600 0700 
I-IIJI.! 
IIUIJdtive dffect 21 3!.1 15 2!.1 27 23 30 
bd~t.avioral clliiiiiJt! 06 10 1 1 1 2 19 I 1 23 
I·WIJ 
ccmiJcst i ve seore 2!.1 41 32 30 30 30 52 
300 309 310 
1 2 05 1 2 
1 2 00 15 
on 01 05 
0000 0000 0240 
42 1 2 4 1 
24 06 24 
45 23 48 
3 11 312 
1 2 02 
10 06 
01 ()] 
0120 0560 
20 42 
15 24 
39 35 
Group 
Means 
7.0 
8.8 
1.4 
373.3 
29.0 
16. 1 
37.5 
t-' 
\0 
""' 
195 
Table 3 
Multivariate Analysis of Variance for 
Depression Symptom Measures 
Source Wilks Lambda F df 
(hypothesis, 
error) 
Treatment Groups .91 .53 6,62 
Time . 71 1. 93 6,28 
Groups X Time .55 1. 61 12,56 
Note 
*E < • OS 
Table 4 
Analysis of Variance for 
MDQ Negative Affect Symptom Cluster 
Source 
Treatment Groups . 
Subjects within Groups 
Time 
Groups X Time 
Within Cells 
Note 
*E. < .OS 
df 
2 
33 
2 
4 
66 
MS 
73.64 
180.20 
196.46 
54.33 
41.04 
F 
.41 
4.79* 
1.32 
196 
197 
Table 5 
Newman-Keuls Post Hoc Tests: 
Means of MDQ Negative Affect Symptom Cluster 
Scores for Time 
Time Post- Follow-up Baseline r 
Periods Treatment 
Means 27.08 27.53 31.33 
Post-
Treatment 27.08 .42 3.97* 3 
Follow-up 27.53 3.55* 2 
Baseline 
*E < .05 
Table 6 
Analysis of Variance for 
Daily Depression Ratings 
Source 
Treatment Groups 
Subjects within Groups 
Time 
Groups X Time 
Within Cells 
Note 
*E < .05 
df 
2 
33 
2 
4 
66 
MS 
21.85 
56.25 
11.73 
15.29 
17.11 
F 
.39 
.69 
.89 
198 
Table 7 
Analysis of Variance for 
Crying Frequency Measure 
Source 
Treatment Groups 
Subjects within Groups 
Time 
Groups X Time 
Within Cells 
Note 
*E.< .OS 
df 
2 
33 
2 
4 
66 
MS 
5.18 
4.90 
1.12 
5.94 
2.94 
F 
1. 06 
.38 
2.02 
199 
200 
Table 8 
Multivariate Analysis of Variance for 
Behavior Change Symptom Measures 
Source Wilks Lambda F df 
(hypothesis, 
error) 
Treatment Groups .95 . 28 6,62 
Time .59 3.21* 6,28 
Groups X Time .66 1.10 12,56 
*E. < .05 
Table 9 
Analysis of Variance for 
MDQ Behavioral Change Symptom Cluster 
Source 
Treatment Groups 
Subjects within Groups 
Time 
Groups X Time 
Within Cells 
Note 
*E < .05 
df 
2 
33 
2 
4 
66 
MS 
38.62 
54.53 
76.40 
12.16 
17.98 
F 
.71 
4.25* 
.68 
201 
202 
Table 10 
Newrnan-Keuls Post Hoc Tests: 
Means of MDQ Behavioral Change Symptom Cluster Measure 
Scores for Time 
Time Follow-up Post- Baseline r 
Periods Treatment 
Means 13.78 14.50 16.58 
Follow-up 13.78 1. 01 3.94* 3 
Post-
Treatment 14.50 2.93* 2 
Baseline 16.58 
*2. < .05 
Table 11 
Analysis of Variance for 
Daily Behavior Change Ratings 
Source 
Treatment Groups 
Subjects within Groups 
Time 
Groups X Time 
Within Cells 
Note 
*E < • 01 
df 
2 
33 
2 
4 
66 
MS 
21.53 
55.11 
81.87 
28.89 
12.73 
F 
.39 
6.43* 
2.27 
203 
204 
Table 12 
Newman-Keuls Post Hoc Tests: 
Means of Daily Behavior Change Ratings 
for Time 
Time Follow-up Post- Baseline r 
Periods Treatment 
Means 7.44 7.89 10.25 
Follow-up 7.44 .76 4.76* 3 
Post-
Treatment 7.89 4.00* 2 
Baseline 10.25 
*E. < • 01 
Table 13 
Analysis of Variance for 
Time Resting Measure 
Source 
Treatment Groups 
Subjects within Groups 
Time 
Groups X Time 
Within Cells 
Note 
*E < .05 
df MS F 
2 71559.25 .11 
33 661645.39 
2 22984.25 1.00 
4 355.10 .02 
66 22935.77 
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Table 14 
Analysis of Variance for 
MSQ overall measure of PMS complaints 
Source 
Treatment Groups 
Subjects within Groups 
Time 
Groups X Time 
Within Cells 
Note 
*E.< .01 
df 
2 
33 
2 
4 
66 
MS 
7.35 
130.12 
198.04 
46.51 
26.34 
F 
.06 
7.52* 
1. 77 
206 
207 
Table 15 
Newrnan-Keuls Post Hoc Tests: 
Means for MSQ Overall Measure of PMS Complaints 
for Time 
Time Follow-up Post- Baseline r 
Periods Treatment 
Means 37.08 37.69 41.42 
Follow-up 37.08 .71 5.05* 3 
Post-
Treatment 37.69 4.34* 2 
Baseline 41.42 
*E.< .01 
MDQ 
NEGAFF 
MDQ 
BEHCHG 
DAILY 
DEP 
DAILY 
BEHCHG 
CRYING 
FREQ 
TIME 
RESTING 
MSQ 
* £<. 05 
** £<.01 
a 
Table 16 
Correlation Matrix 
a 
All Dependent Measures Pretreatment Scores 
MDQ MDQ DAILY DAILY CRYING TIME 
NEGAFF BEHCHG DEP BEHCHG FREQ RESTING 
.55** .42** .34* .47** -.10 
.55** .24 .23 .23 -.06 
.42** .24 .62** .46** .34* 
.34* .23 .62** .41** .32* 
.47** .23 .46** .41** -.00 
-.10 -.06 .34* .32* -.00 
.37* .43** . 33 * .19 .14 .24 
208 
MSQ 
.37* 
.43** 
.33* 
.19 
.14 
.24 
MDQ NEGAFF = MDQ negative affect symptom cluster 
measure (retrospective); MDQ BEHCHG = MDQ behavioral change 
symptom cluster measure (retropsepctive); DAILY DEP =daily 
depression rating measure (prospective); DAILY BEHCHG = 
daily behavior change rating measure (prospective); CRYING 
FREQ =reported crying frequency measure (prospective); TIME 
RESTING= reported time resting measure (prospective); MSQ = 
MSQ overall measure of PMS (retrospective). 
TO 
Table 17 
Individual Subjects Change from Baseline 
and Sign Tests 
POST-TREATMENT FOLLOW-UP 
+ = + = 
MSQ overall measure of PMS 
depression 
treatment 
group 
behavior 
change 
treatment 
group 
control 
group 
9 0 
10 0 
5 1 
3 - 10 0 
2 * 8 1 
6 7 2 
209 
2 * 
3 -
3 
overall 
sign test (n=35; r=ll; p<.05) (n=33; r=8; p<.Ol) 
MDQ negative affect cluster 
depression 
treatment 8 0 4 9 0 3 -
group 
behavior 
change 8 1 3 - 5 1 6 
treatment 
group 
control 7 1 4 6 2 4 
group 
overall 
sign test (n=34; r=ll; p<.lO) (n=33; r=l3; p>.25) 
+ improved; = no change; - worsened; * £<.05; 
number of times the less frequent sign occurs; 
matched pairs whose differences have a sign 
- £<.25; r 
n number of 
210 
Table 17, page 2 
TO POST-TREATMENT FOLLOW-UP 
+ = + = 
MDQ behavioral change cluster 
depression 
treatment 7 0 5 9 0 3 -
group 
behavior 
change 9 0 3 - 8 3 1 
treatment 
group 
control 6 1 5 6 1 5 
group 
overall 
sign test (n=35; r=l3; p<.25) (n=32; r=9; p<.05) 
daily behavi0r change rating 
depression 
treatment 7 0 5 10 0 2 * 
group 
behavior 
change 10 0 2 * 9 0 3 
treatment 
group 
control 8 0 4 6 0 6 
group 
overall 
sign test (n=36; r=ll; p<.05) (n=36; r=ll; p<.05) 
+ improved; = no change; - worsened; * £<.05; - E.< .. 25 i r 
number of times the less frequent sign occurs; n number of 
matched pairs whose differences have a sign 
Table 17, page 3 
TO POST-TREATMENT 
+ = 
daily depression rating 
depression 
treatment 
group 
behavior 
change 
treatment 
group 
control 
group 
overall 
sign test 
6 0 6 
8 1 3 -
6 0 6 
(n=35; r=lS; p>.25) 
crying frequency 
depression 
treatment 
group 
behavior 
change 
treatment 
group 
control 
group 
overall 
sign test 
2 4 6 
5 7 0 
5 4 3 
(n=21; r=9; p>.25) 
211 
FOLLOW-UP 
+ = 
8 1 3 -
6 0 6 
6 0 6 
(n=35; r=lS; p>.25) 
4 2 6 
2 6 4 
3 4 5 
(n=24; r=9; p>.25) 
+ improved; =no change; -worsened; * £<.05; 
number of times the less frequent sign occurs; 
matched pairs whose differences have a sign 
- £<.25; r 
n number of 
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TO POST-TREATMENT FOLLOt'v-UP 
+ = + = 
time resting 
depression 
treatment 4 6 2 4 4 4 
group 
behavior 
change 7 1 4 5 3 4 
treatment 
group 
control 7 1 4 6 2 4 
group 
overall 
sign test (n=28; r=lO; p<.25) (n=27; r=l2; p>.25) 
+ improved; = no change; - worsened; * £<.05; 
number of times the less frequent sign occurs; 
matched pairs whose differences have a sign 
- £<.25; r 
n number of 
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Table 18 
Percentage of Total Possible on Targeted Symptom Clusters 
Based on Screening Assessment Scores 
Subject Negative Affect Behavioral Change 
.II. Cluster Cluster 11' 
x/48 x/30 
101 94 73 
102 65 50 
103 98 87 
104 73 77* 
105 73 70 
106 83 53 
107 100 83 
108 67 63 
109 90 67 
llO 69 53 
lll 73 50 
ll2 54 50 
201 96 67 * endorsed 
202 69 60 greater 
203 81 77 percentage 
204 81 63 of 
205 54 50 behavioral 
206 77 73 change 
207 56 77* cluster 
208 75 80* than of 
209 60 83* negative 
210 71 67 affect 
211 73 63 cluster 
212 77 57 
301 52 50 
302 88 77 
303 79 60 
304 65 77* 
305 71 50 
306 56 53 
307 69 73* 
308 89 63 
309 56 77* 
310 90 77 
3ll 58 77* 
312 96 70 
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Consent Forms 
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Appendix E-1 
Consent Form I 
I understand that I am answering questions (by completing a 
questionnaire and being interviewed) to be used in selecting 
subjects for a psychological investigation involving the 
treatment of premenstrual syndrome and associated 
psychological discomfort. I have been informed that 
although the information I will supply will be available to 
the principal investigator and her supervisor, the 
information will be kept confidential. In addition, I have 
been informed that I am participating in research and 
alternative treatment for may problem is available through 
psychologists and gynecologists in clinics and private 
practice. I have also been informed that I may withdraw 
from this screening session at any time. 
I understand that in order to participate in this study, I 
will be asked to collect assessment data (which will be kept 
confidential) everyday throughout may participation in this 
study. I understand that I will be asked to contact my 
therapist and turn in the data I collect once per week. I 
understand that the procedure for collecting these data will 
be explained to me in full during this screening session. 
I understand that treatment will be conducted on an 
individual basis over a two-week period. I understand that 
I will be asked to attend four sessions, each of 
approximately 50 minutes duration during that two week 
period. I understand that these sessions may be audiotaped 
or observed by the principal investigator or her superv1sor 
and will be kept confidential. I understand that if I am 
eligible, the experimental procedure will be explained to me 
more fully before I commence treatment and that I may 
withdraw from treatment at any time. 
I understand that if I am eligibel for treatment, I have 
agreed to make a $20.00 "data deposit" during this session. 
I understand that I am not paying for any t~eatment that I 
may receive. If I am eligible for treatment, I have agreed 
to have my money refunded, gradually and fully, if I collect 
all the assessment data and come to all required sessions. 
I must also agree to forfeit the money that matches the 
cornrnittments I fail to keep. Specifically, I understand 
that my data deposit will be refunded according to the 
following schedule: 
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If I collect all my assessment data, contact my 
therapist and turn in my data as scheduled and attend all 
scheduled treatment sessions my data deposit will be 
refunded as follows: 
day one or within two days of the onset of 
my first menstrual period .............. $5 
my second menstrual period .......•..... $5 
my third menstrual period .....•.•...... $5 
upon attendance at four treatment sessions .•..... $5 
$20 
I understand that if I have to miss a scheduled session with 
my therapist, I may call in advance to reschedule the 
appointment within two days of the original time. I 
understand that I will need to contact my therapist: 
(a) once per week to turn in my data, 
(b) on the first day or within two days of the onset of 
my next three menstrual periods, and 
(c) by attending the four scheduled treatment sessions 
in order to receive my refund. 
I understand that if I become dissatisfied with this study, 
withdrawal can be arranged promptly and the remainder of my 
data deposit will be refunded. 
I understand that if I am not eligible for this study, I 
will be given a list of referrals (medical and 
psychological) for treatment. 
signed: ____________________________ __ 
witnessed: ---------------------------
date: ____________________________ ___ 
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Consent Form II 
I, 
psychological researqh to 
of Rosemery 0. Nelson, 
involving assessment 
premsntrual syndrome 
discomfort. 
hereby agree to participate in 
be conducted under the supervision 
Professor of Psychology, UNC-G, 
and psychological treatment of 
and associated psychological 
As explained to me, for the next three months I will be 
required to collect assessment data to be turned in on a 
weekly basis. In addition, I understand I will participate 
in four treatment sessions conducted on an individual basis. 
I have been assured that all data will be kept confidential. 
I understand that I will be required to collect assessment 
data daily through my next three menstrual cycles. 
I understand that in the two weeks following my third 
menstrual period, following three months of data collection, 
I will have the opportunity to meet with my therapist for 
four treatment sessions (for the control group). 
I understand that in the two weeks following my first 
menstrual period I will meet with my therapist four times 
and receive training in a cognitive treatment for depression 
(for the depression treatment group) or a behavior 
management procedure for activity changes (for the behavior 
change treatment group). 
I understand that my therapist will be a graduate student in 
psychology who has received training in the techniques 
employed here. Therapists will be supervised by Dr. 
Rosemery 0. Nelson, Professor of Psychology, and Susan 
Leonard, principal investigator. I am aware that these 
supervisors will observe some of my treatment sessions 
through a one way mirror or listen to audio tapes of the 
sessions. 
I understand that if I become dissatisfied with this study, 
withdrawal can be arranged promptly by contacting Susan 
Leonard and the remainder of my data deposit will be 
refunded. 
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I understand that the purpose of this investigation is to 
evaluate methods of treating premenstrual syndrome and 
associated psychological discomfort using methods which have 
been successful with similar problems (not PMS) in the past. 
I realize, however, that there is no guarantee that I will 
be free from premenstrual symptoms and discomfort because I 
participate in this research. Hopefully, my participation 
will contribute to the development of effective treatment of 
premenstrual syndrome and associated discomfort for others, 
as well as for myself. In addition, if at the end of this 
investigation I am not satisfied with my progress, then I 
will receive a referral for continued evaluation and 
treatment. 
signed: ____________________________ __ 
witness: -----------------------------
date: ______________________________ __ 
Appendix F 
Daily Self Assessment 
Name ____________________ __ Date -----------
depression 
behavior change 
number of 
none 
0 1 
little 
2 
very little 
0 1 2 
moderate 
3 4 5 
extreme 
6 
some much 
3 4 5 6 
episodes of crying 
duration of time resting 
engaged in required 
activities 
comments 
219 
menstrual bleeding ------------------------
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Appendix G 
Menstrual Symptom Questionnaire 
Instructions: The first twenty-four items on this 
questionnaire describe symptoms associated with the 
menstrual period. Please indiciate the-degree to which you 
experience each symptom by selecting one of the five 
response choices (not at all, mild, moderate, strong, or 
severe experience of the symptom) and circle the number 
which corresponds to your choice. For item 25, please read 
carefully the descriptions of two types of rnens~rual 
discomfort and select the type which most closely fits your 
experience. 
not at all severe 
Item 
* 1. I feel irritable, easily agitated, 
and am impatient a few days before 
my period. 
2. I have cramps that begin on the 
first day of my period. 
* 3. I feel depressed for several days 
before my period. 
4. I have abdominal pain or discomfort 
which begins one day before my 
period. 
* 5. For several days before my period, 
I feel exhausted, lethargic or 
tired. 
6. I only know that my period is 
coming by looking at the calendar. 
7. I take a prescription drug for the 
pain during my period. 
8. I feel weak and dizzy during my 
period. 
* 9. I feel tense and nervous before my 
period. 
10. I have diarrhea during my period. 
*11. I have backaches several days 
before my period. 
12. I take aspirin for pain during my 
period. 
*13. My breasts feel tender and sore a 
few days before my period. 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
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14. ~y lower back, abdomen, and the 
~nner sides of my thighs begin to 
hurt or be tender on the first day 
of my period. 
15. During the first day or so of my 
period, I feel like curling up in 
bed, using a hot water bottle on my 
abdomen or taking a hot bath. 
*16. I gain weight before my period. 
*17. I am constipated during my period. 
18. Beginning on the first day of my 
period, I have pains which may 
diminish or disappear for several 
minutes and then reappear. 
*19. The pain I have with my period is 
not intense but a continuous dull 
aching. 
*20. I have abdominal discomfort for 
more than one day before my period. 
21. I have backaches which begin the 
same day as my period. 
*22. My abdominal area feels bloated for 
a few days before my period. 
23. I feel nauseous during the first 
day or so of my period. 
*24. I have headaches for a few days 
before my period. 
* denotes congestive items 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2 3 
2 3 
2 3 
2 3 
2 3 
2 3 
2 3 
2 3 
2 3 
2 3 
2 3 
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4 5 
4 5 
4 5 
4 5 
4 5 
4 5 
4 5 
4 5 
4 5 
4 5 
4 5 
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25. TYPE 1 
The pain begins on the first day of menstruation, often 
coming within an hour of the first signs of 
menstruation. The pain is most severe the first day 
and may or may not continue on subsequent days. Felt 
as spasms, the pain may lessen or subside for a while 
and then reappear. A few women find this pain so 
severe as to cause vomiting, fainting or dizziness; 
some others report that they are most comfortable in 
bed or taking a hot bath. This pain is limited to the 
lower abdomen, back and inner sides of the thighs. 
TYPE 2 
There is advanced warning of the onset of menstruation, 
during which the woman feels an increasing heaviness, 
and a dull aching pain in the lower abdomen. This pain 
is sometimes accompanied by nausea, lack of appetite, 
and constipation. eadaches, backaches, and breast pain 
are also characteristic of this type of menstrual 
discomfort. 
The type that most closely fits my experience is TYPE 
(TYPE 2 is scored +5 congestive and TYPE 1 is scored 0) 
Appendix H 
Depression Treatment Materials 
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Cognitive Therapy of Depression Protocol 
Session 1: present rationale for the treatment procedure 
(H-2) 
explain how to identify negative interpretations/self talk: 
use of evaluative words (e.g., should, ought, must), 
catastrophizing (e.g., awful, terrible, can't stand it), 
overgeneralization (e.g., I'll never ••. , I'm incompetent), 
and focusing only on the negative, not seeing the positive. 
give examples (H-3) 
have subject imagine it's her premenstruum and generate 
incidents and identify 3-5 negative self statements 
instruct subject to practice identifying such thoughts and 
record them for next session 
Session 2: review negative self talk subject identified 
in herself 
explain how to dispute depression related statements: via 
hypothesis testing (Becket al., 19i9; pp. 253-255): 
through use of environmental data, going out into the actual 
situation, checking belief against facts, e.g., negative 
thought: "I'm fat," test: get on scale, check charts of 
normal weights, ask M.D. 
logical challenge (Becket al., 
pointing out irrational assumptions, 
logical extreme, identifying positive 
noting discrepant criteria 
1979; pp. 265-270): 
carrying beliefs to 
aspects of situations, 
give examples and 
subjects identified 
generated disputes 
complete 
negative 
homework form 
self talk and 
have subject practice homework: imagine 
premenstruum, dispute negative self talk 
(H-4) using 
in session 
it's her 
instruct subject to practice disputing negative thoughts 
daily using the homework form 
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Session 3: review identification and disputing of 
negative self talk 
give examples and have subject dispute negative talk 
therapist generates 
have subject practice homework: imag~n~ng it's her 
premenstruum, disputing negative self talk (twice for each 
statement she identified) 
instruct subject to practice homework daily 
Session 4: same as Session 3 
instruct subject to continue daily practice an5 to apply the 
technique during her premenstruum 
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Cognitive Therapy of Depression Rationale 
Physical changes associated with premenstrual tension 
are thought to be related to mood changes and an increased 
tendency to feel depressed. Many women complain of feeling 
unhappy or depressed before their period starts. The goal 
of this treatment is to teach you how to control your 
feelings of depression. Individuals often experience 
depressed feelings because of the way they perceive or think 
about various situations. Many psychologists feel it is the 
person's interpretation of the situation, themselves, or the 
future, rather than the actual situation which causes 
depression. In addition, it is believed that we learn to 
interpret situations in certain ways and so we can learn new 
ways to view the same situations. When we feel depressed, 
it may be because the interpretation and thoughts we have 
learned are not reflecting the situation accurately. 
The treatment procedure we will use over the next four 
sessions (today and our next three meetings) is designed to 
teach you to identify and dispute any thoughts or 
interpretations you have during your premenstruum which may 
be making you feel depressed. Through this procedure you 
will learn new ways to view situations which will help 
alleviate these depressed feelings. Thus, three steps are 
involved in this treatment. The first is learning to 
identify the interpretations and thoughts which may be 
causing depression. The second is learning to dispute those 
negative or depressing thoughts through use of logical 
challenge and hypothesis testing. The third step is 
practice in disputing negative thoughts. 
We will start today learning to identify negative 
thoughts. 
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Examples of Negative Thoughts 
From Becket al., 1979; p. 246 and 261 
In order to be happy, I have to be successful in whatever I 
undertake. 
To be happy, I must be accepted by all people at all times. 
If I make a mis~ake, it means I am inept. 
I can't live without you. 
If somebody disagrees with me, it means he doesn't like me. 
My value as a person depends on what others think of rne. 
If it's true in one case, it applies in any case which is 
even slightly similar. 
The only events that matter are failures, deprivation, etc. 
I arn responsible for all bad things, failures, etc. 
If it has been true in the past, then it's always going to 
be true. 
I am the center of everyone's attention - especially my bad 
performances. 
I am the cause of misfortunes. 
Always think of the worst. 
to you. 
It's the most likely to happen 
Everything is either one extreme or another (black or white; 
good or bad). 
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Depression Treatment Homework Form 
(to be completed with therapist during session 2 and 
expanded as appropriate) practice disputing your negative 
self talk using hypothesis testing or logical challenge 
responses 
Automatic negative thought: 
Rational disputing response: 
Automatic negative thought: 
Rational disputing response: 
Automatic negative thought: 
Rational disputing response: 
Automatic negative thought: 
Rational disputing response: 
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Behavior Change Treatment Materials 
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Operant Intervention for Behavior Control Protocol 
Session 1: present rationale (I-2) 
explain techniques of behavior change (Fordyce, 1976; pp. 
83-88): reinforcers, selection of reinforcers, and 
attention as a reinforcer. 
have subject imagine that it's her premenstruum and complete 
an activities form (I-3) identifying behavior which is 
required but low frequency during the premenstruum, high 
frequency rewarding behavior, and significant others 
Session 2: explain activity planning/scheduling 
have subjects schedule required activities for the days 
between this session and the next 
make sure subject schedules rewarding events contingent upon 
required activities specifying duration, frequency, etc. 
Session 3: review impact of and adherence to schedule 
from previous session 
assess effectiveness of scheduled rewarding 
events/activities and revise as needed 
have subject schedule required activities and contingent 
rewarding activities for the days between this session and 
the last session 
Session 4: review the schedule from the previous session 
assess the effectiveness of the scheduled rewarding events 
and revise if necessary 
have subject schedule required activities daily/weekly 
instruct subject to implement this self management technique 
during her next premenstruum 
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Operant Intervention for Behavior Control Rationale 
Physical changes associated with premenstrual tension 
are thought to be related to a tendency to perform and 
behave differently than usual. Many women complain of 
performing inefficiently, staying at home, and avoiding 
normal activities. The experience of being ill, impaired, 
or ineffective is heightened inactivity and avoidance of 
responsibility. Alternatively, a sense of accomplishment 
and well-being is evoked through performance of required 
activities and receipt fo rewards and approval for such 
performance. The goal of this treatment is to help prepare 
you for the negative premenstrual experiences so that you 
will have greater control of your behavior. Many 
psychologists feel that activity level can be increased by 
presentation of contingent positive consequences. The 
alteration of consequences may be achieved by planning or 
scheduling activities and the reward or acknowledgement of 
them. 
The treatment procedure we will use over the next four 
session (today nad our next three meetings) is desaigned to 
teach you to plan ahead for the experiences of the 
premenstruum by scheduling your activities and arranging for 
positive consequences to occur. 
We will start today by identifying high frequency, 
potentially rewarding activities and those required 
activities you tend to avoid during your premenstruum. 
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activities form 
potentially rewarding/high frequency activities 
1 
2 
3 
4 
5 
required activities usually avoided during the premenstruum 
1 
2 
3 
4 
5 
significant others who could serve as helpers 
1 
2 
3 
4 
5 
(at least five activities in the first two categories should 
be identified; more would be fine; at least three helpers 
should be identified) 
Appendix I-4 
Using a daily activity schedule 
adapted from Effective Study Materials 
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The secret of more effective use of time and greater 
enjoyment of living lies in organizing and planning. Each 
person will, of course, plan her own 168 hours to harmonize 
with her unique requirements and interests. 
The idea of a daily activity schedule in dealing with 
PMS is to plan for the premenstrual time period. Carefully 
arranging your time to account for required activities which 
premenstrual distress usually leads you to avoid and 
carefully including clearly pleasant activities to follow 
those required activities will help decrease a sense of 
ineffectiveness and poor performance. You will be 
accomplishing what you need to through planning your time 
and activities to help maintain or improve your normal level 
of functioning. 
Build your schedule around your fixed time 
commitments. Some activities have fixed time requirements 
and others are flexible. FIXED: eating, work, church 
FLEXIBLE: sleeping, recreation 
Borrow time, don't steal it. Whenever an unexpected 
acitivity arises that takes up time you had planned to use 
otherwise, decide immediately where you can trade for "free" 
time to make up the missed time and then adjust your 
schedule for the week. 
It is particularly important not to cheat yourself out 
of the pleasant activities you have scheduled to help you 
complete your required or somewhat undesirable activities. 
Try to have alternative pleasant events in case your 
scheduled pleasant activity is not possible. 
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Debriefing 
The purpose of this study was to evaluate the treatment 
validity of identifying specific target behaviors within the 
premenstrual syndrome. This treatment validity issue is 
concerned with the question: does selection of target 
behaviors and matching treatment tq them enhance treatment 
outcome? That is, the purpose of this study was to assess 
the effectiveness of treatment previously used with symptoms 
of depression or with behavior change symptoms when these 
treatments are used with women who complain of similar 
symptoms associated with premenstrual syndrome. The women 
who have participated in this study have at least mild 
premenstrual symptoms of depression and behavior changes. 
All participants recorded their symptoms for three months. 
Some of the women participated in in the treatment which has 
been used with nonmenstrually related depression and some 
participated in the treatment whioch has been used with 
nonmenstrually related behavior changes. The reason that 
all the women in the study did not participate in the same 
or both treatments is that evidence is needed to demonstrate 
that the logical treatment is, in fact, the most effective 
or efficient treatment for the targeted symptoms. Some 
research has demonstrated that the presumably illogical 
treatment is more effective or more efficient than the 
logical treatment. It is important to experimentally test 
the impact of various treatments on specific symptoms in 
order to demonstrate the effectiveness, rather than assuming 
ef~ectiveness' based upon what seems to be logical. In 
addition, some of the women in the study recorded their 
symptoms daily for three months, but participated in neither 
treatment procedure. Treatment is available to these 
participants upon completion of their three months of data 
collection. The reason that some of the women in the study 
received the experimental treatments during their three 
months of data collection and some (the control subjects) 
did not is so that any effectiveness in symptom management 
can be attributed to the experimental treatment procedure 
and not to the data collection process or the passage of 
time. The use of control subjects is another way to 
experimentally establish the effectiveness of an untried 
treatment procedure. 
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Your participation in this investigation of the 
appropriateness of specific treatment procedures for 
premenstrual symptom management is greatly appreciated. If 
you would like to pursue further professional help for your 
premenstrual symptoms you will be given a list of referral 
sources (including psychologists and gynecologists) in your 
area. For any further assistance please feel free to ask 
the principal investigator. 
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236 
34 
,-.. 
en 
C) 
1-o 
0 32 .. cr. 
1-o 
C) ... 
en 30 :: -u ... 
CJ 28 
C) 
tj.., 
ti-l 
< 
C) 26 > ..... ... 
d 
e.G 
C) 24 z 
'-' 
o· 
c z 
Figure 1: 
MDQ Negative Affect 
Symptom Cluster Scores 
c 
• 
237 
Control Group 
0 .-: 
Behavi.or Change 
Treatment Group 
0 
c 
~Depression 
Treatment 
c Group 
Baseline Post- Follow-up 
Treatment 
11 
t:C 
= 10 -... 
c::l 
c:: 
= 9 0 -Ill Ill 
Q) 
f.< 
8 ~ c 
c. 
>.. -..... 7 d c. 
6 
Figure 2: 
Daily Depression Ratings 
{Average Four Day Totals) 
0 
• 
c 
Baseline 
• 
Post-
Treatment 
238 
Behavior Change 
Treatment Group 
0 
Control 
• Group 
c 
Depression. 
Treatment 
Group 
Follo\v-up 
eo 
::::: .... 
>. 
~ u 
3 co.. 
0 
en 
0 
"" 2 0 en .... 
:::... 
~ 
1 
"" a) ~ 
~ 
0 
:::... 
Q 
c::: 
Figure 3: 
Reported Crying Frequency 
(Average Four Day Totals) 
• 
239 
Behavior Chan~e 
Treatment Group 
0 
0 
·-----=-~~~Control 
Group 
Depression 
Treatment 
c 
Baseline Post-
Treatment 
Group 
Follo\~-up 
,-.. 
en 
Q 
1-< 
0 
() 
cr-
1-< 
Q 
...... 
en 
::: -u 
Q 
t:l:l 
:::: 
~ u -d 
1-< 
0 .... 
> g 
a; 
c:::: 
'-' 
0" 
0 :::: 
20 
18 
16 
14 
12 
10 
Figure 4: 
MDQ Behavioral Change 
Symptom Cluster Scores 
e . 
c~ 
• 
Baseline Post-
Treatment 
240 
Control 
Group 
• 
Behavi.or Change 
Treatment 
-o Group 
D Depressi.on 
Treatment 
Group 
Follo\o~-up 
11 
00 
= .... .., 10 c: 
c: 
a> 
eo 
= 9 c: 
G 
$.4 
0 8 -> 
$ 
-; 
c= 7 
>-
.-4 .... 
~ 
c 6 
Figure 5: 
Daily Behaivor Change Ratings 
(Average Four Day Totals) 
0 
241 
Control 
Group 
• 
0 
Change 
Treatment 
Group 
Depression 
Treatment 
D Group 
Baseline Post- Follow-up 
Treatment 
,...... 360 
Cll 
Q 
""' 
= 340 -' ::;: 
'-' 
1::: ,.. 
320 .;:::; 
""' Cll 
Q 
c:::: 
Q 300 
E 
-' 
E-
'"=' Q 280 
""' ~
0 
§' 
260 c:::: 
242 
Figure 6: 
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Figure 7: 
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Figure 9: 
Behavior Change Treatment Group 
Individual Subject MSQ Scores 
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Control Group 
Individual Subject MSQ Scores 
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Figure 11: 
Depression Treatment Group 
Individual Subject MDQ Negative Affect Scores 
4S 
~~----~~ 
35 a a 
.:o 30 ~a--a 35 :!S 
30 ::o 
2S 15 
a 
35 
~a 
35 a ____-a 
30 30 a 
2S 2S 
20 ----0 20 15 15 
til 
a) a 
f.< 
~ 0 •40 .35 
a 
u 35 a/~ UJ so 
~ 
30 
a~ 
2S 
u 2S 20 
0 
(l) 20 lS co.. 0 
co.. 
< 
(l) 
> 
-~ 
~ .35 .35 d 
00 30 .30 
0 
a) a---- a/ z 2S a 2S 0' 20 ~- 20 Q lS lS ::c: a 
3S 0~ 35 0 
.30 c c .30 
~,--a 2S 25 20 20 lS lS 
30 c 0 35 a 
2S 
~ 
.30 ~,/' 20 ::s 15 :o 
10 a !S 
B.:lscl ine ro:;: Foll<>w !i:tscl inc rost Follow 
Trc~t::cnt U;' Trc:-:ttmcnt U[l 
24i 
Figure 12: 
Behavior Change Treatment Group 
Individual Subject t-IDQ Negative Affect Scores 
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Figure 13: 
Control Group 
Individual Subject MDQ Negative Affect Scores 
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Figure 14: 
Depression Treatment Group 
Individual Subject MDQ Behavioral Change Scores 
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Figure 15: 
Behavior Change Treatment Group 
Individual Subject MDQ Behavioral Change Scores 
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Figure 16: 
Control Group 
Individual Subject MDQ Behavioral Change Scores 
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Figure 17: 
Depression Treatment Group 
Individual Subject Daily Behavior Change Ratings 
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Figure 18: 
Behavior Change Treatment Group 
Individual Subject Daily Behaivor Change Ratings 
::o 20 
1S 0 . 
~0--0 15 10 10 
s 5 o--.__ 
0 0 0 0 
20 20 
Ill 1S 
00 0 15 
::: 10 c----o~ 10 o--.__ •.-1 s 0 .... 5 0 
c:l 0 0 ::::: 
Q) 
00 
::: 
~ 
u 20 20 
~ lS lS 0 
0 o- 0 
~0--0 •.-1 10 10 > :; s ~ 0 0 
Cl) 
l:Q 
>. -•.-1 
c:l 
20 Q 20 
~ 15 15 
0 10 0 10 - 5 0~ 5 0 0 0 ::11 0 0 +" 
0 
E-o 
>. 
ell 
Q 
~ 20 20 = 15 0'--.._ 0 0 15 
o~o--o """ 10 0 10 5 5 
0 0 
20 20 
0 15 o-o 15 
0--0 10 10 0 
5 s 
0 0 
B:.seline Post FoliL>IO e:.~d inc rost Folio• 
Trc:~t~cnt up T~c:ltmc-nt up 
254 
Figure 19: 
Control Group 
Individual Subject Daily Behavior Change Ratings 
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Figure 20: 
Premenstrual and Postmenstrual Group Means 
of Daily Depression and Behavior Change Ratings 
for Baseline and Post-treatment Menses 
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